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In the brain, a high degree of neuronal flexibility is needed for proper development of its 
neuronal network and because the connections between neurons continuously change, e.g. 
during learning and memory formation. To allow flexibility, the brain is able to reorganize 
itself by forming new neuronal connections throughout life and neurons alter the strength of 
their synaptic connections with other neurons in response to activity and experience (a 
process called synaptic plasticity), resulting in an overall neuronal plasticity. Thus, 
neuronal plasticity plays an essential role in information processing in the nervous system. 
The molecular mechanisms underlying this process are, however, still far from being 
completely understood. In this thesis, two proteins that are involved in neuronal plasticity 
are examined, namely the neuroendocrine-specific serine protease inhibitor neuroserpin and 
the neurotrophin brain-derived neurotrophic factor (BDNF). 
The serine protease inhibitors (serpins) and the group of proteins they inhibit, the 
serine proteases, play a role in the mechanisms responsible for the interaction of a (nerve) 
cell with its environment. The environment in which cells reside and which provides the 
structural integrity of tissues is formed by the extracellular matrix (ECM). The integrity of 
the ECM is tightly controlled by a balance between matrix-degrading proteases and 
protease inhibitors. The ECM consists of a complex of collagen, glycoproteins and 
proteoglycans, and an increasing amount of data supports the involvement of several ECM 
molecules in neurite outgrowth and synaptic plasticity (1-4). The serine proteases and 
serpins, and in particular neuroserpin, will be discussed in more detail below.  
The second protein dealt with in this thesis is BDNF, a member of the 
neurotrophin (NT) family and implicated in inter-cellular signaling in the nervous system. 
Neurotrophic factors are traditionally viewed as secretory proteins that regulate long-term 
survival and differentiation of neurons. In addition, it has now been well accepted that NTs 
play an important role in synapse development and plasticity (reviewed in 5-10). The 
family of NTs and especially BDNF will also be described in more detail below. 
 
Serine proteases and serine protease inhibitors 
 
In addition to their role in maintaining ECM integrity, proteases are involved in many other 
biological processes, such as the digestion of proteins to supply amino acids, proenzyme 
activation, clot formation and lysis, angiogenesis and complement activation. To meet these 
needs, a series of families of proteases have evolved, namely the serine proteases, threonine 
proteases, cysteine proteases, aspartyl proteases and metalloproteases. The serine proteases 
form an important group of proteases and their name is derived from the active serine 
residue in their catalytic site. Serine proteases can be divided into two main evolutionary 
groups, namely the chymotrypsin-like serine proteases and the subtilisin-like proprotein 
convertases, and both groups can be further classified into families. The family of trypsin-
like enzymes belongs to the chymotrypsin-like group, includes trypsin, tissue-type 
plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA), kallikreins and 
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plasmin, and has been most extensively characterized (11, 12). For example, t-PA is known 
to cleave plasminogen into plasmin (13) and, in turn, plasmin can cleave ECM components 
involved in neuronal plasticity, such as laminin (14) or the cell-adhesion molecule L1 (15). 
Examples of the group of subtilisin-like proprotein convertases are furin and the 
prohormone convertases 1 and 2.   
 The evolution of serine proteases is paralleled by the development of serine 
protease inhibitors, termed serpins, which constitute a superfamily that currently consists of 
~500 members. Examples of serpin family members are α1-antitrypsin, antithrombin III, 
plasminogen activator inhibitor-1 and -2, C1 inhibitor, thyroxine-binding globulin, maspin 
and neuroserpin, one of the two proteins dealt with in this thesis. Serpins differ from other 
enzyme-inhibiting families by their capacity to undergo a marked conformational change 
and to act as suicide substrate inhibitors; serpins can form an unusually tight and SDS-
stable interaction with their substrate protease after which drastic conformational changes 
take place, rendering both the serine protease and its serpin inactive (reviewed in 16, 17) 
(Figure 1). However, this inherent molecular flexibility also makes serpins susceptible to 
point mutations that result in intermolecular linkage and polymer formation. The effect of 
such protein aggregation is cumulative, with a progressive loss of cellular function, 
eventually resulting in a disease, collectively named serpinopathies (18-21). 
 
 
Figure 1: Conformational transition of serpin family members.  
Members of the serpin superfamily, such as the depicted α1-
antitrypsin, undergo a striking conformational transition to inhibit 
their target protease. After docking, the target serine protease is 
inactivated by movement from the upper to the lower pole of the 
protein. This is associated with the insertion of the reactive centre 
loop of the serpin (R) as an extra strand into β-sheet A of the serpin. 
Adapted from Lomas and Carrell (20). 
 
 
 
 
Neuroserpin 
 
Neuroserpin was discovered more than 16 years ago as a secreted protein from chicken 
dorsal root ganglia cells (22) and received its name because of its expression in the 
developing and adult brain (23, 24). Neuroserpin has also been identified in neuroendocrine 
cells, such as in rat pituitary and adrenal glands (25, 26). Like other serpin family members, 
neuroserpin undergoes a marked conformational transition in order to be able to function as 
an inhibitor. Consequently, a number of mutations in the neuroserpin gene lead to a 
serpinopathy. Thus far, five mutations have been described which lead to polymerization 
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and accumulation of the protein, resulting in neuronal inclusion bodies and subsequent 
neuronal degeneration. These mutations result in the recently described autosomal-
dominant dementia ‘familial encephalopathy with neuroserpin inclusion bodies’ (FENIB) 
(20, 27, 28). 
 In vitro studies have assigned t-PA as a target protease for neuroserpin (24, 29). 
This was supported by the in vivo finding that injection of neuroserpin markedly delays the 
progression of seizure activity in wild-type, but not in t-PA-deficient, mice (30-32). 
Nevertheless, gene-targeting of neuroserpin in mice has implicated the inhibitor to play a 
role in the regulation of emotional behaviour through a mechanism that is at least in part 
independent of t-PA activity (33). Thus, the cognate target of neuroserpin may be another, 
as yet unidentified, serine protease. 
The exact physiological function of neuroserpin in the nervous system remains to 
be elucidated. The temporo-spatial pattern of expression and the fact that it is secreted from 
axons implicate neuroserpin as a regulator of proteolytic events associated with neuronal 
plasticity (23, 24, 29, 34, 35). Since small changes in neuroserpin expression result in 
changes in the number of neuronal cells extending neurits and total neurite length following 
nerve growth factor treatment, neuroserpin may as well play a role in cell communication, 
cell adhesion and/or cell migration (25, 26). Thus, further studies are necessary to unravel 
the exact physiological role of neuroserpin. Part of the research described in this thesis 
involved our attempts to increase the understanding of this serpin. 
 
(Pro-)neurotrophins 
 
The second subject of this thesis, the NT family member BDNF, has also been implicated 
in the mechanism of neuronal plasticity, as will be described in more detail in the next 
section. The NT family consists of structurally related neurotrophic factors that exert a wide 
array of effects in the central and peripheral nervous systems. Currently, the family consists 
of nerve growth-factor (NGF), BDNF, neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-
4/5), and two members that have been identified only in fish and not in other vertebrates, 
namely neurotrophin-6 (NT-6) and -7 (NT-7) (reviewed in 36). 
 NTs exert their actions via two classes of transmembrane receptors, the receptor 
tyrosine kinases (Trk)-A, -B, and –C, and the p75 NT receptor (p75NTR), a member of the 
tumor necrosis factor (TNF) receptor superfamily (reviewed in 37). Whereas p75NTR binds 
all NTs equally well, TrkA preferentially interacts with NGF, TrkB with BDNF and NT-
4/5, and TrkC with NT-3. Interaction of NTs with p75NTR causes the activation of various 
signaling pathways, such as increased c-jun N-terminal kinase or NF- κB activities, 
resulting in effects on cellular apoptosis, survival, neurite elongation and growth arrest. 
Binding of a NT dimer to a specific Trk receptor induces the receptors tyrosine kinase 
activity, leading to the activation of phosphatidylinositol-3-kinase (PI3K), mitogen-
activated protein kinase (MAPK), and phospholipase C-γ (PLC-γ) pathways, resulting in 
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cell survival and differentiation (reviewed in 37-40). In addition to the intact Trks, carboxy-
terminal truncated forms of TrkB and TrkC that lack a tyrosine kinase domain have also 
been described (41-44). The roles of the truncated receptors remain enigmatic, but various 
functions have been suggested, including growth and development (45-47), negative 
modulation of TrkB receptor expression and function (48-50), and calcium signaling in 
glial cells (51). 
 Like many other growth factors, the NTs are synthesized as 30-35-kDa immature 
precursors that are proteolytically cleaved intracellularly, by furin and other proconvertases, 
to release mature ligands of 12-14 kDa (52). In addition, it was recently found that also 
uncleaved proNTs can be released by cells (53-56). NTs are secreted constitutively from 
nonneuronal cells (52), but secretion can be mediated by both constitutive and regulated 
secretory pathways in neurons and neuroendocrine cells (55). Remarkably, the pro-domain 
sequences of individual NTs are highly conserved among vertebrate species, suggesting 
that the prodomains may have an important function. Several regions in the pro-domains 
have been proposed to assist in proper folding and secretion of NTs (54, 57-59). 
Furthermore, it was recently found that proNTs are high-affinity ligands for the p75NTR and 
can induce p75NTR-dependent apoptosis (60). Thus, pro- and mature NTs can elicite 
opposite functional effects by differential interactions with p75 and Trk receptors. 
 
BDNF and neuronal plasticity 
 
In addition to their classic effects on neuronal cell survival and differentiation, NTs, and in 
particular BDNF, have emerged as major regulators of neuronal plasticity. BDNF and its 
receptors are widely expressed in the nervous system, with particularly high expression in 
areas of both developmental and adult synaptic plasticity (reviewed in 61). Furthermore, the 
expression and secretion of both proBDNF and mature BDNF are tightly regulated during 
development and by neuronal activity (6, 62-66). The observations that BDNF modulates 
the efficacy of synaptic transmission in certain forms of short-term synaptic plasticity, long-
term potentiation (LTP) and long-term depression (LTD) (reviewed in 7, 67-69), or the 
growth of dendrites and axons (reviewed in 70-73) led to the hypothesis that BDNF serves 
as a molecular mediator of synaptic plasticity (reviewed in 74). However, a comprehensive 
understanding of the molecular and cellular mechanisms of BDNF function in neuronal 
plasticity is still lacking. Many synaptic functions of BDNF seem to be mediated by the 
TrkB receptor, which triggers intracellular signaling cascades that can alter gene expression 
of for example synapse-associated proteins (75). BDNF appears to exert both pre- and 
postsynaptic roles, since it has been shown to modify presynaptic transmitter release (5, 76-
79), and to have an effect on postsynaptic ion channels (reviewed in 78, 80-82). Currently, 
several hypotheses have been proposed to clarify how the diffusible molecule BDNF can in 
fact achieve local and synapse-specifc modulation (reviewed in 6, 83). In addition, BDNF 
not only acts as a modulator of ion channels that are otherwise gated by membrane voltage 
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or ligands, but also can rapidly gate a Na+ channel, giving BDNF the properties of a 
classical excitatory transmitter (84-86).  
Besides their roles in neuronal cell survival, differentiation and plasticity, there is 
growing evidence that NTs play an even broader role in nervous system functionality. For 
example, NGF and BDNF may be key regulators of the myelination process in the CNS and 
PNS (87-90), enhance neurogenesis (91-93) and stimulate the proliferation of brain 
astrocytes, cardiac myocytes, and microglia (94-99). Other responses to NTs include 
changes in morphology and differentiation (100, 101). Finally, a number of studies have 
reported that BDNF and NGF are involved in malignancies (102-106). Thus, although NTs, 
and more specifically BDNF, have already been characterized extensively, new data 
continuously extend our knowledge about their physiological function.  
 
BDNF in the intermediate pituitary of the amphibian Xenopus laevis 
 
To gain more insight into the roles of pro- and mature BDNF, we use the South-African 
claw-toad frog Xenopus laevis as a model system, and more specifically the melanotrope 
cells of the intermediate pituitary (described in more detail below). In the Xenopus 
melanotrope cells, both proBDNF and mature BDNF proteins have been found (107, 108). 
BDNF secreted by the melanotrope cells can stimulate the release of α-melanophore 
stimulating hormone (α-MSH) and the biosynthesis of the prohormone proopiomelano-
cortin (POMC) in an autocrine manner (107) (Figure 2). 
  
Xenopus laevis intermediate pituitary melanotrope cells as a model system to 
study neuronal plasticity in a neuroendocrine interface 
 
The melanotrope cells of the intermediate pituitary of Xenopus laevis constitute a valuable 
model system to examine the secretory pathway as well as aspects of neuroendocrine and 
neuronal plasticity. The cells play a central role in the process of background adaptation of 
the amphibian. By placing the frog on either a black or a white background, the activity of 
the melanotrope cells and their regulatory neuronal input can be manipulated in vivo in a 
physiological way. In animals that are adapted to a black background, the melanotrope cells 
are biosynthetically very active and produce vast amounts of POMC, which is processed to 
a number of bioactive peptides, including α-MSH. This hormone causes pigment dispersion 
in skin melanophores, giving the animal a black appearance. On a white background, the 
melanotrope cells are inhibited and thus inactive; consequently, the release of α-MSH is 
inhibited and animals appear white. The activity of the melanotrope cells is controlled by 
several brain centres of which the hypothalamic suprachiasmatic nucleus inhibits and the  
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Figure 2: BDNF in the neurointermediate pituitary of Xenopus laevis. 
Schematic representation of a Xenopus intermediate pituitary melanotrope cell, whose activity is controlled 
through direct synaptic innervation from hypothalamic nuclei. In the melanotrope cell, immature and mature 
secretory granules are indicated in dark grey and light grey, respectively. Some of the characteristics of pro- and 
mature BDNF are hypothesized and therefore indicated by question marks. Pro- and mature BDNF may have an 
effect on the melanotrope cell itself (1), on the innervating hypothalamic neurons (2) or on other cells (3). 
Abbreviations: pn, pars nervosa; pi, pars intermedia; ER, endoplasmic reticulum; POMC, proopiomelanocortin; 
pro- and mature BNDF, pro- and mature brain-derived neurotrophic factor; α-MSH, α-melanophore stimulating 
hormone. 
 
 
magnocellular nucleus stimulates the biosynthesis and release of α-MSH (reviewed in 109- 
111). Neurons from the suprachiasmatic nucleus (suprachiasmatic melanotrope-inhibiting 
neurons; SMINs) make direct synaptic contacts with the melanotrope cells and the structure 
of these so-called varicosities depends on the adaptation state of the animal: more than 
double the number of active synaptic zones are present on the melanotropes of white- 
relative to black frogs (112) (Figure 3). 
During white-background adaptation, the physiological response (drop of blood 
plasma α-MSH levels) takes place within 30 minutes after the animal is placed on a white 
background (113). This is thought to be regulated by the initial release of the 
neurotransmitter GABA from hypothalamic SMINs (114). However, immediate synaptic 
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changes are likely also necessary to ensure that already during the first few days of 
adaptation the melanotrope cells will stay inactive. During a more prolonged adaptation to a 
white background (at least a week), the melanotrope cells themselves undergo drastic 
morphological changes and become biosynthetically inactive (115). Conversely, when a 
white animal has to adapt to a black background, the immediate response involves the 
release of α-MSH that is stored in storage granules in the inactive melanotrope cells of the 
white animal (115, 116). Again, for a more prolonged adaptation, in this case to a black 
background, gradual morphological changes will lead to larger and biosynthetically active 
melanotrope cells and less elaborate inhibitory varicosities. Thus, manipulation of 
melanotrope cell activity is accompanied by differences in neuronal plasticity.  
 
 
 
 
Figure 3: Neuroendocrine plasticity of Xenopus intermediate pituitary melanotrope cells.  
Schematic representation of synaptic and endocrine plasticity at the level of the intermediate pituitary melanotrope 
cell during the process of background adaptation of the amphibian Xenopus laevis. See text for details. 
Abbreviations: ER, endoplasmic reticulum; α-MSH, α-melanophore stimulating hormone. 
 
 
Xenopus laevis transgenesis for functional studies 
 
To perform functional studies on neuroserpin and BDNF, we used the technique of stable 
Xenopus laevis transgenesis (117, 118). With this technique we can direct the expression of 
the protein of interest to various tissues by using cell type-specific promoter sequences in 
front of the protein-encoding cDNA. For example, using the POMC gene promoter (119) 
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transgenic animals can be generated that overexpress the transgene (in this thesis 
neuroserpin or BDNF) specifically in the melanotrope cells of the intermediate pituitary. 
An important advantage of the use of this promoter is that the level of transgene expression 
can be regulated by placing the frog on a white or black background, resulting in low or 
high transgene promoter activity, respectively. 
 
Aim and outline of thesis 
 
Research on the functioning of the brain fascinates and intrigues many people. Up to date, 
still many aspects of brain functioning remain elusive and need further investigation, one 
aspect being the molecular mechanism of neuronal plasticity. As mentioned above, 
neuroserpin and BDNF may play a role in neuronal plasticity. However, the exact 
physiological function of neuroserpin remains unclear and although BDNF has been quite 
extensively characterized, new data continue to broaden the functional spectrum of this 
protein in nervous system functionality. In this thesis, aspects of the physiological roles of 
neuroserpin and BDNF are therefore explored. In chapter 2, the identification and 
expression profile of neuroserpin in Xenopus laevis is presented. We found that Xenopus 
neuroserpin shows a high degree of amino acid sequence identity with neuroserpin proteins 
from other species, and that it was expressed mainly in neuronal and neuroendocrine 
tissues. In the neuroendocrine intermediate pituitary, neuroserpin formed a stable complex 
with a putative substrate, which was dependent on the degree of melanotrope cell activation 
(chapter 3). In an attempt to learn more about the physiological role of neuroserpin, we 
used the technique of stable Xenopus transgenesis in combination with the POMC gene 
promoter to overexpress neuroserpin and a mutant form of the protein specifically in the 
intermediate pituitary melanotrope cells. The generation and analyses of these animals is 
described in chapter 4. To explore the physiological role of BDNF in more detail, 
transgenic frogs were generated and analysed with overexpression of pro- and mature 
BDNF specifically in the melanotrope cells. We found that unprocessed proBDNF may 
result in endoplasmic reticulum stress in the melanotrope cells and a block of transport of a 
number of secretory pathway proteins (chapter 5). In addition, we observed that a 
relatively high level of transgene expression of mature BDNF in the melanotrope cells 
resulted in glial cell proliferation and axonal outgrowth and myelination (chapter 6). 
Finally, in chapter 7 the results described in this thesis are summarized, discussed and 
placed into a broader context.  
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Abstract 
 
Serine protease inhibitors form a diverse family of proteins of which most members inhibit 
target serine proteases. Neuroserpin is a member of this family. Here, we have 
characterized neuroserpin in the non-mammalian species Xenopus laevis and found a high 
degree of amino acid sequence conservation, especially of the reactive center loop, of the 
Xenopus protein compared to mammalian and chicken neuroserpin sequences, suggesting a 
conserved target specificity. Neuroserpin mRNA and protein were expressed throughout 
Xenopus development, while in the adult frog high mRNA expression was found in 
neuronal and neuroendocrine tissues, and the reproductive organs, and the neuroserpin 
protein was detected mainly in brain and pituitary. More specifically, in Xenopus pituitary 
neuroserpin mRNA was expressed higher in the neurointermediate lobe than in the pars 
distalis. At the protein level, we detected a 55-kDa neuroserpin protein in the pars nervosa, 
two neuroserpin proteins of 44- and 50-kDa in the melanotrope cells of the pars intermedia, 
and a 46-kDa product in the pars distalis. On the basis of its relatively high degree of 
sequence conservation and its expression pattern, we conclude that Xenopus neuroserpin 
may play an important physiological role, e.g. as a serine protease inhibitor during 
development, and for proper neuronal and neuroendocrine cell functioning. 
 
Introduction 
 
The proteolytic cleavage of peptide bonds in proteins is a critical step in many biological 
processes, such as digestion of proteins to supply amino acids, proenzyme activation, clot 
formation and lysis, tissue remodelling, angiogenesis, complement activation and the 
maintenance of the extracellular matrix. An important class of proteolytic enzymes are the 
serine proteases, named after the active serine in their catalytic site. To maintain 
homeostasis, the proteolytic activity of proteases needs to be tightly regulated. Inhibition of 
serine proteases is provided by a superfamily of serine protease inhibitors (serpins) which 
currently consists of ~500 known members. Serpins differ from other enzyme inhibitory 
families in that they are able to undergo a marked conformational change and act as suicide 
target inhibitors; they enter into a covalent interaction with their  target protease, after 
which drastic conformational changes take place, rendering both the serine protease and its 
serpin inactive (reviewed in 1-3). 
 Neuroserpin is a serpin that was first identified as an axonally secreted protein 
from chicken dorsal root ganglion cultures (4). The protein is primarily expressed in the 
nervous system throughout embryonic development and adulthood (5-7), and in 
neuroendocrine cells such as rat pituitary and adrenal glands (8, 9). Thus far, the protein has 
been characterized in only a number of mammalian species (e.g. human, rat, mouse) and 
chicken. The primary structure of neuroserpin suggested that this serpin inhibits trypsin-like 
serine proteases, like tissue-type plasminogen activator (t-PA), urokinase-type plasminogen 
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activator (u-PA) and trypsin, and interactions of neuroserpin with these  target proteases 
have indeed been confirmed experimentally in vitro (6, 10-12). Based on kinetic analyses 
and expression patterns, t-PA appears to be the most likely target for neuroserpin in the 
nervous system (10, 13), although the in vitro interaction of t-PA with neuroserpin is short-
lived, suggesting that the physiological effect of a t-PA-neuroserpin interaction may be 
more complex than previously thought (14). 
 In this study, we have isolated the full-length cDNA for Xenopus laevis 
neuroserpin, have identified from the database a second Xenopus neuroserpin sequence, and 
performed a comparative analysis of the now known Xenopus sequences with other known 
neuroserpin amino acid sequences. We also studied the expression of Xenopus neuroserpin 
mRNA and protein during development of the frog and in the adult animal, in particular in 
the neuroendocrine pituitary gland. 
 
Materials and methods 
 
Animals 
South African claw-toed frogs, Xenopus laevis, were reared in the Central Animal Facility 
of the Radboud University of Nijmegen, The Netherlands. The animals were adapted to a 
black background by keeping them in black buckets for at least three weeks at 22°C, with a 
light/dark cycle of 12 h. Experimental procedures were performed under the guidelines of 
the Dutch law concerning animal welfare. 
 
Antibodies 
Two anti-neuroserpin antibodies were used: rabbit polyclonal IgG against human 
recombinant neuroserpin (α-NS-L; generous gift of Dr. D.A. Lawrence, American Red 
Cross Holland Laboratory, Rockville, Maryland, USA; 10) and rabbit polyclonal IgG 
against human recombinant neuroserpin (α-NS-M; generous gift of Dr. Lomas, University 
of Cambridge, Cambridge, UK; 15). The dilutions used for Western blotting were 1:5,000 
and 1:10,000 for α-NS-L and α-NS-M, respectively, and 1:300 for immunocytochemistry 
(α-NS-L). Tubulin was detected using the monoclonal E7 anti-tubulin antibody (1:1,500; 
Developmental Studies Hybridoma Bank, Rockland, Gilbertsville, USA), and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with a rabbit polyclonal antibody 
(1:10,000; Trevigen, Gaithersburg, MD, USA). 
 
RNA isolation 
For RNA isolation, 10-20 embryos of a number of developmental stages (generated by in 
vitro fertilization) and various dissected Xenopus tissues were frozen in liquid nitrogen. 
Next, total RNA was isolated using Trizol reagent, according to the manufacturer’s 
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instructions (Life Technologies, Inc.). The RNA was dissolved in 20 µl RNase-free H2O 
and the concentration was measured with a GeneQuant RNA/DNA calculator (Pharmacia).  
 
Reverse transcription PCR (RT-PCR) 
For RT-PCR, two μg total RNA was reverse transcribed into cDNA in a 20 μl reaction mix 
containing first strand buffer (Invitrogen), 10 mM DTT, 0.5 mM dNTPs, 20 U RNasin 
(Promega) and 100 U Superscript II (Invitrogen) for 1.5 hrs at 37°C. The full-length cDNA 
clone of Xenopus neuroserpin was obtained by performing a PCR using Xenopus brain 
cDNA as a template. The following primer set was developed on the basis of database 
Xenopus neuroserpin-related ESTs (accession numbers NCBI nucleotide database: 
BG264770, BG407876, BI312920, BG233110, BF428341 and BI315484): NS-fw(BamHI): 
5’-GGCGGATCCATGCATCACTTCATATTACTC-3’, starting at the putative start codon 
(underlined), and NS-rev(XbaI): 5’-GCGTCTAGATTAGAGCTCTTCAAAATCATGG-3’, ending at 
the putative stop codon (underlined). The PCR amplification was carried out in a reaction 
mixture containing Pfu buffer (Fermentas), 0.05 units/μl Pfu Turbo DNA polymerase 
(Fermentas), 200 μM dNTPs, 0.5 μM of each primer and 1 μl cDNA (35 amplification 
cycles: 30 sec at 95°C, 2 min at 49°C and 1 min 30 sec at 72°C). To examine Xenopus 
neuroserpin mRNA expression in a number of developmental stages and tissues from adult 
frogs, the following forward and reverse primers were used: 5’- 
ATTGAAAGCCCATTTGATTGAAG-3’ and 5’- GGATGCATGACCCTTCCCAT-3’, respectively. As 
controls, Xenopus GAPDH cDNA (forward primer 5’-GCCGTGTATGTGGTGGAATCT-3’ and 
reverse primer 5’-AAGTTGTCGTTGATGACCTTTGC-3’) and ornithine decarboxylase (ODC) 
cDNA (forward primer 5’- GTCAATGATGGAGTGTATGGATC-3’and reverse primer 5’-
TCCATTCCGCTCTCCTGAGCAC- 3’) were amplified. Of each primer 0.5 μM was used in a 25-
μl reaction volume containing PCR-buffer (Fermentas), 200 μM dNTPs, 3 mM MgCl2, 1 
unit Taq polymerase (Fermentas) and 2 μl cDNA. The neurointermediate lobe (NIL) and 
pars distalis (PD) cDNAs were diluted 5 times before use. Thirty amplification cycles were 
performed: 1 min at 94°C, 1 min at 45°C (for neuroserpin and ODC) or 53°C (for 
GAPDH), and 1 min at 72°C. PCR-products were analyzed on a 2% agarose gel. To 
quantify the relative amounts of neuroserpin mRNA in the NIL and PD of the pituitary, 
detection of the PCR products was performed using a BioChemi imaging system and 
signals were analyzed using LabWorks 4.0 software (UVP BioImaging systems, 
Cambridge, UK). Total raw densities of 390-bp neuroserpin were normalized to the 
corresponding 230-bp GAPDH samples (n = 4). A paired t test was used for statistical 
analysis. 
 
Cloning and sequence analysis of Xenopus neuroserpin 
For cloning, the Xenopus neuroserpin cDNA generated by RT-PCR was isolated from an 
agarose gel using the QIAEX II Agarose gel extraction kit (Qiagen). After digestion with 
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BamHI and XbaI, the neuroserpin 1245-bp cDNA insert was ligated into the pCS2+ vector 
(16), resulting in the pCS2+-NS construct. Finally, full-length Xenopus neuroserpin cDNA 
was cycle sequenced using the ABI 310 Prism. For this, three different primers were used: 
NS-fw(BamHI), NS-rev(XbaI) and NS-fw366 (5’-CCATATCAGCGACAAGTTCATCCAG-3’) 
(accession number Xenopus neuroserpin: AM050698). Next, the deduced Xenopus 
neuroserpin amino acid sequence was aligned with other species neuroserpin amino acid 
sequences using the Vector NTI program (InforMax, Inc.). Amino acid sequences were 
obtained from the NCBI protein database and the amino acid sequence of pig neuroserpin 
was deduced from its mRNA sequence found in the NCBI nucleotide database. Accession 
numbers were: Xenopus laevis MGC84260 protein, AAH74366; human neuroserpin, 
CAB03626; mouse neuroserpin, CAA04939; pig neuroserpin, AY609517; chicken 
neuroserpin, CAA96493; Drosophila Spn4.1, CAD21892; human protease nexin-1, 
P07093; human antithrombin III, NP_000479; human angiotensinogen, CAI14864; and 
human pigment epithelium-derived factor, NP_002606. 
 
Western blotting 
For Western blot analyses, homogenates of the pituitary pars intermedia (PI), pars nervosa 
(PN), NIL (the PI and PN together), and PD, embryos of various developmental stages, 
neuroserpin mRNA-injected embryos, and tissues from adult Xenopus, were made in lysis 
buffer (250 mM sucrose, 1% Triton X-100, 10 mM Tris (pH 8.0), 1 mM EDTA, 1μM 
PMSF, 0.1 mg/ml soybean trypsin inhibitor) using a glass homogenizer. After 20 min 
incubation on ice, the samples were centrifuged for 20 min (18,000g). The supernatant was 
separated on a 10% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride 
membrane (0.45 μM Hybond-P, Amersham Pharmacia Biotech) or nitrocellulose (Protran; 
used for the analysis of adult tissue samples) using a BioRad mini-protean II cell system 
(Bio-Rad). For immunodetection, blots were washed one time in PBS and incubated for at 
least one hour in blocking buffer (5% skimmed milk and 1% Tween in PBS). Subsequently, 
blots were incubated with primary antiserum in blocking buffer for 16 hours (4°C). After 
three rinses in wash buffer (1% skimmed milk and 1% Tween in PBS), blots were 
incubated in horseradish peroxidase (HRP)-conjugated goat-anti-rabbit IgG (1:5,000) or 
HRP-conjugated goat-anti-mouse IgG (1:5,000) for 45 min. Following three rinses in wash 
buffer and one rinse in PBS, the proteins were visualized by incubating blots in Lumi-
LightPLUS Western blotting substrate (Roche) and subsequent exposure to X-ray film 
(Eastman Kodak). For quantification of neuroserpin protein levels in brain tissue, remaining 
tissue of the head and the tail of stage 49/50 tadpoles, detection was performed using a 
BioChemi imaging system and signals were analyzed using LabWorks 4.0 software (UVP 
BioImaging systems, Cambridge, UK). Total densities of 55-kDa neuroserpin were 
normalized to the corresponding tubulin samples (n = 4). An unpaired t test was used for 
statistical analysis. 
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Immunocytochemistry 
For microscopic analysis of neuroserpin protein expression, Xenopus brain with the 
pituitary attached was dissected and fixed in 4% paraformaldehyde in PBS. After 
cryoprotection in 10% sucrose-PBS, sagittal 20-μm cryosections were mounted on poly-L-
lysine coated slides, dried for 2 h at 45°C and immunohistochemistry was performed as 
described previously (17), using α-NS-L as a primary antibody at a dilution of 1:300 and 
goat-anti-rabbit FITC (Nordic) as a second antibody (dilution 1:50). To examine FITC 
fluorescence, cryosections were viewed under a Leica DM RA fluorescenct microscope and 
photographs were taken with a Cohu High-Performance CCD Camera using the Leica Q 
Fluoro software. Slides were also analyzed with an MRC 1024 CLSM. 
 
RNA injections 
For oocyte injection, neuroserpin RNA was produced according to the High Yield Capped 
RNA Transcription Kit (Ambion), using the pCS2+-NS vector. Next, 1-cell Xenopus 
embryos (generated by in vitro fertilization) were injected with 1 ng RNA or 0.1x MR 
solution (10 mM NaCl, 0.18 mM KCl, 0.2 mM CaCl2, 0.1 mM MgCl2, 0.5 mM Hepes-
NaOH, pH 7.6). After 2 h, 4-cell embryos were selected and subsequently monitored in 
time. A number of embryos were frozen 24, 48 and 72 h post injection, and used for 
analysis on Western blot. 
 
Results 
 
Cloning of Xenopus neuroserpin and comparative analysis of Xenopus, mammalian, 
chicken and Drosophila neuroserpin sequences 
Since neuroserpin is a recently identified new member of the serpin superfamily and has 
only been described in a limited number of species, we were interested in identifying 
neuroserpin in our model system, the amphibian Xenopus laevis. To this end, we performed 
RT-PCR and amplified, cloned and sequenced a specific product of 1248 bp. Alignment of 
the deduced amino acid sequence with the mammalian and chicken neuroserpin sequences, 
and with the Drosophila Spn4.1 amino acid sequence (the closest Drosophila homologue to 
neuroserpin; 18), revealed an overall identity of 64, 73 and 32%, respectively (Fig. 1A). 
From the comparative analysis, we conclude that we have identified neuroserpin in 
Xenopus laevis. In addition, during the preparation of this article a database search yielded 
Xenopus laevis unidentified protein MGC84260, which showed 95% amino acid sequence 
identity with the Xenopus neuroserpin protein we had cloned and represents a second 
Xenopus neuroserpin (Fig. 1A). A number of other Xenopus protein pairs have been shown 
to occur, including for POMC (19), prohormone convertase PC2 (20), amyloid precursor 
protein APP (21), D2 dopamine receptor (22) and serum albumins (23), and these pairs are 
present because a whole-genome duplication event has occurred in the species Xenopus  
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Figure 1: Amino acid sequence comparison between Xenopus neuroserpin and mammalian, chicken and 
insect neuroserpin proteins. 
(A) Alignment of the amino acid sequences of Xenopus laevis neuroserpin (NS-1), Xenopus laevis MGC84260 
protein (NS-2), and human, mouse, pig and chicken neuroserpin (NS) proteins and the Drosophila Spn4.1 protein. 
The one-letter amino acid notation is used. Residues identical among all four species are white on a black 
background, while residues conserved in three or more species are black on a dark grey background. Conservative 
amino acid changes are depicted black on a light grey background. The reactive center loop (RCL) is underlined. 
The two putative N-linked glycosylation sites are indicated with an asterisk, and the predicted signal peptide 
sequences are overlined with a dashed line. (B) Alignment of the RCLs of various neuroserpin sequences, and the 
human inhibitory serpins protease nexin-1 (PN-1) and antithrombin III (AT III), and noninhibitory serpins 
Chapter 2 
 28 
angiotensinogen (AGT) and pigment epithelium-derived factor (PEDF). Residues conserved in three or more 
species are white on a black background and conservative amino acid changes are depicted black on a dark grey 
background. The amino acids are numbered P17–P5’, which corresponds to the nomenclature of Schechter and 
Berger (25). The cleavage site between the P1 and P1’ residues is indicated with an arrow.  
 
 
laevis ~35 million years ago (24). Since the magnitude of sequence identity observed 
between the two Xenopus neuroserpin proteins (95%) is similar to those found for the other 
Xenopus protein pairs (92-95%), it is likely that the two Xenopus neuroserpins do not 
correspond to allelic variants but rather that they are also the result of the genome 
duplication. On the basis of its homology with other serpins, we have annotated the reactive 
center loop (RCL) of Xenopus neuroserpin as the segment ranging from Glu 346 to Tyr 367 
(underlined in Fig. 1A). The amino acids flanking the scissile bond of an RCL are generally 
denoted P1 and P1’, and adjacent amino acid residues in the amino-terminal and carboxy-
terminal directions are numbered P2, P3, P4, etc. and P2’, P3’, P4’, etc., respectively (25). 
The RCL of Xenopus neuroserpin is highly similar to that of the mammalian and chicken 
neuroserpin sequences and differed only by two P residues (a serine at position P9 and an 
asparagine at position P3; Fig. 1B). This is consistent with a function for Xenopus 
neuroserpin as an inhibitory serpin, since noninhibitory serpins show sequence divergence 
from inhibitory serpins, especially in the P12-P9 residues of the hinge region. More 
specifically, inhibitory serpins, such as neuroserpin, protease-nexin 1 (PN-1) and 
antithrombin III (AT III), contain alanines at positions P12-P9 in >50% of the cases, 
whereas noninhibitory serpins, such as angiotensinogen (AGT) and  pigment epithelium-
derived factor (PEDF), lack this consensus sequence (2) (Fig. 1B). The reactive site P1 
residue in the neuroserpin proteins in all species examined is an arginine, suggesting tha 
neuroserpin inhibits trypsin-like serine proteases, similar to PN-1 and AT III that also have 
an arginine at the P1 position. In contrast, the region around the P1 site of the Drosophila 
Spn4.1 protein consists of the basic amino acids arginine (P3)-arginine (P2)-lysine (P1)-
arginine (P1’), which suggests that Spn4.1 targets serine proteases with a basic recognition 
site. This prediction was confirmed by several groups that have found in vitro complex 
formation of Spn4.1 with furin, a member of the family of subtilisin-like proprotein 
convertases, with a consensus arginine (P4) - X (P3) - arginine/lysine (P2) - arginine (P1) 
cleavage site (18, 26, 27). 
 
Neuroserpin mRNA and protein expression during Xenopus development 
We then investigated the expression of neuroserpin mRNA and protein during the 
development of Xenopus laevis up to stage 47 (staging of embryos according to 28). Using 
semi quantitative RT-PCR to analyse the two Xenopus neuroserpin gene transcripts, we 
found expression of neuroserpin mRNA throughout development (Fig. 2A). More 
specifically, neuroserpin mRNA was already expressed at relatively high levels during all 
stages of oocyte development (stages I-VI), indicating that it was present maternally. 
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Figure 2: Neuroserpin mRNA and protein expression during Xenopus development 
(A) Neuroserpin (NS) mRNA levels were measured with RT-PCR in three stages of oocyte development (stages I-
II, III-IV and V-VI) and several stages of tadpole development. Glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) and ornithine decarboxylase (ODC) mRNA expression were used as internal controls for RNA isolation 
and cDNA synthesis (32, 33). The results shown are a representative of two independent experiments. (B) NS 
protein expression in various developmental stages was examined by Western blotting using the anti-neuroserpin 
antibodies α-NS-L and α-NS-M. Analysis of tubulin protein expression served as a control for the loaded amount 
of protein. The asterisk indicates a non-specifically bound immunoreactive product. (C) Relative expression of 55-
kDa neuroserpin in brain, remaining tissue of the head and tail of stage 49/50 embryos. Values of 55-kDa 
neuroserpin expression were normalized to tubulin protein levels and are expressed in arbitrary units (a.u.) ± SEM. 
Significant differences are indicated by asterisks (** for p<0.01 and *** for p<0.001; n=4).  
 
  
 In addition, expression of the neuroserpin protein was examined in various 
developmental stages. After western blotting using two different anti-neuroserpin antisera 
(α-NS-L and α-NS-M), we detected with both antibodies a specific neuroserpin product of 
~55-kDa in all stages examined (Fig. 2B). At developmental stage 49/50, 55-kDa 
neuroserpin was more abundantly expressed in brain tissue than in the remaining tissue of 
the head (two-fold lower) or tail (three-fold lower) of the tadpole (Fig. 2C), suggesting that 
during development expression of neuroserpin is restricted to neuronal tissue. In an attempt 
to clarify the function of neuroserpin during Xenopus development, we injected Xenopus 
fertilized eggs in the one-cell stage with Xenopus neuroserpin RNA. This resulted in an 
overexpression of the Xenopus neuroserpin protein, but no abnormal phenotype of the 
injected embryos was observed (data not shown). 
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Tissue distribution of neuroserpin mRNA and protein in adult Xenopus laevis 
Next, we performed RT-PCR analysis to examine neuroserpin mRNA expression in various 
tissues of adult Xenopus laevis. Relatively high expression of neuroserpin mRNA was 
found in brain, testis, oviduct and oocytes. Neuroserpin mRNA was moderately expressed 
in liver, spleen, kidney, lung and heart, whereas weak to no expression was found in 
stomach, intestine, gall bladder, bladder and skeletal muscle (Fig. 3A). Neuroserpin protein 
expression was examined by Western blotting using the two anti-neuroserpin antisera α-
NS-L and α-NS-M, and a specific product with a molecular weight of ~55 kDa was 
detected only in brain (Fig. 3B and data not shown).  
 
 
 
Figure 3: Neuroserpin mRNA and protein expression in various Xenopus tissues 
(A) Neuroserpin (NS) mRNA levels were examined in various Xenopus tissues by RT-PCR. Analysis of 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA expression served as a control. The results shown 
are a representative of two independent experiments. (B) NS protein expression in various adult Xenopus tissues 
was examined by Western blotting using the anti-neuroserpin antibody α-NS-L. Analysis of GAPDH protein 
expression was used as a control for the loaded amount of protein. The asterisks indicate non-specifically bound 
products. 
 
 
Neuroserpin mRNA and protein expression in Xenopus pituitary 
Finally, we examined in more detail the expression of neuroserpin mRNA and protein in a 
neuroendocrine tissue, namely in Xenopus pituitary. Using RT-PCR we found a three-fold 
higher expression of neuroserpin mRNA in the NIL compared with the PD (Fig. 4A, B). 
Neuroserpin protein expression in the two parts of the pituitary (NIL and PD) and in brain 
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was analyzed by Western blotting using the anti-neuroserpin antibodies α-NS-L and α-NS-
M. In the NIL, we found a major product of ~55 kDa that was expressed in lower amounts 
in the PD. This product corresponded to the main neuroserpin protein detected in brain 
(Figs. 3B and 4C). In addition, neuroserpin products of ~44 and ~50 kDa were found in the 
NIL, and a ~46-kDa product was detected in the PD (Fig. 4C). 
 
 
 
 
Figure 4: Neuroserpin mRNA and protein expression in Xenopus pituitary 
(A) Neuroserpin (NS) mRNA levels were examined in the pituitary neurointermediate lobe (NIL) and pars distalis 
(PD) by RT-PCR. Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA expression was measured as a 
control. The results are a representative of four independent experiments. (B) Quantification of relative amounts of 
NS mRNA in the NIL and PD. Values were normalized to GAPDH mRNA levels and expressed as means in 
arbitrary units (a.u.) ± SEM. A significant difference is indicated with two asterisks (p<0.01; n=4). (C) NS protein 
expression in the NIL and PD of the pituitary, and in brain tissue was detected by Western blotting using two 
different polyclonal anti-neuroserpin antisera (anti-NS-L and anti-NS-M). Analysis of tubulin protein expression 
was used as a control for the loaded amount of protein. 
 
 
To study the localization of neuroserpin protein in the pituitary, cryosections were 
made and neuroserpin was detected using anti-neuroserpin antibody α-NS-L. We found 
expression of neuroserpin in the PN, PI and in parts of the PD (Fig. 5A). More specifically, 
in the PN neuroserpin protein was found in fibre-like structures, whereas in the PI the 
protein was localized in vesicle-like structures throughout the melanotrope cells (Fig. 5B).  
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Figure 5: Localization of neuroserpin protein in Xenopus pituitary cells 
(A) Cryosections were made of part of Xenopus brain (Br), and the pars nervosa (PN), pars intermedia (PI) and 
pars distalis (PD) of the pituitary. Neuroserpin protein was detected using anti-neuroserpin antibody α-NS-L. The 
white arrows indicate neuroserpin-positive regions in the PD and the area enclosed by the white box is enlarged in 
B. Scale bar = 200 μm. (B) Closer inspection of neuroserpin protein expression in the PN and PI of the pituitary, 
using confocal scanning laser microscopy. Scale bar = 10 μm. 
 
 
Discussion 
 
Serpins are important regulators of intra- and extracellular proteolysis by serine proteases. 
Neuroserpin represents a recently identified serpin family member, which is expressed 
primarily in neuronal and neuroendocrine tissues. Thus far, several roles for neuroserpin 
have been proposed, among which an involvement in neuronal plasticity and learning (10), 
neuronal cell survival (12), neurite outgrowth, and intercellular communication in mature 
neuroendocrine tissues by the regulation of cell adhesion (29). 
In this study, we identified two Xenopus laevis neuroserpin cDNAs. It is likely that 
the two sequences represent products derived from two Xenopus neuroserpin-A and -B 
genes, since Xenopus is a tetraploid species as a result of a whole-genome duplication that 
occurred ~35 million years ago (24). Comparative analysis of the deduced Xenopus 
neuroserpin amino acid sequences with known mammalian and chicken neuroserpin and 
Drosophila Spn4.1 sequences revealed that the neuroserpin RCL comprises one of the most 
conserved regions. Since the RCL is an important domain of serpins responsible for target 
specificity, this high degree of sequence identity implies a possible conservation of the 
target of neuroserpin in Xenopus. Thus far, the target for neuroserpin is elusive, but several 
(trypsin-like) proteases  have been suggested, of which t-PA is considered a likely  target 
(6, 11, 12). In contrast, the Drosophila Spn4.1 sequence has a stretch of basic amino acids 
in its RCL which constitutes a recognition sequence for subtilisin-like proprotein 
convertases, and binding of the proprotein convertase furin to Drosophila Spn4.1 has 
indeed recently been described (18, 26, 27). 
 Neuroserpin is expressed during development, and in mouse embryos and human 
foetal tissues mRNA expression was detected mainly in the nervous system (6, 10). We 
found that neuroserpin mRNA and protein were expressed throughout Xenopus 
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development, and that neuroserpin protein expression became restricted to brain tissue. 
Interestingly, we detected neuroserpin mRNA already in all stages of oocyte development, 
indicating that this mRNA is maternally derived. We could not attribute a clear function to 
neuroserpin during early Xenopus development, since neuroserpin RNA micro-injections 
did not result in a change of phenotype of the developing embryos. 
Neuroserpin mRNA expression was also detected in almost all Xenopus tissues 
examined, with relatively high expression in brain, pituitary and the reproductive organs, 
moderate expression in liver, kidney, lung, and heart, and weak to no expression in 
stomach, intestine, gall bladder, spleen, bladder and skeletal muscle. In mouse and human, 
neuroserpin mRNA was predominantly expressed in neuronal tissues and weak expression 
has been found in heart, kidney, testis and pancreas (6, 7, 10). In these studies with 
mammalian tissues, Northern blot analysis was used to detect neuroserpin mRNA, whereas 
we measured mRNA levels with the more sensitive technique of RT-PCR. This could 
explain why in Xenopus we found a broader tissue distribution of neuroserpin mRNA than 
has been reported for mouse and human. At the protein level, neuroserpin was detected 
predominantly in Xenopus brain and pituitary tissue, in line with findings in mouse and rat 
(6, 8). 
We examined the expression of neuroserpin protein in the Xenopus pituitary in 
more detail. A main neuroserpin product of 55 kDa was detected in nerve fibers of the PN 
and in brain, indicating that it likely represents a neuronal form of neuroserpin. 
Furthermore, we found differently sized neuroserpin products in the NIL (44 and 50 kDa) 
compared with the PD (46 kDa). These data suggest that various forms of neuroserpin 
protein are expressed in different pituitary cell types. In rat pituitary, a number of forms of 
the protein have also been found in the PI and PD, with molecular weights of 55 and 53 
kDa, respectively (8). The multiple forms we detected in the Xenopus pituitary cell types 
probably represent post-translational modifications of the neuroserpin protein. Previously, 
we found that 44-kDa neuroserpin and the neuronal 55-kDa protein are non-N-linked-
glycosylated neuroserpins, whereas the 50-kDa protein has sugar groups attached at two 
asparagines (30). In addition, the 46-kDa form of neuroserpin, detected in the PD was also 
N-linked glycosylated (data not shown). 
 In the melanotrope cells of the pituitary PI, neuroserpin was present in vesicles, in 
line with findings of Hill et al. (8) who detected the neuroserpin protein in rat 
neurendocrine dense-cored secretory vesicles. Also in PC12 and AtT20 cell lines 
transfected with neuroserpin, the protein was localized in secretory granules (31). Proposed 
functions of neuroserpin in the pituitary include the regulation of intragranular proteases 
and, following regulated secretion, inhibition of enzymes regulating cell-extracellular 
matrix interactions (29). On the basis of results from studies on Drosophila Spn4.1, 
Osterwalder et al. (18) also suggested that neuroserpin, the closest vertebrate Spn4.1 
orthologue, might function intracellularly as a regulator of prohormone processing. 
However, unlike Spn4.1, neuroserpin lacks the di-basic amino acid recognition sequence 
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for proprotein convertases in its RCL and therefore it is unlikely that neuroserpin will 
inhibit prohormone convertases, such as furin. 
In conclusion, we identified neuroserpin in the amphibian Xenopus laevis and 
compared the deduced amino acid sequence with known mammalian and chicken 
neuroserpin and Drosophila Spn4.1 sequences. The high degree of sequence identity, 
especially in the RCL, suggests a conserved target specificity of the protein. Neuroserpin 
mRNA was expressed throughout Xenopus development and in a number of tissues in the 
adult animal, with high expression levels in neuronal and neuroendocrine tissues. 
Neuroserpin protein was also detected throughout development and in the adult animal 
mainly in brain and pituitary. Furthermore, we found expression of various forms of the 
neuroserpin protein in different pituitary cell types, namely a neuronal neuroserpin protein 
of 55 kDa in the nerve fibers of the PN, products of 44 and 50 kDa in vesicle-like structures 
in the neuroendocrine melanotrope cells of the PI, and a 46-kDa protein in distinct cell 
populations of the PD. Together, our results support an important role for neuroserpin 
during development and in neuronal and neuroendocrine cell functioning. 
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Abstract 
 
Inhibitors of serine proteases (serpins) are important regulators of intra- and extracellular 
proteolytic pathways, and they function by forming an irreversible complex with their 
substrate. Neuroserpin represents a neuroendocrine-specific serpin family member that is 
expressed in brain regions displaying synaptic plasticity. In this study, we explored the 
biosynthesis of endogenous neuroserpin in a neuroendocrine model system, namely the 
melanotrope cells of Xenopus intermediate pituitary. The biosynthetic activity of these cells 
can be physiologically manipulated (high and low production of the prohormone 
proopiomelanocortin [POMC] in black and white animals, respectively), resulting from a 
synaptic plasticity in innervating hypothalamic neurons. We found that neuroserpin was 
also differentially expressed in the Xenopus intermediate, but not anterior, pituitary with a 
three-fold higher mRNA- and >30-fold higher protein expression in the active versus the 
inactive melanotrope cells. Two newly synthesized glycosylated forms of the neuroserpin 
protein (47 and 50 kDa) were produced and secreted by the active cells. Intriguingly, 
neuroserpin was found in an ~130-kDa sodium dodecyl sulphate-stable complex in the 
active, but not in the inactive, melanotrope cells, which correlated with the high and low 
POMC expression levels, respectively. In conclusion, we report on the biosynthesis of 
neuroserpin in a physiological context, and we find that the induction of neuroserpin 
expression and the formation of the 130-kDa neuroserpin-containing complex are linked to 
neuroendocrine cell activation. 
 
Introduction 
 
Serine proteases, such as plasminogen activators, plasmin and thrombin, are known 
primarily for their role in blood coagulation and fibrinolysis. In addition, the proteolytic 
activity of these proteases is important for maintaining the integrity of the extracellular 
matrix (ECM). In the nervous system, serine proteases regulate plasticity in the developing 
as well as the mature brain (reviewed in 1, 2). For example, tissue-type plasminogen 
activator (t-PA) is expressed in the nervous system and has been implicated to play a role in 
synaptic plasticity and memory development (3, 4). Serine protease inhibitors (serpins) 
form a large family that can be found both intracellularly and extracellularly and regulates a 
number of physiological processes, such as coagulation, fibrinolysis, complement 
activation, angiogenesis and apoptosis. The primary function of most members is to 
neutralize intracellular and extracellular proteolytic pathways. One characteristic of the 
inhibitory serpin family members is the way in which they inhibit their substrate. Also 
known as suicide inhibitors, these serpins form sodium dodecyl sulphate (SDS)-stable 
complexes with their target protease, and complex formation is considered to be 
biologically irreversible (reviewed in 5). The rapid clearance of the serpin-protease 
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complex takes place by binding of the complex to its receptor and subsequent 
internalization (6, 7). 
Neuroserpin is a newly identified member of the serpin family primarily expressed 
in brain during late stages of development and during adulthood in regions that exhibit 
synaptic plasticity (8, 9). Furthermore, neuroserpin has been identified in neuroendocrine 
cells, e.g. in rat pituitary and adrenal glands (10). t-PA has been considered to be a target 
protease for neuroserpin (9, 11, 12), although gene-targeting of neuroserpin in mice has 
implicated the inhibitor as playing a role in the regulation of emotional behavior through a 
mechanism that is, at least in part, independent of t-PA activity (13). Like other serpin 
family members, neuroserpin undergoes a marked conformational transition to be able to 
function as an inhibitor. Inevitably, this delicate process also renders the molecule 
susceptible to point mutations. Five mutations in the neuroserpin gene have been described, 
and they indeed lead to polymerization and accumulation of the protein, resulting in 
neuronal inclusion bodies and subsequent neuronal degeneration. This process underlies the 
recently described autosomal-dominant dementia known as familial encephalopathy with 
neuroserpin inclusion bodies (FENIB) (14, 15; reviewed in 16). 
 Thus far, the biosynthesis of only transfected recombinant neuroserpin has been 
studied (17). In this study, we examined the expression and biosynthesis of endogenous 
neuroserpin in the neuroendocrine melanotrope cells of the intermediate pituitary of 
Xenopus laevis. The process of background adaptation of this amphibian provides the 
opportunity to manipulate in a physiological way, in vivo, the activity of the melanotrope 
cells as well as their regulatory neuronal input. In animals adapted to a black background, 
the melanotrope cells are very active and produce vast amounts of the prohormone 
proopiomelanocortin (POMC), which is processed to a number of bioactive peptides, 
including α-melanophore-stimulating hormone (α-MSH). This hormone causes pigment 
dispersion in skin melanophores, giving the animal a black appearance. In white-
background-adapted animals, the activity of the melanotrope cells is inhibited by neurons 
originating from the hypothalamic suprachiasmatic nucleus, which make direct synaptic 
contacts with the melanotrope cells. Thus, manipulation of melanotrope cell activity is 
accompanied by differences in synaptic plasticity (reviewed in 18). Here we find that 
neuroserpin mRNA and protein expression are also induced in the biosynthetically active 
melanotrope cells from black-adapted animals compared with the inactive cells of white 
animals. Neuroserpin was synthesized as a 47-/50-kDa protein and formed, presumably 
with its substrate, a stable ~130-kDa complex, the formation of which was dependent on 
the color of the background of the animal and thus the melanotrope cell activity. 
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Materials and Methods 
 
Animals  
South African claw-toed frogs, Xenopus laevis, were reared in the Central Animal Facility 
of the Radboud University of Nijmegen, The Netherlands. The animals were adapted to 
their background by keeping them in either white or black buckets for at least three weeks 
at 22°C, with a light/dark cycle of 12 h. Experimental procedures were performed under the 
guidelines of the Dutch law concerning animal welfare. 
 
Antibodies  
Four anti-neuroserpin antibodies were used: mouse monoclonal IgG and rabbit polyclonal 
IgG against human recombinant neuroserpin (mα-NS and α-NS-L, respectively; generous 
gifts of D.A. Lawrence, American Red Cross Holland Laboratory, Rockville, Maryland, 
USA; 19), rabbit polyclonal IgG against human recombinant neuroserpin (α-NS-M, 
generous gift of D. Lomas, University of Cambridge, Cambridge, UK; 17), and rabbit 
polyclonal IgG directed against the C-terminal region of rat neuroserpin 
(CGRVMHPETMNTSGHDFEEL; α-NS-PEP) (generous gift of N. Birch, University of 
Auckland, New Zealand; 10). The dilutions used were 1:400 (α-NS-L) and 1:300 (mα-NS 
and α-NS-PEP) for immunoprecipitation and 1:5,000 (α-NS-L), 1:2,500 (mα-NS) and 
1:10,000 (α-NS-M) for Western blotting. Tubulin, POMC and p24δ2 were identified on 
Western blots using a monoclonal anti-tubulin antibody (1:1,500) (generous gift of Dr. J. 
Fransen, Radboud University, Nijmegen, The Netherlands; 20), a polyclonal anti-POMC 
antibody (1:20,000) (ST62; generous gift of Dr. S. Tanaka, Shizuoka University, Shizuoka, 
Japan; 21) and the polyclonal anti-p24δ1/2 antibody 1262CH (1:5,000) (as described 
previously in 22), respectively. 
 
Separation of Xenopus pars nervosa and intermediate pituitary  
To compare neuroserpin protein expression in the pars nervosa with that in the intermediate 
pituitary, the two lobes were separated. To isolate the melanotrope cells from the 
neurointermediate lobe (NIL), NILs were dissected, washed several times in sterile 
Xenopus XL15 (10 mM glucose, 2 mM CaCl2, 1% kanamycin (Life Technologies, Inc.), 
1% antibiotic/antimycotic (Life Technologies, Inc.) in 67% Leibovitz’s-15 medium (Life 
Technologies, Inc.) and transferred to XL15 containing 0.25% (wt/vol) trypsin. After 
incubating for 45 min at 20°C, XL15 was added and the lobes were suspended by seven 
passages through a siliconized Pasteur’s pipet. The cell suspension was transferred to a 
syringe and filtered through a nylon filter (pore size 60 μm). Finally, the melanotrope cells 
were collected by centrifugation (10 min at 6000 rpm) and the remaining pars nervosa was 
collected from the filter. Alternatively, the pars nervosa and intermediate pituitary were 
separated by dissection under a microscope. After separation, homogenates of cells and 
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lobes were made in lysis buffer (250 mM sucrose, 1% Triton X-100, 10 mM TrisCl, 1 mM 
EDTA (pH7.4), 1μM phenylmethylsulfonyl fluoride (PMSF), 0.1 mg/ml soybean trypsin 
inhibitor) using a glass homogenizer. After 20 min incubation on ice, the samples were 
centrifuged for 20 min (153,000 rpm, 4°C). Sample buffer (50 mM TrisCl (pH6.8), 100 
mM dithiothreitol (DTT), 2% SDS, 0.1% bromephenol blue, 10% glycerol) was added to 
the supernatant, and the samples were heated for 30 min at 37°C. 
 
Western blotting  
Homogenates of the NIL, the pars nervosa, intermediate pituitary, and isolated melanotrope 
cells were prepared as described above. Samples (corresponding to 25-33% of one NIL) 
were separated on a 10% SDS-polyacrylamide gel and transferred to polyvinylidene 
difluoride membrane (PVDF) membrane (0.45 μM Hybond-P, Amersham Pharmacia 
Biotech) using a BioRad (Hercules, CA) mini-protean II cell system. Molecular weight 
markers were run alongside the samples to be analyzed. For immunodetection, blots were 
washed one time in PBS and incubated for at least 1h in blocking buffer (5% skimmed milk 
and 1% Tween 20 in PBS). Subsequently, blots were incubated with primary antiserum in 
blocking buffer for 16 h (4°C). After three rinses in wash buffer (1% skimmed milk and 1% 
Tween 20 in PBS), blots were incubated in horseradish peroxidase (HRP)-conjugated goat-
anti-rabbit or mouse IgG (1:5,000) for 1 h. After three rinses in wash buffer and one rinse in 
PBS, the proteins were visualized by incubating blots in Lumi-LightPLUS Western blotting 
substrate (Roche Diagnostics, Manheim, Germany) and by subsequent exposure to X-ray 
film (Eastman Kodak, Rochester, NY). For quantification of relative neuroserpin protein 
levels in black- compared with white-adapted animals, detection was performed using a 
BioChemi imaging system (UVP, Inc., Upland, CA) and signals were analyzed using 
LabWorks 4.0 software (UVP BioImaging systems, UVP, Inc., Cambridge, UK). Total 
densities of 44-, 47-/50- and 55-kDa neuroserpin products were normalized to the 
corresponding tubulin samples (n = 3). Subsequently, the values found for 44-kDa 
neuroserpin in white-adapted animals were set at 1, and relative protein levels of 44-, 47-
/50- and 55-kDa neurserpin were calculated. The mean differences of 44- and 47-/50-kDa 
neuroserpin were plotted in a graph and a paired t test was used for statistical analysis. 
 
Metabolic cell labeling and immunoprecipitation  
For metabolic cell labeling, NILs of black-adapted Xenopus were rapidly dissected and 
preincubated in Ringer’s medium (112 mM NaCl, 15 mM Hepes pH 7.4, 2 mM KCl, 2 mM 
CaCl2, 2 mg/ml glucose and 0.3 mg/ml BSA) for 15 min at 22°C. Radioactive labeling of 
newly synthesized proteins was performed by incubating the NILs in Ringer’s medium 
containing 5 mCi/ml Tran35S label (ICN Radiochemicals, Irvine, CA) for 30 or 90 min at 
22°C. After the pulse labeling, NILs were rinsed in Ringer’s medium and, in case a chase 
was performed, incubated in Ringer’s medium supplemented with 0.5 mM L-methionine 
for 150 min at 22°C. Subsequently, lysates were prepared as described above. 
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Immunoprecipitation was performed in TTD buffer (50 mM HEPES, 140 mM NaCl, 0.1% 
Triton-X100, 1% Tween-20, 1 mM EDTA, 1 mg/ml deoxycholate (DOC), 1 μM PMSF, 0.1 
mg/ml soybean trypsin inhibitor) supplemented with SDS (final concentration of 0.075%) 
and antiserum. After overnight rotation at 4°C, immune complexes were precipitated with 
protein A-sepharose (Amersham-Pharmacia Biotech), washed four times with TTD buffer 
and analyzed on a 10% SDS-polyacrylamide gel. 
 
N-glycosidase F treatment  
For protein deglycosylation, N-glycosidase F (which cleaves N-linked sugar chains from 
proteins) was used. The NIL lysates were boiled for 10 min in 6 mM HEPES (pH7.4) 
containing 0.06% SDS and subsequently supplemented with 0.5% Nonidet P-40, 10 μg/ml 
soybean trypsin inhibitor, and 0.1 μM PMSF, and incubated with or without 40 mU/ml N-
glycosidase F (Roche Diagnostics) for 1.5 h at 37°C.  
 
Two-dimensional gel electrophoresis and protein analysis  
For two-dimensional gel electrophoretic analysis, NILs were dissected and the tissues were 
homogenized using a glass potter in 40 mM Tris base (pH9.5) and 10 mM Pefablock 
(Roche). Proteins were trichloroacetic acid precipitated, air-dried, and dissolved in lysis 
buffer (7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), 1% DTT and 0.8% IPGphor buffer (pH3-10; Amersham-
Bioscience, Little Chalfont, Buckinghamshire, UK). The samples were separated by 
isoelectric point (pI) (pH3-10 gradient in the first dimension) and subsequently by 
molecular weight on 10% SDS-PAGE. Neuroserpin products were then identified by 
Western blotting using the α-NS-L antibody. Protein spots were analyzed using matrix-
assisted laser desorption ionization-time-of-flight-mass spectrometry (MALDI-TOF MS) 
and liquid chromatography-electrospray ionization mass spectrometry (LC/ESI-MS) as 
described previously (23). 
 
Real-time quantitative RT-PCR analysis  
The NIL and anterior lobe (AL) of the pituitary of black- and white-adapted Xenopus were 
dissected collected in Trizol (Life Technologies, Inc.) and total RNA was isolated 
according to the manufacturer’s instructions. The RNA was then dissolved in 20 µl RNase-
free H2O and the concentration was measured with a GeneQuant RNA/DNA calculator 
(Biochem Ltd., Cambridge, UK). One μg total RNA was reverse transcribed; first-strand 
cDNA synthesis was performed using 11 µl RNA and 1 µl pd(N)6 (random primers, 5 
mU/µl, Roche) at 70°C for 10 min, followed by double-strand synthesis in 20 µl strand 
buffer (Life Technologies, Inc.) with 10 mM DTT, 20 U RNAsin (Promega, Madison, WI), 
0.5 mM dNTPs (Roche), and 100 U reverse transcriptase (SuperScript II, Life 
Technologies, Inc.) at 37°C for 90 min. Samples were diluted five times in RNase-free H2O 
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and subjected to real-time quantitative RT-PCR on a 5700 GeneAmp PCR system (PE 
Applied Biosystems, Wellesley, MA) as follows: 5 µl template cDNA was added to 20 µl 
SYBR green buffer (PE Applied Biosystems) with 3 mM MgCl2, 0.2 m dNTPs (PE Applied 
Biosystems), 0.6 µM of each primer, and 0.625 U AmpliTaq gold (PE Applied 
Biosystems). To amplify the neuroserpin nucleotide sequence, the forward primer 5’-
ATTGAAAGCCCATTTGATTGAAG -3’ and reverse primer 5’-TCAAGACCTCCTTTAGGTTCACTAC-
TT -3’ were used and for glyceraldehydes-3-phosphate dehydrogenase (GAPDH) the 
primers 5’-GCCGTGTATGTGGTGGAATCT-3’ and 5’-AAGTTGTCGTTGATGACCTTTGC-3’, 
respectively. PCR conditions were 95°C for 10 min followed by 40 reaction cycles of 95°C 
for 15 sec, and 60°C for 1 min each. For each reaction, the cycle threshold (Ct) was 
determined, i.e. the cycle number at which fluorescence was detected above an arbitrary 
threshold (0.5). At this threshold, Ct values were within the exponential phase of the 
amplification. Ct values for neuroserpin mRNAs in lobes from black- vs. white-adapted 
animals were normalized to that of the internal standard (GADPH) mRNA. To examine the 
length of the amplified DNA, the reaction products were run on a 2.5% agarose gel and 
visualized with ethidium bromide. 
 
Results 
 
Neuroserpin mRNA and protein expression in the pituitary of black- and white-
adapted Xenopus 
We used quantitative RT-PCR to examine neuroserpin mRNA expression in the NIL and 
the AL of the pituitary of black- and white-adapted Xenopus. Neuroserpin mRNA was 
detected in both lobes of the pituitary. A three-fold higher level of neuroserpin mRNA was 
found in the NIL of black-adapted animals than in that of white-adapted animals (3.2 ± 1.1-
fold induction, n=6). Neuroserpin mRNA levels were not significantly different in the ALs 
of black and white animals (Fig. 1). Thus, neuroserpin mRNA expression was up-regulated 
specifically in the biosynthetically active Xenopus melanotrope cells. 
 
 
 
Figure 1: Neuroserpin mRNA levels in the neurointermediate 
and anterior pituitary of black- and white-adapted Xenopus.  
Neuroserpin mRNA levels in the neurointermediate lobe (NIL) and 
the anterior lobe (AL) of the pituitary of black-adapted (BA; black 
bars) compared to those in white-adapted (WA; grey bars) animals 
were measured by quantitative RT-PCR. All values were 
normalized to GAPDH mRNA levels and are expressed as means ± 
SEM. A significant difference is indicated by an asterisk (p<0.05). 
 
 
 
Chapter 3 
 44 
Western blot analysis with a number of anti-neuroserpin antibodies (α-NS-L, α-
NS-M, α-NS-PEP and mα-NS) was performed to study the steady-state neuroserpin protein 
levels in the NILs of black- and white-adapted Xenopus. In NIL lysates of black-adapted 
animals, we detected with α-NS-L, α-NS-M and mα-NS expression of ~44-, ~47-/50- and 
~55-kDa neuroserpin proteins. Furthermore, using the two polyclonal anti-neuroserpin 
antisera α-NS-L and α-NS-M, an immunoreactive product of ~130 kDa was found (Fig 
2A); the three additional products of ~57-, ~60- and ~70 kDa are considered to be 
nonspecifically interacting products, as in each case they were recognized by only one of 
the two antibodies (Fig 2A, asterisks). The NS-PEP antibody was not appropriate for 
Western blot analysis, and the fact that the 130-kDa product was not detected with the 
monoclonal antibody mα-NS was due presumably to epitope masking. Using α-NS-L, α-
NS-M and mα-NS for analysis of NILs of white-adapted animals, only the 44-, 47-/50- and 
55-kDa proteins, but not the 130-kDa product, were found (Fig. 2A). At least a 30-fold 
higher level of expression of the 130-kDa neuroserpin-containing product was detected in 
the active melanotrope cells of black-adapted animals, compared with the inactive cells of 
white animals. The 44-kDa neuroserpin protein was up-regulated three-fold in the NIL of 
black- compared with white-adapted animals (2.8 ± 0.3-fold induction, n=3), whereas 47-
/50- and 55-kDa neuroserpin expression did not differ significantly (Fig. 2B and data not 
shown). 
 
The 130-kDa neuroserpin-containing complex is expressed in Xenopus intermediate 
pituitary cells  
Because the NIL consists of the intermediate pituitary (the neuroendocrine melanotrope 
cells) and the pars nervosa (endings of neurons originating from the hypothalamus), we 
decided to study the site of neuroserpin protein expression in the Xenopus NIL in more 
detail. For this purpose, we separated the pars nervosa from the intermediate pituitary cells 
using two different strategies. First, the pars nervosa and intermediate pituitary were 
physically separated by dissection under a microscope. In a second approach, the 
melanotrope cells of the intermediate pituitary were isolated from the NIL by trypsin 
treatment; the remaining tissue after this treatment consisted mainly of the pars nervosa. 
Remarkably, we found that 55-kDa neuroserpin was expressed exclusively in the pars 
nervosa from black- and white-adapted Xenopus (Fig. 2C), whereas 47-/50-kDa 
neuroserpin and the 130-kDa complex were present in the melanotrope cells of the 
intermediate pituitary in black-adapted animals (Fig. 2C, upper panel). In the NIL of white-
adapted animals, 47-/50-kDa neuroserpin expression levels were below the detection limit. 
The low amount of the 130-kDa product found in the pars nervosa following dissection or 
trypsin treatment probably originated from residual intermediate pituitary melanotrope 
cells, caused by incomplete separation of the two parts of the pituitary. The observed 
differences in the ratios between the 130-kDa complex and 55-kDa neuroserpin in the 
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NIL(e.g. Figs. 2A and 2D) were therefore probably caused by variations in tissue dissection 
(especially concerning the amount of pars nervosa tissue). 
We next wanted to investigate whether neuroserpin is glycosylated in the Xenopus 
NIL. After N-glycosidase-F treatment of a NIL lysate, the migrations of the 130-kDa 
product and 47-/50-kDa neuroserpin shifted to products of ~115 kDa and ~44 kDa, 
respectively, whereas the migration of 55-kDa neuroserpin was not affected (Fig. 2D). This 
finding indicates that only the 130-kDa product and 47-/50-kDa neuroserpin are N-linked 
glycosylated. 
 
Biosynthesis and post-translational modification of neuroserpin in the Xenopus 
neurointermediate pituitary  
Pulse metabolic cell labeling of the Xenopus NIL for 30 or 90 min and subsequent 
immunoprecipitation analysis of the newly synthesized proteins with three anti-neuroserpin 
antisera (α-NS-L, NS-PEP, and mα-NS) revealed the production of two newly synthesized 
neuroserpin proteins with molecular weights of ~47- and ~50 kDa (Fig. 3A and data not 
shown). Following a 2.5-h chase period, the newly synthesized neuroserpins were secreted 
into the incubation medium as products with slightly higher molecular weights (~48- and 
~51 kDa) than the two neuroserpin products in the cells (Fig. 3B). Treatment of the 
immunoprecipitated newly synthesized neuroserpins with N-Glycosidase-F gave an ~44-
kDa product in both the cells and the medium, indicating that the 47- and 50-kDa 
neuroserpins and the two secreted forms are N-linked glycosylated (presumably on one 
residue in the 47-/48-kDa and two in the 50-/51-kDa forms) (Fig. 3C). The observed 
differences in molecular weights between the neuroserpins produced in the cells and 
secreted into the medium may thus be due to a modification of the N-linked sugar groups. 
After a 2.5-h chase period, but not after a 1-h pulse labeling, a product of ~130 kDa was 
immunoprecipitated from the cell lysates, suggesting that this product may represent a 
complex of newly synthesized neuroserpin with another protein and that this complex is not 
formed immediately after neuroserpin synthesis; we did not detect this complex in the 
media (Fig. 3C). Because treatment of the immunoprecipitate with N-glycosidase-F 
resulted in a shift of the newly-synthesized 130-kDa to an ~115-kDa product, the complex 
was N-linked glycosylated (Fig. 3C), in line with the western blot results (Fig. 2D).  
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Figure 2: Neuroserpin protein levels in the neurointermediate pituitary of black- and white-adapted 
Xenopus.  
(A) Lysates of neurointermediate lobes (NILs) of black- and white-adapted frogs (BA and WA, respectively) were 
separated by SDS-PAGE. After Western blotting, neuroserpin (NS) was identified using the polyclonal anti-
neuroserpin antisera α-NS-L and α-NS-M and the monoclonal anti-neuroserpin antibody mα-NS. Tubulin was 
used as a control for loading equal amounts of protein. Nonspecifically bound proteins are indicated with asterisks. 
(B) Quantification of 44- and 47-/50-kDa neuroserpin (NS) protein expression in NILs of BA and WA animals 
relative to 44-kDa neuroserpin expression in WA animals, which was set at 1. Values were normalized to tubulin 
protein levels and expressed as mean differences ± SEM. A significant difference is indicated by an asterisk 
(p<0.05). (C) The 130-kDa complex is expressed in the melanotrope cells of the intermediate pituitary of black-
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adapted Xenopus. Melanotrope cells of the intermediate pituitary were isolated from the neurointermediate lobe 
(NIL) of BA and WA animals by either dissection of the pars intermedia (PI) tissue from the pars nervosa (PN) 
(dissected) or trypsin treatment of the NIL tissue (enzymatic). Extracts of PI- and PN-tissues were separated on 
10% SDS-PAGE and subjected to Western blot analysis with anti-neuroserpin antibody α-NS-L. Nonspecifically 
interacting proteins are indicated with asterisks. (D) NIL lysate of BA animals was treated with N-glycosidase F 
and subsequently subjected to SDS-PAGE and immunoblotting with α-NS-L. 
 
 
 
Figure 3: Biosynthesis and release of neuroserpin by the intermediate pituitary cells of Xenopus.  
(A) Neurointermediate lobes (NILs) were pulse labeled for 90 min. Cell lysates were directly analysed on SDS-
PAGE (total, representing 5% of the total cell lysate) or immunoprecipitated using the anti-neuroserpin antibodies 
α-NS-L, α-NS-PEP, or mα-NS, followed by resolving the immunoprecipitates with SDS-PAGE. When using mα-
NS in the immunoprecipitation, a number of newly synthesized proteins, such as the proform of the prohormone 
convertase PC2 (proPC2) and POMC bound nonspecifically to the antibody (asterisks). (B) NILs were pulse 
labeled for 90 min and chased for 2.5 h, and the cell lysate (c) and incubation medium (m) were directly analyzed 
on SDS-PAGE (totals, representing 5% of the total cell lysate and 20% of the incubation medium, respectively) or 
immunoprecipitated using α-NS-L, α-NS-PEP, or mα-NS, followed by SDS-PAGE. The secreted neuroserpin 
(NS) proteins and nonspecifically bound proteins are indicated with arrow heads and asterisks, respectively. (C) 
NILs were pulse labeled for 60 min or pulse labeled for 60 min and chased for 2.5 h. Cell lysates and media were 
treated with N-glycosidase F before immunoprecipitation and subsequent SDS-PAGE. The abbreviations used are: 
NS, neuroserpin; proPC2, pro-prohormone convertase 2; POMC, proopiomelanocortin; deg., deglycosylated. 
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The 130-kDa neuroserpin-containing complex is acidic  
Because of the striking characteristics of the 130-kDa neuroserpin-containing product 
(difference in expression levels in the NILs of black- and white-adapted Xenopus, and the 
newly synthesized 130-kDa product is not formed in the first hour of chase) we were 
interested in the nature of this high-molecular weight product. In view of its size, it is not 
likely that the 130-kDa product would simply represent a multimerization of the 47-/50-
kDa neuroserpin. One feature of serpins is their unusually strong binding to their substrate 
(reviewed in 24). We hypothesized that the 130-kDa product might be an SDS-stable 
complex of neuroserpin with a serine protease such as t-PA, urokinase-type plasminogen 
activator (u-PA), plasmin, or thrombin, since these four proteins have been found to be in 
vitro substrates for neuroserpin (19, 9, 11). These potential substrates are basic proteins 
with a calculated pI of ~8.2, ~8.8, ~7.2, and ~7.3, respectively. To estimate the pI of the 
130-kDa neuroserpin-containing complex in the NIL, two-dimensional gel electrophoresis 
of NIL protein extracts combined with immuodetection of neuroserpin was performed. We 
found that, in line with the calculated pI of Xenopus neuroserpin (pI 5.4), 47-/50-kDa 
neuroserpin, 55-kDa neuroserpin, and the 130-kDa complex are acidic products with a pI of 
~5.6, ~5.2, and ~5.3, respectively (Fig. 4), indicating that the 130-kDa neuroserpin-
containing complex displays a pI similar to that of neuroserpin itself. This observation 
implies that the binding partner of neuroserpin in the 130-kDa complex is also an acidic 
protein and makes it unlikely that, in the intermediate pituitary of black-adapted Xenopus, 
this complex is formed by binding of neuroserpin to the basic proteins t-PA, u-PA, plasmin, 
or thrombin. 
 
 
 
Figure 4: Neuroserpin and the neuroserpin-containing 
complex are acidic in the neurointermediate pituitary of 
Xenopus.  
Two-dimensional gel electrophoresis (pH gradient in the 
first dimension and SDS-PAGE in the second dimension) 
of a lysate of the neurointermediate lobe of black-adapted 
Xenopus followed by Western blot analysis with anti-
neuroserpin antibody α-NS-L.  
 
 
  
 In an attempt to identify the substrate of neuroserpin in the 130-kDa complex, we 
separated NIL proteins by two-dimensional gel electrophoresis, recovered a number of 
protein spots from the region in which the 130-kDa complex migrated, and analyzed the 
spots by MALDI-TOF-MS or by directly combined LC/ESI-MS. Unfortunately, the protein 
amounts were below the detection limit (data not shown), presumably due to the low 
expression level of the complex.  
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Dynamics in the expression of the 130-kDa complex in the intermediate pituitary 
during background adaptation of Xenopus  
An interesting characteristic of Xenopus laevis is its ability to adapt its skin color to its 
background. The process of background adaptation is mediated by α-MSH, a cleavage 
product of POMC that is produced at high levels in the intermediate pituitary melanotrope 
cells of a black-adapted animal. Because of the clear differential expression of the 130-kDa 
neuroserpin-containing complex in the inactive and active melanotrope cells of white and 
black animals, respectively, we were interested in the time course of the formation of this 
complex during background adaptation. For this analysis, the expression of the 130-kDa 
complex in the NIL was examined in white animals adapting to a black background and 
vice versa for various time periods. In white animals adapting to a black background, we 
first detected the complex after five days of adaptation; its level gradually increased until 
maximum expression levels were reached after 21 days, similar to the level found in fully 
black-adapted animals (i.e. adapted to a black background for more than three weeks). The 
time course of expression of the 130-kDa complex was similar to that of POMC and the 
p24δ2 protein (a putative receptor for endoplasmic reticulum to Golgi cargo transport) with 
in each case a change of >30-fold (Fig. 5A). In black animals adapting to a white 
background, the expression levels of the 130-kDa complex dropped considerably already 
after one day of adaptation, followed by a slow decrease such that, after 16 days, the 
expression was not detectable anymore. In contrast, during this adaptation the levels of 
POMC and p24δ2 only decreased gradually (Fig. 5B). Thus, during adaptation to a white 
background, the time course of expression of the 130-kDa complex differed from those of 
POMC and p24δ2. 
 
 
 
Figure 5: Dynamics in the expression of the neuroserpin-containing complex in the intermediate pituitary 
during background adaptation of Xenopus.  
(A) Fully white-adapted (>21 days; WA) animals were adapted to a black background for 3, 5, 7, 11, 14 or >21 
days (fully black-adapted; BA). The neurointermediate lobes were isolated and analyzed on Western blot using 
anti-neuroserpin antibody α-NS-L. For reference, protein expression of POMC, p24δ2, and tubulin was analyzed. 
(B) Fully BA animals were adapted to a white background for 1, 2, 4, 8, 16 or >21 days (WA). Experimental 
conditions as under A. In both A and B, representatives of three independent experiments are shown. 
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Discussion 
 
Serine proteases form a large family of intra- and extracellular proteases, and have been 
implicated in a wide variety of biological processes. For example, in the nervous system, 
proteolysis of the ECM by serine proteases is an important step in the process of synaptic 
plasticity (25). Obviously, these proteolytic events ask for a delicate control that is provided 
by regulatory antiproteases called serpins. Neuroserpin is a recently described serpin that is 
mainly expressed in neuronal and neuroendocrine cells. In this study, the expression and 
biosynthesis of neuroserpin in the neuroendocrine melanotrope cells of the intermediate 
pituitary of the amphibian Xenopus laevis were examined. The Xenopus neurointermediate 
pituitary forms a highly plastic system that can be physiologically manipulated. The 
plasticity is exhibited by both the innervating hypothalamic neurons and the melanotrope 
cells, at the levels of proteins, subcellular structures, and synapses (reviewed in 18). 
We found that, in the Xenopus melanotrope cells, neuroserpin was initially 
synthesized as a 44-kDa protein that was subsequently once or twice N-linked glycosylated 
to products of 47- and 50 kDa, respectively. Glycosylation occurred rapidly after synthesis, 
as mainly the glycosylated forms were detected during the metabolic cell labeling studies. 
Both 47- and 50-kDa neuroserpin were secreted into the incubation medium in a slightly 
modified form, probably as a result of a modification of the N-linked sugar chains, the 
nature of which remains to be determined. These results constitute the first report on the 
biosynthesis of neuroserpin under physiological conditions. In the only other biosynthetic 
study reported thus far, transfected cells were used, and four forms of newly synthesized 
neuroserpin (45, 47/48, 50 and 55 kDa) were found of which the 47-/48-, 50- and 55-kDa 
forms were glycosylated (17). Previous Western blot analyses of mammalian tissues and 
transfected cells have revealed that the molecular weights for steady-state neuroserpin 
range from 40 to 55 kDa (19, 9, 26, 10). The sizes we detected for immunoreactive 
Xenopus neuroserpin (44-, 47-/50- and 55-kDa forms) lie within the same range. Because 
55-kDa neuroserpin was expressed specifically in the Xenopus pars nervosa, which consists 
of biosynthetically inactive nerve endings, it was not surprising that we did not detect 
newly synthesized 55-kDa neuroserpin when the NIL was metabolically labeled. 
Furthermore, we found the 55-kDa neuroserpin protein in Xenopus brain extracts (data not 
shown) suggesting that this neuroserpin product represents a neuronal form, whereas 44- 
and 47-/50-kDa neuroserpin produced in the melanotrope cells of the intermediate pituitary 
are neuroendocrine forms of the protein. Remarkably, 55-kDa neuroserpin was not N-
linked glycosylated and is thus probably otherwise post-translationally modified. Some 
serpins are regulated in their antiproteolytic activity by binding of a ligand such as heparin 
(27). However, heparin-binding seems unlikely for neuroserpin as previous studies have 
suggested that the antiproteolytic activity of neuroserpin is heparin independent (26). 
 In addition to 44-, 47-/50- and 55-kDa neuroserpin, a further immunoreactive 
product with a molecular weight of 130 kDa was detected. In principle, a neuroserpin 
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multimer may explain the presence of the high-molecular weight product. Although 
polymerization of certain serpins is generally caused by mutant forms of the protein 
(reviewed in 16), serpins may indeed show spontaneous polymerization under physiological 
conditions (28, 29). However, Xenopus neuroserpin dimer or trimer formation would have 
resulted in a complex of ~100- and ~150 kDa, respectively. Since the newly synthesized 
130-kDa product was immunoprecipitated only after the 2.5-h chase and not after the 1-h 
pulse incubation, the occurrence of this product likely reflects the coimmunoprecipitation 
of neuroserpin with a tightly bound substrate. In general, serpins form a tight complex with 
their substrate (reviewed in 5). We therefore hypothesize that the 130-kDa neuroserpin-
containing product represents an SDS-stable complex of 47-/50-kDa neuroserpin with a 
substrate. Characterization of the 130-kDa neuroserpin-containing complex using two-
dimensional gel electrophoresis revealed that both neuroserpin and the 130-kDa complex 
are acidic (pI ~5.4). Because the currently known (in vitro) serine protease substrates for 
neuroserpin (t-PA, u-PA, plasmin, and thrombin) are basic proteins, the observed pI of the 
complex indicates that these enzymes do not constitute the substrate for Xenopus 
neuroserpin. Unfortunately, our attempts to further characterize the 130-kDa complex using 
MALDI-MS and LC/ESI-MS were not successful because of the low endogenous 
expression levels of the complex. This is not a unique situation. For instance, Misra et al. 
(30) observed a high-molecular mass complex containing a serine protease with presumably 
a serpin, but they could also not identify the associated protein. Recently, Drosophila serine 
protease inhibitor 4 (SP-4), the closest invertebrate ortholog of neuroserpin, has been found 
to inhibit in vitro the subtisilin-like proprotein convertase furin (31). However, the amino 
acid sequence of the reactive site of Xenopus neuroserpin (with an arginine and a 
methionine at positions P1 and P1’, respectively) suggests that this serpin will preferably 
bind a trypsin-like substrate rather than a proprotein convertase such as furin, as the type of 
target protease is thought to be specified by the positions P1 and P1’ of the reactive site (32, 
33); an arginine and methionine at P1 and P1’, respectively, are also found in chicken 
neuroserpin which  most likely targets trypsin-like proteases (26). Moreover, in view of the 
molecular weight of furin (~57 kDa) a neuroserpin-furin complex of 130 kDa would be 
unlikely. In mouse cortical cultures and embryonic fibroblasts, the very low density 
lipoprotein receptor (VLDL receptor) and the low density lipoprotein receptor-related 
protein (LRP) have been shown to bind and internalize neuroserpin (34). Again, because of 
their sizes it is not to be expected that the Xenopus VLDL receptor or LRP (~100- and ~101 
kDa, respectively) will form a 130-kDa complex with Xenopus neuroserpin. Thus, at 
present the identity of the substrate interacting with Xenopus neuroserpin remains unclear. 
Of special interest was the observation that the 130-kDa complex was expressed 
specifically in the melanotrope cells of the intermediate pituitary and not in the pars 
nervosa, and that in our biosynthetic studies the complex was not detected in the medium. 
The complex may thus be formed intracellularly during the transport of neuroserpin 
through the secretory pathway or in the melanotrope ECM. Furthermore, the complex was 
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found in the melanotropes of only black- and not white-adapted animals, correlating with 
high and low POMC expression levels, respectively. These findings suggest that the 
formation of the complex is linked to melanotrope cell activation. The melanotrope cells 
play a key role in the physiological process of background adaptation of Xenopus. When 
the animal is on a black background, the melanotrope cells are biosynthetically highly 
active, producing large amounts of POMC and releasing α-MSH. On a white background, 
the cells are inactive, α-MSH release is inhibited and the animal turns white. Inhibition of 
the melanotrope cells is effected by contacting synapses that appear at the ultrastructural 
level as axon varicosities of neurons originating from the suprachiasmatic nucleus of the 
hypothalamus (suprachiasmatic melanotrope-inhibiting neurons, SMINs) (35-38). The 
terminal varicosities of these inhibitory neurons are much larger and more numerous in 
white- than in black-adapted animals (more than double the number of active synaptic 
zones are present on the melanotropes of white- relative to black frogs) (35). When a black 
animal is placed on a white background, a fast inhibition of melanotrope cell activity is 
necessary for the animal to shut off α-MSH secretion instantly. The immediate 
physiological response (drop of plasma α-MSH levels) takes place within 30 min after the 
animal is placed on a white background (39) and may be regulated by the initial release of 
the neurotransmitter GABA from the SMINs (40). However, to ensure that the melanotrope 
cells stay inactive during the first few days of adaptation, immediate synaptic changes are 
also necessary. Obviously, the morphological changes associated with the conversion of the 
highly active melanotrope cell into a biosynthetically inactive cell take more time (at least 
one week), which is reflected by only a gradual decrease of POMC expression during such 
a time period. In black animals adapting to a white background we found a relatively fast 
decrease in the amount of the 130-kDa neuroserpin-protease complex, possibly through 
internalization of the complex by the melanotrope cells, implying that the protease and thus 
proteolytic activity in the melanotrope ECM would be readily available. In melanotropes of 
white animals adapting to a black background, the 130-kDa complex was detected only 
after five days of adaptation, allowing protease activity in the cell matrix to be still present 
during the first days of black-background adaptation. Thus, in the first days of adaptation to 
either a black- or a white background, protease activity is available in the melanotrope 
ECM and may regulate the formation of the pertinent matrices; for maintenance of the 
ECM, a proper balance between matrix proteases and their inhibitors is essential (reviewed 
in 1). Because the ECM is thought to play an important role in synaptic plasticity (reviewed 
in 25, 41-43), changes in the melanotrope ECM will allow the synaptic plasticity of the 
hypothalamic neurons and thus enable the dramatic morphological changes that occur in the 
melanotrope cell during background adaptation of Xenopus. 
In conclusion, we report for the first time on the biosynthesis of neuroserpin under 
physiological conditions, and find that neuroserpin and a 130-kDa neuroserpin-containing 
complex are up-regulated in the biosynthetically active neuroendocrine melanotrope cells 
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of the intermediate pituitary of black-adapted Xenopus laevis. Because the formation of the 
130-kDa complex is linked to melanotrope cell activation, neuroserpin may be somehow 
involved in the shaping of the melanotrope ECM and thus in the regulation of the synaptic 
plasticity of hypothalamic neurons that directly innervate this cell. 
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Abstract 
 
Neuroserpin is a member of the serine protease inhibitor (serpin) superfamily that is 
predominantly expressed in neuronal and neuroendocrine tissues. The exact physiological 
role of neuroserpin remains unclear. Mutations in the neuroserpin gene (e.g. G392E) are 
linked to the autosomal dominant dementia Familial Encephalopathy with Neuroserpin 
Inclusion Bodies (FENIB). To study functional aspects of neuroserpin, we used the 
Xenopus intermediate pituitary neuroendocrine melanotrope cell as a model system. This 
cell regulates the process of background adaptation of the frog, and exhibits plasticity at 
both the synaptic and endocrine level. Via stable Xenopus transgenesis green fluorescent 
protein (GFP)-tagged neuroserpin or mutant neuroserpin(G392E) fusion products were 
expressed specifically in the melanotrope cells. Newly synthesized and steady-state levels 
of the transgene fusion products varied from relatively low (mutant neuroserpin) to high 
(neuroserpin), and in the transgenic melanotrope cells the fusion proteins were transported 
through the secretory pathway and secreted. Transgene expression of the fusion proteins did 
not affect endogenous neuroserpin protein levels and melanotrope cell functioning was not 
detectably altered, as determined by metabolic cell labeling and Western blot analysis of 
various secretory pathway proteins. Intriguingly, at the ultrastructural level we observed 
intercellular gaps between the transgenic melanotrope cells that were not detected between 
wild-type cells, implying an effect of the exogenous (mutant) neuroserpin on the 
extracellular matrix of the melanotrope cell. Thus, the neuroendocrine serine protease 
inhibitor neuroserpin may affect the extracellular matrix of neuroendcrine cells. 
 
Introduction 
 
The superfamily of serine protease inhibitors (serpins) is involved in a number of 
fundamental biological processes and is associated with numerous familial disorders (1-4). 
One characteristic of serpins is their ability to undergo drastic conformational changes 
when inhibiting their substrates. After binding of the substrate protease to the reactive 
center loop (RCL) of the serpin, the P1-P1’ bond of the RCL will be cleaved, and a drastic 
rearrangement will incorporate the N-terminal residues of the loop into the middle of the A-
β-sheet as strand 4A. This conformational change inactivates the protease by translocating 
it over 70 Å to the opposite pole of the serpin and disrupting the catalytic site (reviewed in 
5, 6). As a consequence of this molecular flexibility of serpins, mutations affecting the 
structural stability can result in aberrant intermolecular linkage and the formation of 
polymers (reviewed in 7). 
Neuroserpin is a member of the serpin superfamily that is primarily expressed in 
neuronal- and neuroendocrine tissues (8-13). Specific mutations in the neuroserpin gene 
lead to a disease called ‘familial encephalopathy with neuroserpin inclusion bodies’ 
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(FENIB). This disorder is characterized clinically as an autosomal dominantly inherited 
dementia, histologically by unique neuronal inclusion bodies and biochemically by 
polymers of neuroserpin (14). Currently, five different point mutations in the neuroserpin 
gene have been described that result in FENIB, which provided evidence that the number of 
inclusions is directly related to the molecular instability caused by the mutation and 
inversely proportional to the age of onset of dementia. For example, the least disruptive 
S49P mutation caused dementia after age 45 and the presence of neuroserpin inclusion 
bodies in only a few neurons. By contrast, the more severely disruptive G392E mutation 
resulted at age 13 in progressive myoclonus epilepsy, with many inclusions present in 
almost all neurons (15). Although it is now mechanistically understood how polymerization 
of mutated neuroserpin takes place, little information is available concerning the 
intracellular trafficking and processing of the protein. 
 The physiological role of neuroserpin in the nervous system and neuroendocrine 
tissues remains elusive. A number of functions for the protein have been proposed, such as 
a regulatory role in synaptic growth and in the development of synaptic plasticity in the 
nervous system (9, 10, 12, 16-22), as well as in secretory vesicle function or intercellular 
communication between endocrine cells (13). Furthermore, there is a growing body of 
evidence demonstrating the participation of tissue-type plasminogen activator (t-PA) in a 
number of physiological and pathological events in the central nervous system, and the role 
of neuroserpin in these processes as the natural regulator of t-PA activity (22-26).  
 To gain more insight into the physiological role of neuroserpin and the 
pathophysiological role of mutated neuroserpin, we used the intermediate pituitary 
melanotrope cells of the South-African claw-toed frog Xenopus laevis as a model system. 
These neuroendocrine cells are responsible for the process of background adaptation of this 
amphibian by coordinating the release of the proopiomelanocortin (POMC) cleavage 
product α-melanophore stimulating hormone, which causes pigment dispersion in skin 
melanophores.  On a black background, the melanotrope cells are very active, producing 
vast amounts of POMC, whereas on a white background the activity of the cells is inhibited 
by hypothalamic neurons, which make direct synaptic contacts with the melanotrope cells. 
Thus, the biosynthetic activity of these neuroendocrine cells and the degree of their 
innervation by regulatory hypothalamic neurons can be manipulated in a physiological way 
by placing the animal on a black or a white background (reviewed in 27-29). 
In this study, we generated and analyzed transgenic Xenopus with overexpression 
of green fluorescent protein (GFP)-tagged neuroserpin or mutant neuroserpin(G392E) 
specifically in the intermediate pituitary melanotrope cells.  
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Materials and methods 
 
Animals 
South African claw-toed frogs, Xenopus laevis, were reared in the Central Animal Facility 
of the Radboud University of Nijmegen (Nijmegen, The Netherlands). The animals were 
adapted to their background by keeping them in either white or black buckets, with the 
lights turned on in cycles of 12 h. Experimental procedures were performed under the 
guidelines of the Dutch law concerning animal welfare, and permit RBD0166 (H10) to 
generate and house transgenic Xenopus. 
 
Antibodies 
For Western blotting, immunoprecipitation analysis and immunocytochemistry, the 
following antibodies were used. To detect neuroserpin, we used a rabbit polyclonal IgG 
against human recombinant neuroserpin (α-NS-L; generous gift of Dr. D.A. Lawrence, 
American Red Cross Holland Laboratory, Rockville, Maryland, USA; 9). GFP was detected 
with an anti-GFP antibody (generous gift of Dr. B. Wieringa, Radboud University, 
Nijmegen, The Netherlands; 30) and tubulin was detected with the monoclonal anti-tubulin 
antibody E7 (Developmental Studies Hybridoma Bank, Rockland, Gilbertsville). Xenopus 
calnexin was detected with an anti-calnexin antibody (31), BiP with an anti-BiP antibody 
(32) (generous gifts of Dr. K. Geering, University of Lausanne, Lausanne, Switzerland), 
POMC with an anti-POMC antibody (ST62; generous gift of Dr. S. Tanaka, Shizuoka 
University, Japan; 33), POMC and a POMC-derived product with an anti-
adrenocorticotropic hormone (ACTH) antibody (34), prohormone convertase PC2 with an 
anti-PC2 antibody (generous gift of Dr. W. Van de Ven, University of Leuven, Belgium; 
35) and p24δ1/2 with anti-p24-antibody 1262N (36). 
 
Generation of constructs used for Xenopus laevis transgenesis 
For transgenesis, two different constructs encoding the fusion proteins GFP-neuroserpin 
and GFP-neuroserpin(G392E) were generated. For the construct encoding GFP-
neuroserpin, neuroserpin-encoding DNA was amplified by PCR using Pfu enzyme 
(Fermentas), forward primer NS-XbaI sense 2 (5’-GGGGTCTAGATTAGAGCTCTTCAAAATCA-
TGG-3’), reverse primer NS-XhoI-sense (5’-GGGGCTCGAGCGTTTGGTACTAGTGTCCATG-3’) 
and 1 ng pCS2+-NS vector (described in 8) as template DNA, according to the 
manufacturer’s instructions. The amplified neuroserpin PCR-fragment was then cloned in 
frame behind the GFP sequence of pPOMC(A)2+-SP-GFP (described in reference 37), 
resulting in the pPOMC-SP-GFP-NS construct. To generate the construct encoding the 
mutant GFP-neuroserpin(G392E) fusion protein, we used the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene) with the pPOMC-SP-GFP-NS construct as input DNA and 
the following primer: 5’-GGATCAGTCTTGTTTATGGAAAGGGTCATGCATCCAG-3’ (mutation 
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leading to amino acid change is underlined), resulting in the pPOMC-SP-GFP-NS(G392E) 
construct. 
 
Xenopus laevis transgenesis 
To create transgenic frogs, linear 2829-kb SalI/NotI DNA fragments were generated from 
the pPOMC-SP-GFP-NS and pPOMC-SP-NS(G392E) constructs, respectively. These 
linear fragments were used for stable Xenopus transgenesis (38, 39) (Fig. 1). A number of 
injection rounds resulted in animals transgenic for the fusion protein GFP-NS and the 
mutant fusion protein GFP-NS(G392E). To generate F1 offspring, the testes of male 
transgenic Xenopus laevis frogs were isolated and used for in vitro fertilization of eggs 
harvested from wild-type Xenopus laevis females, resulting in transgenic line 55 (pPOMC-
SP-GFP-NS) and line 84 (pPOMC-SP-GFP-NS(G392E)). 
 
 
 
Figure 1: Flow diagram of the 
stable Xenopus transgenesis 
procedure and the generation 
of F1 transgenic animals.  
This scheme represents the 
modified transgenesis technique 
described by the group of 
Mohun (38). For the generation 
of F1 transgenic animals, we 
used either transgenic sperm and 
wild-type eggs or transgenic 
eggs in combination with wild-
type sperm. 
 
 
 
 
 
Isolation of Xenopus melanotrope cells 
Intermediate pituitary melanotrope cells from wild-type and transgenic Xenopus were 
isolated as described previously (40). Briefly, neurointermediate lobes (NILs) were 
dissected, washed several times in sterile Xenopus XL15 (10 mM glucose, 2 mM CaCl2, 
1% kanamycin (Life Technologies, Inc.), 1% antibiotic/antimycotic (Life Technologies, 
Inc.) in 67% Leibovitz’s-15 medium (Life Technologies, Inc.)) and transferred to XL15 
containing 0.25% trypsin. After 45 min incubation, XL15 was added and the melanotrope 
cells were mechanically dissociated from the NIL by 7 passages through a siliconized 
Pasteur’s pipet. Next, the cell suspension was filtered and the melanotrope cells were 
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collected by centrifugation. For primary culturing, cells were resuspended in a small 
volume of serum-free XL15 medium, and seeded on poly-L lysine-coated coverslips. After 
1 hour, XL15/10% FCS was added and the cells were cultured for two days at room 
temperature (RT) in a humified chamber before using them for immunocytochemistry.  
 
Immunocytochemistry 
For immunocytochemistry, primary cultures of melanotrope cells were washed three times 
in Xenopus PBS (XPBS; 69% PBS), fixed in 2% paraformaldehyde/PBS for 1.5 hr at RT, 
and subsequently washed three times in 50 mM NH4Cl/PBS and three times in 0.1% 
Triton/XPBS (XPBS-T). Antibody incubations were performed sequentially for 1 hr in 2% 
bovine serum albumine (BSA)/XPBS-T at RT. Anti-ACTH (1:2000) was used as a primary 
antibody and Alexa 568-conjugated goat anti-rabbit antibody (1:500) was used to visualize 
the first antibody-antigen complex. Finally, cells were washed three times in XPBS-T, two 
times in XPBS and once in MQ, and cover slips were mounted in Mowiol (10% [wt/vol]; 
CalBiochem, La Jolla, CA; 15% glycerol; 100 mM Tris-HCl, pH 8.5; 2.5% NaN3). 
Fluorescence was analyzed with an MRC 1024 confocal laser scanning microscope 
(BioRad). 
 
Metabolic cell labeling and immunoprecipitation 
Metabolic cell labeling was performed as described previously (40). Briefly, Xenopus NILs 
were rapidly dissected, pre-incubated for 15 min in Ringer’s medium (112 mM NaCl, 15 
mM Hepes (pH7.4), 2 mM KCl, 2 mM CaCl2, 2 mg/ml glucose, and 0.3 mg/ml BSA), and 
newly synthesized proteins were radioactively labelled with 5 mCi/ml Tran35S label for 30 
min. Following a 180-min chase period in Ringer’s medium supplemented with 0.5 mM L-
methionine and with or without 1*10-7 M or 2*10-8 M apomorphine, lysates were made in 
100 μl lysis buffer (50 mM Hepes, 140 mM NaCl, 0.1% Triton-X100, 1% Tween 20, 1 mM 
EDTA, 1 mg/ml deoxycholate, 1 μM phenylmethylsulfonyl fluoride, 0.1 mg/ml soybean 
trypsin inhibitor). The lysates and newly synthesized proteins secreted into the incubation 
media were resolved by SDS-PAGE and visualized by fluorography. The amounts of newly 
synthesized 37-kDa POMC and of the 18-kDa POMC cleavage product (both the cellular 
and secreted protein) were quantified by densitometry using a phosphoimager (BioRad). 
The relative processing of 37-kDa POMC was estimated by the ratio of 37-kDa to 18-kDa 
POMC (total of cellular and secreted protein), and the relative secretion by the ratio of 
secreted 18-kDa to cellular 18-kDa POMC (n=3). An unpaired t test was used for statistical 
analysis. Immunoprecipitation was performed in lysis buffer with 0.075% SDS in the 
presence of the anti-GFP antiserum (1:1000). After overnight rotation at 4°C, immune 
complexes were precipitated with protein-A-sepharose (Amersham Pharmacia Biotech), 
washed four times with lysis buffer and analysed via SDS-polyacrylamide gel 
electrophoresis. 
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Western blot analysis 
To examine steady-state protein expression levels by Western blot analysis, NIL lysates 
(described above) were separated on a polyacrylamide gel with or without SDS (denaturing 
and native conditions, respectively) and proteins were transferred to nitrocellulose 
membranes (protran, Schleicher & Schuell, Dassel, Germany) by electroblotting. Blots 
were blocked for 1 hour in blocking buffer (5% non-fat dried milk in PBS containing 1% 
Tween 20) and incubated overnight with primary antiserum (1:5000 anti-NS-L; 1:5000 
anti-GFP; 1:500 anti-tubulin; 1:10000 anti-Cal; 1:10000 anti-BiP; 1:20000 anti-POMC; 
1:5000 anti-PC2 or 1:5000 anti-p24) in blocking buffer. Bound antibodies were detected 
with peroxidase-conjugated goat-anti-rabbit or goat-anti-mouse antiserum followed by 
chemiluminescence (Lumilight plus, Roche Diagnostics, Manheim, Germany). Signals 
were visualized with a BioChemi Imaging System, and relative quantification by 
densitometry was performed with Labworks 4.0 software (UVP BioImaging systems, 
Cambridge, UK). The densities of the various signals were normalized to the corresponding 
tubulin signals (n = 3). An unpaired t test was used for statistical analysis. 
 
Electron microscopy 
For ultrastructural studies, freshly dissected NILs of wild-type Xenopus and Xenopus 
transgenic for GFP-neuroserpin or GFP-neuroserpin(G392E) were used. Whole lobes were 
fixed overnight at 4°C in 2% glutaraldehyde in 0.1 M phosphate buffer (PB, pH 7.3). 
Following rinsing in the same buffer, fixed tissues were osmicated for one hour in 1% 
osmium tetroxide in 0.1 M PB, rinsed in PB, dehydrated through graded series of ethanol 
and embedded in Epon 812. One-micron thick sections were cut and stained with toludine 
blue. Subsequently, the sections were examined in a phase-contrast microscope (Dialux 20, 
Leitz). Ultrathin sections were cut, double contrasted with uranyl-acetate/lead-citrate and 
photographed in a transmission electron microscope (JEOL 1010). 
 
Results 
 
Generation of Xenopus with transgene expression of neuroserpin or mutant 
neuroserpin(G392E) specifically in intermediate pituitary melanotrope cells 
To study the role of neuroserpin in a physiological context, we generated via stable 
Xenopus laevis transgenesis F0 and F1 lines with cell-specific transgene expression of 
GFP-neuroserpin (line 55) or GFP-neuroserpin(G392E) (line 84) (Fig. 2A). Melanotrope 
cell-specific transgene expression was accomplished by cloning the GFP-neuroserpin DNA 
fragments behind a Xenopus POMC gene promoter fragment (41). The transgenic tadpoles 
were identified by direct screening for GFP fluorescence in the pituitary (Fig. 2B). 
We next examined the biosynthesis of the newly synthesized transgene products in the 
melanotrope cells of transgenic lines 55 and 84. For this purpose, NILs of wild-type and 
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transgenic animals were metabolically labeled for 30 min and chased for 180 min.  
Following immunoprecipitation analysis of the lysates using an anti-GFP antibody, we 
detected newly-synthesized GFP-neuroserpin and GFP-neuroserpin(G392E) fusion proteins 
of ~80 kDa in the transgenic NILs (Fig. 3A, left panel). The levels of newly synthesized 
GFP-neurserpin (line 55) were ~5-fold higher than newly synthesized mutant GFP-
neuroserpin(G392E) (line 84), which was detected only after prolonged exposure of the 
film.  
 
 
Figure 2: Generation of transgenic Xenopus 
laevis with GFP-tagged neuroserpin or 
mutated neuroserpin(G392E) expression 
specifically in the intermediate pituitary 
melanotrope cells. 
 (A) Schematic representation of the constructs 
that were used to generate transgenic line 55 
(neuroserpin) and line 84 (neuroserpin(G392E)) 
Xenopus. Abbreviations: pPOMC, promoter 
fragment of the Xenopus proopiomelanocortin 
gene; S, signal peptide; GFP, green fluorescent 
protein; NS, neuroserpin; NS(G392E), 
neuroserpin with a G392E point mutation, which 
is indicated with an asterisk. (B) GFP 
fluorescence in intermediate pituitaries (indicated 
with a white arrow) of transgenic tadpoles of lines 
55 and 84.  
 
 
 To examine the steady-state expression levels of the transgene products in line-55 
and -84 animals, we performed Western blot analysis of NIL lysates with an anti-
neuroserpin and anti-GFP antibody. With both antibodies, we detected an ~6-fold higher 
expression level of ~80-kDa GFP-neuroserpin in lobes of line-55 animals than the 
expression level of ~80-kDa mutant GFP-neuroserpin(G392E) in lobes of transgenic line-
84 animals (Fig. 3B; left panels), in line with the results of the biosynthetic studies. 
 We then wondered whether the transgene products were also secreted by the 
transgenic melanotrope cells. Following metabolic cell labeling, we therefore performed 
immunoprecipitation analysis of the incubation media using an anti-GFP antibody, and 
detected ~80-kDa GFP-neuroserpin and GFP-neuroserpin(G392E) products in the media of 
the transgenic NILs (Fig. 3A, right panel). Additionally, the media were analyzed by 
Western blotting using an anti-neuroserpin antibody, which revealed an ~80-kDa GFP-
neuroserpin product in the incubation medium of transgenic line 55 (Fig. 3B, right panel), 
whereas the expression levels of GFP-neuroserpin(G392E) were probably too low to detect 
the secreted transgene product in the medium (Fig. 3B, right panel). 
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 Using the anti-neuroserpin antibody, we also detected endogenous neuroserpin 
products of ~47-, 50-, 55- and 130-kDa in wild-type and transgenic animals (Fig. 3B, upper 
left panel; 8, 40). The expression levels of the endogenous neuroserpin proteins and the 
130-kDa complex appeared not to be affected by GFP-neuroserpin or GFP-
neuroserpin(G392E) transgene expression, since we did not detect significant differences in 
endogenous neuroserpin expression levels between the NILs of wild-type and transgenic 
line 55 or 84 animals (Fig. 3B, upper left panel). 
 
 
 
Figure 3: Newly-synthesized and steady-state levels of GFP-neuroserpin and GFP-neuroserpin(G392E) in 
transgenic Xenopus intermediate pituitary melanotrope cells and secreted into the incubation medium. 
 (A) Newly synthesized green fluorescent protein (GFP)-neuroserpin or GFP-neuroserpin(G392E) fusion proteins 
produced in the neurointermediate lobes (cells) and secreted into the incubation media (medium) after metabolic 
labeling of wild-type (wt) and transgenic lines-55 and -84 lobes. Immunoprecipitation was performed using an 
anti-GFP antibody. Both a short and long exposure of the gel are shown (upper and lower panel, respectively). (B) 
Western blot analysis of neurointermediate lobe lysates (cells) and incubation media (medium) of adult wt and 
transgenic line-55 and line-84 animals using an anti-neuroserpin (anti-NS) or anti-GFP antibody. Analysis of 
tubulin protein expression served as a control for protein loading. Abbreviations: NS, neuroserpin; GFP-NS, GFP-
tagged neuroserpin fusion protein; GFP-NS(G392E), GFP-tagged neuroserpin protein with a G392E mutation. 
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 Thus, transgenic Xenopus were generated with relatively high transgene 
expression of GFP-neuroserpin (line 55) and relatively low transgene expression of mutant 
GFP-neuroserpin(G392E) (line 84) in the melanotrope cells of the intermediate pituitary. 
The transgene products were secreted by the melanotrope cells and furthermore did not 
have a detectable effect on the steady-state expression levels of the endogenous neuroserpin 
proteins.  
 
Intracellular localization of the neuroserpin fusion proteins in the transgenic Xenopus 
melanotrope cells 
We next wondered about the intracellular localization of the transgene GFP-neuroserpin 
and GFP-neuroserpin(G392E) fusion products, and we therefore isolated melanotrope cells 
from wild-type and transgenic line-55 and -84 animals to examine direct GFP fluorescence 
using confocal microscopy. In the melanotropes of transgenic lines 55 (GFP-neuroserpin) 
and 84 (GFP-neuroserpin(G392E)), the fusion proteins were localized in vesicle-like 
structures (Fig. 4; left panels). To find out whether these vesicle-like structures were part of  
the secretory pathway of the transgenic melanotrope cells, immunocytochemistry was 
performed on the cells using an anti-ACTH antibody, recognizing POMC and a POMC-
derived cleavage product. As expected, in the melanotrope cells fluorescence was detected 
in the ER and in vesicles of the secretory pathway (Fig. 4; right panels). The observed 
fluorescence of GFP-neuroserpin (line 55) and GFP-neuroserpin(G392E) (line 84) partially 
colocalized with the fluorescence of POMC and the POMC-derived cleavage product in the 
melanotropes, indicating that a portion of the transgene GFP-neuroserpin and GFP- 
 
 
 
 
 
Figure 4: Localization of GFP-neuroserpin and GFP-
neuroserpin(G392E) in the transgenic Xenopus 
melanotrope cells. 
Intracellular localization of GFP-neuroserpin or GFP-
neuroserpin(G392E) fusion proteins (left panels) and of 
proopiomelanocortin (POMC and a POMC-derived product 
in primary-cultured melanotrope cells of black-adapted wild-
type (wt), and transgenic line-55 and line-84 Xenopus. 
Shown are confocal microscopy pictures of the direct 
fluorescence of the transgene GFP-neuroserpin products 
(GFP) or immunofluorescence of the POMC/POMC-derived 
product (POMC). Scale bar: 5 μm. 
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neuroserpin(G392E) fusion products were localized in the secretory pathway. The other 
part may well be localized in the endosomal and lysosomal compartment of the 
melanotrope cell. Localization in the secretory pathway is in line with immunoprecipitation 
and Western blot analyses in which the transgene fusion products were detected in the 
incubation media of the transgenic melanotrope cells (Fig. 3) and with the reported 
subcellular localization of endogenous neuroserpin (8, 21).  
 
Biosynthesis and processing of POMC and secretion of POMC-derived peptides by 
melanotrope cells of wild-type Xenopus or Xenopus transgenic for GFP-neuroserpin 
or GFP-neuroserpin(G392E) 
To examine the effect of GFP-neuroserpin or GFP-neuroserpin(G392E) transgene 
expression on melanotrope cell functioning, and  more specifically on the biosynthesis and 
processing of POMC and the secretion of POMC-derived peptides, we performed pulse-
chase analyses on NILs of black-adapted wild-type and transgenic line-55 and -84 animals. 
After quantification of the amounts of newly synthesized 37-kDa and 18-kDa POMC 
produced in the NILs from wild-type and transgenic line-55 (GFP-neuroserpin) and line-84 
(GFP-neuroserpin(G392E)) animals, we did not detect significant differences in the 
biosynthesis, processing and secretion of 37- and 18-kDa POMC by the melanotrope cells 
of line-55 or -84 compared with wild-type animals (Fig. 5).  
 
Figure 5: Newly synthesized proteins 
produced in the intermediate pituitary 
cells of wild-type Xenopus and Xenopus 
transgenic for GFP-neuroserpin or GFP-
neuroserpin(G392E). 
Neurointermediate lobes (cells) of black-
adapted wild-type (wt) and transgenic line-
55 (GFP-neuroserpin) and line-84 (GFP-
neuroserpin(G392E)) Xenopus were pulse 
labeled for 30 min and chased for 180 min. 
Newly synthesized proteins extracted from 
the lobes (cells) and secreted into the 
incubation media (medium) were resolved 
by SDS-PAGE and visualized by 
fluorography. The amounts of newly 
synthesized 37-kDa POMC and of the 18-
kDa POMC cleavage product were 
quantified by densitometry using a 
phosphoimager (n=3). Shown is a 
representative of three independent 
experiments. Abbreviations: (pro)PC2, 
(pro)prohormone convertase 2; POMC, 
proopiomelanocortin. 
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 Since neuroserpin may play a role in synaptic plasticity and the transgene GFP-
neuroserpin fusion products are secreted by the melanotrope cells (Fig. 3B), we wondered 
whether secreted GFP-neuroserpin had influenced the synaptic plasticity exerted by the 
hypothalamic fibers that directly innervate the melanotrope cells. We therefore performed 
pulse-chase analyses in the presence of the dopamine-agonist apomorphine; dopaminergic 
neurons of hypothalamic origin directly innervate and inhibit the regulated secretion by the 
melanotrope cells (27, 29). Furthermore, we examined melanotrope cells that were in 
different states of synaptic innervation by using line-55 animals that were adapted to a 
white or a black background for various time periods. We did not detect significant 
differences in the biosynthesis and processing of newly synthesized POMC and secretion of 
the POMC-derived peptides between wild-type and transgenic line-55 melanotrope cells 
(data not shown), indicating that the regulation of the biosynthetic activity of the transgenic 
cells was not affected.  
Together, these results indicate that the biosynthetic and secretory processes in the 
transgenic melanotrope cells of lines 55 and 84 are not affected. 
 
Steady-state expression of various secretory pathway proteins in the 
neurointermediate lobe of wild-type Xenopus and Xenopus transgenic for GFP-
neuroserpin or GFP-neuroserpin(G392E) 
Next, we examined whether the transgene expression of GFP-neuroserpin (line 55) or GFP-
neuroserpin(G392E) (line 84) had an effect on the expression of secretory pathway proteins 
other than POMC. For this purpose, we used Western blotting to examine the steady-state 
expression levels of the endoplasmic reticulum (ER) chaperones calnexin and binding 
protein BiP, the prohormone convertase 2 (PC2), POMC, and p24δ1/2 (putative receptors for 
ER to Golgi cargo transport) in the NILs of wild-type and transgenic lines-55 and -84 
animals. After quantification, we did not detect significant differences in the expression of 
these proteins between wild-type and transgenic line-55 or -84 animals (Fig. 6). 
 
Ultrastructure of melanotrope cells from wild-type Xenopus or Xenopus transgenic for 
GFP-neuroserpin or GFP-neuroserpin(G392E) 
Finally, to study any effects of GFP-neuroserpin or GFP-neuroserpin(G392E) transgene 
expression on the ultrastructure of the transgenic melanotrope cells, electron microscopy 
analysis was performed. After careful examination of the ultra-thin slices, the overall 
ultrastructures of the transgenic melanotrope cells of lines 55 and 84 were comparable with 
that of wild-type cells (Fig. 7). For example, no abnormalities were found in the nucleus, 
ER or secretory granules. However, in transgenic line-55 melanotrope cells more lysosomes 
were present, and in sections of the transgenic intermediate pituitaries of lines 55 and 84 
more intercellular gaps were observed compared with wild-type intermediate pituitaries 
(Fig. 7). 
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Figure 6: Steady-state levels of a number of secretory pathway 
proteins in the intermediate pituitary cells of wild-type 
Xenopus and Xenopus transgenic for GFP-neuroserpin or 
GFP-neuroserpin(G392E). 
Western blot analysis of Xenopus neurointermediate lobe lysates 
of wild-type (wt) and transgenic line-55 (GFP-neuroserpin) and 
line-84 (GFP-neuroserpin(G392E)) animals using antibodies 
directed against calnexin, binding protein BiP, prohormone 
convertase 2 (PC2), proopiomelanocortin (POMC), p24δ1/2 and 
tubulin. The results shown are representatives of three independent 
experiments. 
 
 
 
 
 
 
 
 
 
 
Figure 7: Ultrastructure of melanotrope cells from wild-type Xenopus and Xenopus transgenic for GFP-
neuroserpin or GFP-neuroserpin(G392E). 
Ultrastructural analysis by electron microscopy on melanotrope cells from wild-type (wt) and transgenic line-55 
(GFP-neuroserpin) or line-84 (GFP-neuroserpin(G392E)) Xenopus. Examples of a number of intracellular 
structures are indicated, such as the nucleus (n), endoplasmic reticulum (ER), secretory granules (white arrow 
heads) and lysosomes (l). Intercellular gaps are indicated with black arrows and cell-cell boundaries with a dotted 
line. Scale bars: 5 μm (wt) and 2.5 μm (lines 55 and 84). 
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Discussion 
 
Neuroserpin is a neuronal- and neuroendocrine-specific serpin (8-13) for which several 
physiological functions and target proteases have been suggested, but whose exact role 
remains elusive. A number of mutated forms of neuroserpin have been implicated in the 
pathophysiology of the dementia FENIB, and until now only in vitro cell systems have been 
used to study the cellular fate of the mutant neuroserpin proteins (42). In order to explore in 
vivo the physiological role of neuroserpin and the pathophysiological role of mutated 
neuroserpin, we used the intermediate pituitary neuroendocrine melanotrope cells of 
Xenopus laevis as a model system. To regulate the process of background adaptation of the 
frog, these cells and the hypothalamic neurons that contact them exhibit a high degree of 
plasticity, which can be observed at the level of proteins, subcellular structures and 
synapses (reviewed in (28, 29, 43). Via the technique of stable Xenopus transgenesis, frogs 
were generated with transgene expression of GFP-tagged neuroserpin or mutated 
neuroserpin(G392E) specifically in the melanotrope cells. In this way, we created 
transgenic line 55 with GFP-neuroserpin transgene expression and transgenic line 84 with 
GFP-neuroserpin(G392E) expression. In both transgenic lines, the transgene fusion 
products were secreted by the melanotrope cells. 
 Transgene expression of GFP-neuroserpin (line 55) or GFP-neuroserpin(G392E) 
(line 84) did not result in a clear effect on the transgenic melanotrope cells, as was 
examined via metabolic cell labeling and Western blot analyses. In addition, in transgenic 
line-84 animals, we have not detected the cell-biological characteristics observed in cells 
transfected with FENIB mutant neuroserpin. The histological characteristic of FENIB 
concerns the presence of neuroserpin inclusion bodies which accumulate in the ER and are 
formed by polymers of the mutated neuroserpin protein (14, 42). Electron microscopy and 
native gel electrophoresis did however not show neuroserpin inclusion bodies or polymer 
formation of the GFP-neuroserpin(G392E) protein in transgenic line-84 melanotrope cells  
(data not shown). Possibly, the expression levels of the transgene were too low in line 84 to 
induce such a phenotype. Alternatively, the time of adaptation of the transgenic animals to 
a black background (and therefore the time during which the melanotrope cells were 
exposed to the transgene product) has been too short. We have shown previously that the 
time of background adaptation of transgenic frogs can be important to create a phenotypic 
effect of transgene expression (37, 44). In transfected COS-7 cells, already 24 h post-
transfection accumulation of the Portland neuroserpin mutant (S52R) has been observed 
(42). The neuroserpin(G392E) mutant that we have used in our studies is the most severely 
disrupting and ‘polymerogenic’ mutation thus far known, resulting in an early onset of the 
disease (7, 15, 45), suggesting that polymer formation of GFP-neuroserpin(G392E) would 
readily occur. Nevertheless, transgene expression of GFP-neuroserpin (line 55) and GFP-
neuroserpin(G392E) (line 84) resulted in a phenotype at the ultrastuctural level, since in the 
two independently generated transgenic lines intercellular gaps between the transgenic 
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melanotrope cells were observed. Such gaps are normally not found in pituitaries from 
wild-type animals and also not in other transgenic intermediate pituitaries, such as for 
p24δ1/2 and the V-ATPase accessory subunit Ac45 (data not shown). These observations 
imply that the transgene expression of neuroserpin affected the structure of extracellular 
matrix (ECM) of the melanotrope cells, and therefore suggest a role for neuroserpin in the 
regulation of the integrity of the ECM. The molecular mechanism behind this observed 
effect remains elusive. Possibly, the expression of the neuroserpin transgene product 
resulted in an extensive inhibition of an extracellular target protease that is involved in the 
regulation of ECM integrity.  
 In conclusion, we report on the generation and analysis of Xenopus laevis with 
transgene expression of GFP-tagged neuroserpin and mutant neuroserpin(G392E) 
specifically in the intermediate pituitary melanotrope cells. Expression of the transgene 
fusion products did not have a clear effect on melanotrope cell functioning, but did result in 
an effect on the melanotrope cell ECM. These results raise the possibility that neuroserpin 
is part of a mechanism regulating the integrity of the ECM. 
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Abstract 
 
Brain-derived neurotrophic factor (BDNF) is a neuronal survival and differentiation factor, 
and a modulator of synaptic plasticity in the central and peripheral nervous systems. Recent 
studies have shown that besides mature BDNF also the noncleaved proprotein proBDNF 
can be released by cells and exert yet another biological effect, namely inducing cellular 
apoptosis. Here we studied functional aspects of pro- and mature BDNF by using the 
technique of stable transgenesis of the amphibian Xenopus laevis.  A number of transgenic 
lines were generated that overexpressed proBDNF, mature BDNF or green fluorescent 
protein (GFP)-tagged (mutant) proBDNF fusion proteins specifically in the Xenopus 
intermediate pituitary melanotrope cells. These neuroendocrine cells endogenously produce 
both pro- and mature BDNF. The transgenic melanotrope cells overexpressing mature 
BDNF are discussed in chapter 6. In this chapter, we analysed transgenic melanotrope cells 
overexpressing intact proBDNF and GFP-proBDNF. We found that in the various 
transgenic lines the GFP-proBDNF protein was processed differently, giving rise to 
different levels of mature BDNF. Transgene expression of unprocessed GFP-proBDNF or a 
noncleavable GFP-proBDNF mutant fusion protein resulted in endoplasmic reticulum (ER) 
stress, probably due to misfolding of the transgene product, and an impaired transport of 
secretory proteins in these cells. In transgenic melanotrope cells expressing an untagged, 
noncleavable proBDNF mutant protein, we did not observe an effect on the biosynthesis, 
processing and secretion of newly synthesized proteins, presumably owing to the low levels 
of transgene expression. Together, our results suggest that intact GFP-proBDNF causes ER 
stress and impaired secretory protein transport in transgenic Xenopus melanotrope cells. 
 
Introduction 
 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family that 
regulates neuronal survival and differentiation, and also modulates synaptic plasticity in the 
central and peripheral nervous systems (reviewed in 1-5). In addition, BDNF has recently 
been implicated in various other biological events such as neuronal and glial cell 
proliferation (6-8) and myelination (9-12). 
Like other neurotrophin family members, BDNF is initially synthesized as a 
precursor of 249 amino acids (proBDNF). The N-terminal fragment of ~112 amino acids, 
or the ‘pro-region’, can then be proteolytically cleaved by furin or prohormone convertases 
PC1/PC2 to form mature BDNF (13, 14). BDNF can be secreted via either the regulated or 
constitutive pathway, depending on the available secretory pathways in a given cell 
(reviewed in 15). Furthermore, interaction between a motif in the tertiary structure of 
BDNF and the sorting receptor carboxypeptidase E directs BDNF mainly to the regulated 
secretory pathway for activity-dependent release in AtT20 cells and cortical neurons (16, 
17). Besides this sorting motif in mature BDNF, the pro-sequence itself also influences 
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sorting, since a valine-to-methionine (val-66-met) substitution in the prodomain impaired 
proBDNF-sorting from the Golgi complex into secretogranin II-positive vesicles, which 
markedly reduced activity-dependent secretion of mature BDNF. This val-66-met 
substitution is a recognized polymorphism in the human bdnf gene that is associated with 
memory impairment and increased susceptibility to neuropsychiatric disorders (18-20). 
 Recently it was discovered that mature BDNF as well as proBDNF can be 
secreted, and the proteins appear to exert opposite biological effects by differential binding 
to two different receptors. Mature BDNF preferentially binds to and activates the TrkB 
receptor tyrosine kinase, inducing cell survival and differentiation signaling pathways, 
whereas proBDNF has a higher affinity for p75NTR, leading to cellular apoptosis (21; 
reviewed in 3, 5). This finding increased the complexity of understanding the physiological 
role of BDNF in the nervous system, and the molecular and cellular mechanisms 
underlying this role in many cases remain elusive. 
 In our studies, we use the South-African claw-toed frog Xenopus laevis as a model 
system, and more specifically the melanotrope cells of the intermediate pituitary. These 
cells regulate the process of background adaptation of this amphibian by releasing pigment 
dispersing α-melanophore stimulating hormone (α-MSH), a cleavage product of the 
prohormone proopiomelanocortin (POMC) (reviewed in 22-24). In the Xenopus 
melanotrope cells, both proBDNF and mature BDNF are present (25, 26), and when 
secreted by these cells mature BDNF can stimulate in an autocrine manner the release of α-
MSH and the biosynthesis of POMC (25).  
To gain more insight into the physiological role of pro- and mature BDNF, we 
used Xenopus transgenesis as a tool to cell-specifically overexpress proBDNF, mature 
BDNF or proBDNF fused to green fluorescent protein (GFP). This chapter describes the 
generation and analysis of a number of transgenic lines. In transgenic melanotrope cells 
expressing a non-tagged, noncleavable proBDNF, we did not detect significant effects, 
probably because of the relatively low levels of transgene expression. However, transgene 
expression of unprocessed GFP-proBDNF resulted in endoplasmic reticulum (ER) stress, 
implying the importance of the prodomain for a proper folding of proBDNF. In addition, 
these transgenic lines showed an impaired processing of newly synthesized secretory 
pathway proteins in the melanotrope cells.  
 
Materials and Methods 
 
Animals 
South African claw-toed frogs, Xenopus laevis, were reared in the Central Animal Facility 
of the Radboud University of Nijmegen (Nijmegen, The Netherlands). The animals were 
adapted to their background by keeping them in black buckets, with the lights turned on in 
cycles of 12 h. Experimental procedures were performed under the guidelines of the Dutch 
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law concerning animal welfare and permit RBD0166 (H10) to generate and house 
transgenic Xenopus. 
 
Antibodies 
An anti-BDNF antibody directed against the first 20 amino acid residues of mature BDNF 
(anti-BDNF; Santa Cruz) detected both proBDNF and mature BDNF on Western blots. 
GFP and tubulin were detected using a polyclonal anti-GFP antibody (anti-GFP; generous 
gift of Dr. B. Wieringa, Radboud University, Nijmegen, The Netherlands; 27) and the 
monoclonal anti-tubulin antibody E7 (Developmental Studies Hybridoma Bank, Rockland, 
Gilbertsville), respectively. Xenopus calnexin was detected with an anti-calnexin antibody 
(29), BiP with and anti-BiP antibody (29) (generous gifts of Dr. K. Geering, University of 
Lausanne, Lausanne, Switzerland), POMC with an anti-POMC antibody for Western 
blotting (ST62; generous gift of Dr. S. Tanaka, Shizuoka University, Japan; 30) or with an 
anti-adrenocorticotropic hormone (ACTH) antibody for immunocytochemistry (Biogenesis, 
Poole, UK), prohormone convertase PC2 with an anti-PC2 antibody against recombinant 
mature human PC2 (generous gift of Dr. W. Van de Ven, University of Leuven, Belgium; 
31) and p24δ2 with anti-p24-antibody 1262N (32). 
 
Cloning 
A number of constructs were made to obtain the linear DNA fragments that were used for 
Xenopus transgenesis. First, a fusion construct with GFP fused to the C-terminus of 
proBDNF was generated. For this, PCR amplification of the rat BDNF sequence was 
carried out in a reaction mixture containing Tgo buffer (Roche), 0.8 units Tgo DNA 
polymerase (Roche), 250 μM dNTPs, 0.5 μM of each primer and 1 μl rat brain cDNA (5 
amplication cycles: 1 min at 94°C, 1 min at 56°C and 1 min 30 sec at 72°C followed by 30 
amplification cycles of: 1 min at 94°C, 1 min at 70°C and 1 min 30 sec at 72°C). The 
following forward and reverse primers were used: 5’- GGGGAAGCTTGTTCCACCAGGTG-
AGAAGAGTGATG- 3’ (containing a HindIII restriction site (underlined)) and 5’- 
GGGGGGATCCCCGCTTTCTTCCCCTTTTAATGGTCAG- 3’ (containing an EcoRI restriction site 
(underlined) and an extra lysine and arginine codon (bold)). Subsequently, the amplified 
BDNF sequence was cloned via HindIII and EcoRI digestion into the pPOMC(A)2+-GFP 
vector (33), resulting in pPOMC-proBDNF-GFP. Secondly, fusion constructs were made in 
which GFP was fused to the N-terminus of proBDNF. For this, PCR amplification of the rat 
BDNF sequence was carried out in a reaction mixture containing Pfu buffer (Fermentas), 
0.05 units/μl Pfu Turbo DNA polymerase (Fermentas), 200 μM dNTPs, 0.5 μM of each 
primer and 1 ng pPCG(A)2+-BDNF vector DNA (De Groot et al., 2006) (35 amplification 
cycles: 30 sec at 95°C, 1 min at 50°C and 1 min 30 sec at 72°C). The forward primer used 
was 5’- GGGGGAATTCAAAAGGGCGCCCATGAAAGAAGCAAACG-3’ (containing an EcoRI 
restriction site (underlined) and an extra lysine and arginine codon (bold)) and the reverse 
primer 5’- GGGTCTAGAGCGCAAATGACTGTTTC-3’ (containing an XbaI restriction site 
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(underlined)). The EcoRI- and XbaI- digested PCR fragment was cloned into the 
pPOMC(A)2+-SP-GFP vector (34), resulting in the pPOMC-SP-GFP-proBDNF construct 
(used to generate transgenic line 78). The construct that was used to generate transgenic 
line 73 has been described previously (34; pPOMC-SP-GFP-proBDNF), except that it does 
not contain the two extra lysine and arginine amino acids between the GFP and BDNF 
sequence. Third, to generate a noncleavable GFP-proBDNF fusion protein, the two arginine 
residues constituting the cleavage site were mutated into two alanines using the 
QuickChange Site-directed Mutagenesis Kit (Stratagene). For this, we used the pPOMC-
SP-GFP-proBDNF construct described here as template DNA and primer 5’- 
CATGTCTATGAGGGTTGCCGCGCACTCCGACCCCGCC- 3’ (nucleotides responsible for amino 
acid substitution are underlined) for PCR amplification, resulting in the pPOMC-SP-GFP-
proBDNF(AA) construct, which was used to generate transgenic line 92. Fourth, double 
constructs were generated to overexpress untagged proBDNF or noncleavable proBDNF 
via Xenopus transgenesis. To generate transgenic line 6, we used construct pPCG-proBDNF 
described previously (34). The construct encoding the noncleavable proBDNF mutant 
protein expressed in transgenic line 111 was generated by cloning the AvaI- XbaI insert of 
pPOMC-SP-GFP-proBDNF(AA) into the pPCG-proBDNF vector (digested with AvaI and 
XbaI), resulting in the pPCG-proBDNF(AA) construct. 
 
Generation of transgenic Xenopus 
To create transgenic frogs, linear SalI/NotI DNA fragments were generated from the 
constructs pPOMC-SP-GFP-proBDNF (2552 bp (line 78) or 2546 bp (line 73)), pPOMC-
SP-GFP-proBDNF(AA) (2546 bp), pPCG-proBDNF (3577 bp) and pPCG-proBDNF(AA) 
(3577 bp) and a linear SalI/PauI fragment was generated from the construct pPOMC-
BDNF-GFP (2349 bp). These linear fragments were used for stable Xenopus transgenesis 
(34-36). A number of injection rounds resulted in animals transgenic for the fusion proteins 
GFP-proBDNF (line 73 and 78) and GFP-proBDNF(AA) (line 92), and non-tagged 
proBDNF (line 6) and noncleavable proBDNF(AA) (line 111). To generate F1 offspring, 
the testes of male transgenic Xenopus frogs were isolated and used for in vitro fertilization 
of eggs harvested from wild-type Xenopus females. 
 
Metabolic cell labeling 
Pituitary NILs were metabolically labeled as described previously (37). NILs were pulsed 
for 30 min and chased for 180 min. The amounts of newly synthesized 37-kDa POMC and 
of the 18-kDa POMC cleavage product (total of cellular and secreted protein) were 
quantified by densitometry using a phosphoimager (BioRad). Relative processing of 37-
kDa POMC was estimated by the ratio of 37-kDa to 18-kDa POMC and was presented in 
arbitrary units (n=3). An unpaired t test was used for statistical analysis and wild-type 
values were set at 1. 
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Western Blot analysis 
To detect steady-state protein levels in neurointermediate lobes (NILs) of transgenic and 
wild-type animals, Western blot analysis was performed after metabolic cell labeling as 
described previously (37), using the anti-BDNF, anti-GFP, anti-tubulin, anti-calnexin, anti-
BiP, anti-POMC, anti-p24 and anti-PC2 antibodies as primary antiserum. Signals were 
visualized with a BioChemi Imaging System, and relative quantification by densitometry 
was performed with Labworks 4.0 software (UVP BioImaging systems, Cambridge, UK). 
The densities of the various signals were normalized to the corresponding tubulin signals (n 
= 3). An unpaired t test was used for statistical analysis. 
 
Immunocytochemistry 
Paraffin sectioning and immunocytochemistry were performed as described previously 
(34). The anti-BDNF and anti-ACTH antibodies were used as primary antiserum. 
 
TUNEL assay 
To detect apoptotic cells, a TUNEL assay was performed on paraffin sections of NILs from 
wild-type and transgenic line-111 animals according to the manufacturer’s instructions (In 
Situ Cell Death Detection Kit, POD; Roche). Treatment of the sections with DNaseI or 
performing the reaction without enzyme acted as a positive and negative control for the 
assay. 
 
Results 
 
Generation of Xenopus transgenic for GFP-tagged or non-tagged proBDNF and 
noncleavable proBDNF(AA) 
We used various constructs to generate transgenic frogs that overexpress proBDNF, a 
noncleavable form of proBDNF (proBDNF(AA)) or these proteins fused to GFP (Fig. 1A). 
A Xenopus POMC gene promoter fragment was employed to express the transgene 
products specifically in the melanotrope cells of the intermediate pituitary. Transgenic 
tadpoles were identified by screening for GFP fluorescence in the pituitary (GFP-proBDNF 
and GFP-proBDNF(AA) fusion constructs) or in muscle tissue (non-tagged proBDNF and 
proBDNF(AA)). We created a number of transgenic Xenopus lines with overexpression of 
the GFP-proBDNF fusion protein (lines 73 and 78, of which transgenic line-78 animals had 
an extra arginine and lysine residue between the GFP and proBDNF sequence), GFP-
proBDNF(AA) fusion protein (line 92), proBDNF (line 6) or proBDNF(AA) (line 111) in 
the intermediate pituitary melanotrope cells (Fig. 1B). For unknown reasons, we did not 
succeed in generating animals that were transgenic for the proBDNF-GFP fusion protein, 
while the sequence of the construct was correct and transfected cells showed expression and 
fluorescence of the proBDNF-GFP protein (data not shown). 
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Figure 1: Generation of transgenic Xenopus with overexpression of GFP-tagged or non-tagged proBDNF or 
noncleavable proBDNF in the intermediate pituitary. 
(A) Schematic representation of the linear DNA fragments that were used for Xenopus transgenesis. 
Abbreviations: pPOMC, promoter of the proopiomelanocortin gene; proBDNF, proform of brain-derived 
neurotrophic factor; proBDNF(AA), proform of brain-derived neurotrophic factor with a mutated cleavage site 
resulting in noncleavable proBDNF; S, signal peptide of proBDNF; sp, signal peptide cloned in front of GFP; 
GFP, green fluorescent protein; Cac, cardiac actin gene promoter. (B) GFP fluorescence in transgenic Xenopus 
tadpoles. Tadpoles transgenic for GFP-proBDNF or GFP-proBDNF(AA) were identified via screening of 
fluorescence in the intermediate pituitary, and transgenic for PCG-proBDNF or PCG-proBDNF(AA) by GFP 
fluorescence in muscle. The various transgenic lines that were generated are indicated below the photographs. 
 
 
To examine the expression of the various transgene products in NIL lysates of 
adult transgenic animals, we performed Western blot analysis using anti-BDNF (Fig. 2A) 
and anti-GFP (Fig. 2B) antibodies. Using the anti-BDNF antibody, in transgenic line-73 
NILs we detected the ~65-kDa fusion protein GFP-proBDNF and 14-kDa mature BDNF. In 
contrast, in transgenic NILs from line 78, we observed only expression of 65-kDa GFP-
proBDNF. Thus, in various F0 animals with GFP-proBDNF expression the transgene was 
differentially processed, resulting in expression of either relatively high levels of mature 
BDNF (line 73) or the barely processed GFP-proBDNF fusion protein (line 78). In the NILs 
of transgenic line-92 animals, we detected besides the 65-kDa GFP-proBDNF(AA) fusion 
protein, a product of ~62 kDa, which probably corresponded to a non-glycosylated fusion 
protein. As expected, these line-92 mutant fusion proteins were not proteolytically cleaved. 
Remarkably, the amounts of the immunoreactive 46-kDa product that was reacting 
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nonspecfically with the antibody and that was detected in all NIL lysates were reduced in 
the NILs of line-78 and-92 animals, suggesting a possible effect of the uncleaved GFP-
proBDNF fusion protein on protein expression. Finally, transgenic NILs from lines 6 and 
111 showed a moderate transgene expression of ~14-kDa mature BDNF and 35-kDa 
proBDNF, respectively (Fig. 2A). In line with the results obtained with the anti-BDNF 
antibody, Western blot analysis with the anti-GFP antibody showed the 65-kDa GFP-
proBDNF fusion protein in lines 73 and 78, and the two 62- and 65-kDa GFP-proBDNF 
fusion proteins in line 92. In addition, in line 73 we observed a product of ~45 kDa 
representing a cleavage product of the GFP-proBDNF product. As expected, with this 
antibody no products were detected in wild-type, and transgenic lines-6 and -111 NILs (Fig. 
2B). 
To examine whether the melanotrope cells also secreted the transgene products, 
NILs were incubated in media that were subsequently used for Western blot analysis using 
the anti-BDNF antibody. We found only secretion of mature BDNF in line 73, and of GFP-
proBDNF(AA) in line 92. No secreted mature BDNF, proBDNF or GFP-proBDNF fusion 
protein was detected when NILs of wild-type animals or of animals of transgenic lines 78, 
92 and 111 were incubated (Fig. 2C). 
 
 
 
 
 
Figure 2: Steady-state protein expression in 
Xenopus intermediate pituitary cells 
transgenic for GFP-tagged or non-tagged 
proBDNF or noncleavable proBDNF. 
Western blot analysis of neurointermediate 
(NIL) lobe lysates (cells) of adult wild-type 
(wt) and adult transgenic animals (lines 73, 78, 
92, 6 and 111) using an anti-BDNF antibody 
(α-BDNF) (A) or an anti-GFP antibody (B). A 
non-specific immunoreactive ~46kDa product 
in A is indicated with an asterisk. (C) Western 
blot analysis of incubation media (medium) of 
NILs from adult wt and adult transgenic 
animals (lines 73, 78, 92, 6 and 111) using α-
BDNF. NILs were incubated for 3 h. 
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Effect of transgene expression of intact proBDNF or GFP-proBDNF on the 
biosynthesis and processing of POMC and the secretion of POMC-derived peptides by 
the transgenic Xenopus intermediate pituitary cells 
Next, the effects of transgene expression on melanotrope cell functioning, and more 
specifically the biosynthesis and processing of POMC and the secretion of POMC-derived 
peptides, were studied. The effects of the transgene expression of mature BDNF (lines 73 
and 6) have been described elsewhere (34). Here we report on the findings in transgenic 
animals with expression of unprocessed GFP-proBDNF (line 78), noncleavable GFP-
proBDNF(AA) (line 92) and noncleavable proBDNF(AA) (line 111). Metabolic labeling of 
NILs showed that following a 30-min pulse and a 180-min chase period in transgenic line-
111 animals with expression of noncleavable proBDNF (proBDNF(AA)), the biosynthesis 
and processing of POMC and secretion of POMC-derived peptides did not differ 
significantly from that by NILs of wild-type animals (Figs. 3C and D). In contrast, we 
found in transgenic line-78 and line-92 animals significantly less processing of newly 
synthesized 37-kDa POMC into 18-kDa POMC (Figs. 3A and B). Quantification of the 
amounts of 37-kDa and 18-kDa POMC in wild-type and transgenic animals revealed ~15-
fold and ~3-fold less processing in transgenic line-78 and -92 animals, respectively (Fig. 
3D). In addition, the processing of pro-prohormone convertase 2  (proPC2),  the pro-form 
of the enzyme involved in the proteolytic maturation of POMC, was also affected since in 
line-78 and -92 animals mainly the pro-forms of the enzyme were detected, whereas in 
wild-type NILs mature PC2 was present and secreted (Figs. 3A and B). 
 
Effect of transgene expression of intact proBDNF or GFP-proBDNF on steady-state 
levels of various secretory pathway proteins in Xenopus melanotrope cells 
To examine possible effects of the transgene expression of unprocessed GFP-proBDNF 
(line 78), noncleavable GFP-proBDNF(AA) (line 92) or noncleavable proBDNF (line 111) 
on the expression levels of a number of proteins in the melanotrope cells, Western blot 
analysis was performed on NIL lysates. We observed no differences in the steady-state 
levels of PC2, of the ER chaperone calnexin, of the putative ER-to-Golgi cargo receptor 
p24δ2, and of POMC. In contrast, we found an ~10-fold and ~5-fold up-regulation of 
steady-state expression of the ER chaperone BiP in transgenic line-78 and -92 animals, 
respectively, compared with BiP expression in NILs from wild-type and transgenic line-111 
animals (Figs. 4A and B).  
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Figure 3: Newly synthesized proteins produced in intermediate pituitary cells of wild-type Xenopus and 
Xenopus transgenic for unprocessed or noncleavable GFP-proBDNF or noncleavable proBDNF. 
Neurointermediate lobes (NILs) of black-adapted wild-type (wt) and transgenic line 78 (A), line 92 (B) or line 111 
(C) animals were pulse labeled for 30 min and chased for 180 min. Newly synthesized proteins extracted from the 
lobes were resolved by SDS-PAGE and visualized by fluorography. Abbreviations: (pro)PC2, (pro)prohormone 
convertase 2; GFP-proBDNF, green fluorescent protein fused to the proform of brain-derived neurotrophic factor; 
POMC, proopiomelanocortin. (D) Quantification of the processing of 37-kDa POMC into 18-kDa POMC. 
Densities of 37-kDa and 18-kDa POMC signals were determined and the ratio of 37-kDa to 18-kDa is given in 
arbitrary units (AU). Values are expressed as means ± SEM (n=3). Significant differences are indicated (**: 
p<0.01; ***: p<0.001). 
 
 
Effect of transgene expression of intact proBDNF on cellular apoptosis 
To detect any possible effects of proBDNF(AA) transgene expression (line 111) on cellular 
apoptosis, we used a TUNEL assay on paraffin sections of pituitaries of both wild-type and 
transgenic line-111 animals. We first performed immunocytochemistry to detect BDNF and 
POMC as a marker for the intermediate pituitary melanotrope cells. We found strong 
POMC staining in the intermediate pituitaries of both wild-type and transgenic line-111 
animals (Fig. 5A and B, respectively) and detected clearly more BDNF staining in the 
intermediate pituitaries of transgenic line-111 animals compared to wild-type animals, 
confirming the proBDNF(AA) transgene expression in line 111 (Fig. 5D and C, 
respectively). However, using the TUNEL assay we were not able to detect significant 
differences in the number of apoptotic cells in the pituitaries of wild-type (Fig. 5E) 
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compared to transgenic animals (Fig. 5F). Treatment of the sections with DNaseI or 
performing the reaction without enzyme acted as a positive and negative control for the 
assay, respectively, which indicated that the assay had worked properly (Figs. 5G and H). 
 
 
 
 
Figure 4: Steady-state levels of various secretory pathway proteins in intermediate pituitary cells of wild-
type Xenopus and Xenopus transgenic for unprocessed or noncleavable GFP-proBDNF or noncleavable 
proBDNF. 
(A) Western blot analysis of neurointermediate lobes of wild-type (wt) and transgenic line-78, -92 and -111 
animals using antibodies directed against proopiomelanocortin (POMC, prohormone convertase 2 (PC2), calnexin, 
BiP, p24δ2 and tubulin. The results shown are representatives of three independent experiments. (B) Quantification 
of the relative protein expression levels of POMC, PC2, calnexin, BiP and p24δ2 in wt and transgenic lines-78, -92 
and -111 neurointermediate lobes. Values (in arbitrary units (AU)) are expressed as means ± SEM (n=3). 
Significant differences are indicated (**: p<0.01; ***: p<0.001). 
 
 
Discussion 
 
The neurotrophin family member BDNF is a well-known neuronal survival and 
differentiation factor that has also been implicated in the process of synaptic plasticity 
(reviewed in 1-5). Like its family members, BDNF is produced as a proprotein that can be 
cleaved in the secretory pathway after which the mature protein is released from the cells 
(13, 14). However, in recent years the prodomain of neurotrophins has gained interest 
because exciting new data have shown that besides the mature form of BDNF also 
proBDNF can be released and that, compared with mature BDNF, the proform exerts an 
opposite effect on cells, namely the induction of apoptosis or facilitation of hippocampal 
long-term depression (18, 20, 38-40). In addition, the prodomain appears to be involved in 
the sorting of proBDNF to the proper subcompartment of the secretory pathway (15, 17).  
 In our study, we used the intermediate pituitary melanotrope cells of Xenopus 
laevis as a model system to study functional aspects of pro- and mature BDNF. For this, we  
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Figure 5: TUNEL assay on the pituitaries of wild-type Xenopus and Xenopus transgenic for noncleavable 
proBDNF. 
Immunocytochemistry on paraffin sections of wild-type (A, C) and transgenic line-111 (B, D) pituitaries to detect 
proopiomelanocortin (POMC; A, B), and brain-derived neurotrophic factor (BDNF; C, D). Abbreviations: pn, pars 
nervosa; pi, intermediate pituitary and pd, pars distalis. Scale bar = 100 μm. (E-H) Photographs of fluorescence of 
paraffin sections after a TUNEL assay to detect apoptotic cells in the pituitaries of wild-type (E) and transgenic 
line-111 (F) animals. Wild-type pituitaries were also used to perform a positive (G) and negative (H) control for 
the assay, by treating the sections with DNaseI or performing the reaction without enzyme, respectively. The 
intermediate pituitaries are encircled in white. Scale bar = 200 μm. 
 
 
generated transgenic Xenopus with expression of pro- or mature BDNF, or of GFP-tagged  
versions of these proteins specifically in the melanotrope cells. First, in transgenic line-111 
animals with transgene expression of noncleavable proBDNF(AA) in the pituitary 
melanotrope cells, we did not detect secreted proBDNF(AA) and did not find significant 
effects on the biosynthesis and processing of POMC and the secretion of POMC-derived 
peptides or on cellular apoptosis.  Possibly, these findings are due to the relatively low 
levels of transgene expression in line 111. 
Remarkably, we found that in various independently generated F0 animals 
transgenic for GFP-proBDNF the fusion protein was processed with different efficiencies. 
For example, transgenic line-73 animals showed effective GFP-proBDNF processing 
resulting in transgene expression of high amounts of mature BDNF, whereas line-78 
animals expressed a not efficiently processed intact fusion protein. This differential 
processing efficiency was observed in more independently generated transgenic F0 animals 
with GFP-proBDNF expression (data not shown). Possibly, in different transgenic animals 
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the transgenes are translated in different subcompartments of the ER, resulting in 
differences in protein folding and processing efficiencies. 
 Interestingly, in transgenic animals with transgene expression of non-processed or 
uncleaved GFP-proBDNF (lines 78 and 92) we found an up-regulation of the ER chaperone 
BiP. In general, upregulation of BiP is considered to be a hallmark of the unfolded protein 
response (UPR) (reviewed in 41-43). The UPR is a collective name for adaptive signaling 
mechanisms that the ER has developed to cope with accumulation of unfolded or misfolded 
proteins in the ER lumen, which can be caused by a number of biochemical and 
physiological stimuli imposing stress to the ER. The observed up-regulation of BiP in the 
transgenic melanotropes of our line-78 and line-92 animals implies that in these animals the 
folding of the fusion protein is impaired, leading to an accumulation of unfolded transgene 
product and ER stress. Possibly, the GFP moiety of the GFP-proBDNF fusion protein 
impaired a proper folding of the transgene protein in the ER. The prodomain of NGF, and 
thus presumably also of BDNF, is important for a proper folding of the proneurotrophin 
(44, 45), and therefore GFP N-terminally fused to BDNF might interfere with a proper 
intramolecular chaperone function of the prodomain. Remarkably, the GFP-proBDNF 
transgene product was processed highly efficient in the melanotrope cells of line-73 
animals. A C-terminally GFP-tagged BDNF fusion protein expressed in injected cortical 
neurons has been shown to be biologically active, mimicking the releasing characteristics of 
untagged BDNF (46, 47). Accordingly, we have tried to generate transgenic frogs with 
transgene expression of proBDNF-GFP, but unfortunately for unknown reasons we did not 
succeed in generating such transgenic animals (data not shown). 
In the transgenic melanotrope cells of lines 78 and 92, the ER stress also resulted 
in an impaired processing of POMC and of the processing enzyme proPC2. Previous 
studies have shown that overexpression of transgene proteins in cell lines, e.g. blood 
coagulation factor VIII (48, 49), or antitrombin III (50) can cause exhaustion of the 
capacity of the protein folding machinery, resulting in the accumulation of unfolded, 
aggregated proteins in the ER and activation of the UPR. However, in our case such an 
effect seems not to result from our transgenic approach per se, since in our lab we have thus 
far generated multiple transgenic lines with overexpression of other transgene products that 
were directed to the secretory pathway, like the serine protease inhibitor neuroserpin 
(chapter 4) or prion protein (51), in which we have not observed a UPR. 
The accumulation and lack of secretion of unprocessed GFP-proBDNF by the 
melantorope cells of our transgenic line-78 animals reminded us of transfection studies 
dealing with cellular aspects of the BDNF val-66-met polymorphism. In these studies, 
trafficking of proBDNFMET was altered from the regulated secretory pathway to a more 
concentrated distribution of the protein in the cell body of polarized neurosecretory cells, 
and a decrease in regulated BDNF secretion (18, 20). We now find that unprocessed 
proBDNF can induce ER stress and a block of protein transport and processing of other 
secretory pathway proteins, which implies that intact BDNF affects neuroendocrine cell 
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functioning. We propose that the impaired intracellular trafficking of proBDNFMET also 
imposes stress to the ER, resulting in a reduced transport, processing and secretion of other 
neuronal secretory pathway proteins. Eventually, this may lead to multiple effects of 
proBDNFMET on neuronal cell functioning, possibly explaining some aspects of the wide 
variety of phenotypes observed in individuals carrying the BDNFMET polymorphism. 
In conclusion, we generated and analysed transgenic Xenopus with expression of 
pro- and mature BDNF, and GFP-tagged versions of these proteins to study aspects of the 
physiological role of pro- and mature BDNF in the Xenopus intermediate pituitary 
melanotrope cells. We found that transgene expression of noncleavable proBDNF(AA) did 
not result in a clear phenotype, presumably due to the low levels of transgene expression. 
However, transgene expression of intact GFP-proBDNF resulted in ER stress and a block in 
secretory protein transport. These results imply that intact proBDNF can affect the transport 
of proteins through the (regulated) secretory pathway, resulting in an impaired functioning 
of neuroendocrine cells. 
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Abstract 
 
Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family of neuronal 
cell survival and differentiation factors, but is thought to be involved in neuronal cell 
proliferation and myelination as well. To explore the role of BDNF in vivo, we employed 
the intermediate pituitary melanotrope cells of the amphibian Xenopus laevis as a model 
system. These cells mediate background adaptation of the animal by producing high levels 
of the prohormone proopiomelanocortin (POMC) when the animal is black adapted. We 
used stable Xenopus transgenesis in combination with the POMC gene promoter to generate 
transgenic frogs overexpressing BDNF specifically and physiologically inducible in the 
melanotrope cells. Intriguingly, an ~25-fold overexpression of BDNF resulted in 
hyperplastic glial cells and myelinated axons infiltrating the pituitary, whereby the 
transgenic melanotrope cells became located dispersed among the induced tissue. The 
infiltrating glial cells and axons originated from both peripheral and central nervous system 
sources. The formation of the phenotype started around tadpole stage 50 and was induced 
by placing white-adapted transgenics on a black background, i.e. following activation of 
transgene expression. The severity of the phenotype depended on the level of transgene 
expression, since the intermediate pituitaries from transgenic animals raised on a white 
background or from transgenics with only an ~5-fold BDNF overexpression were 
essentially not affected. In conclusion, we show in a physiological context that, besides its 
classical role as neuronal cell survival and differentiation factor, in vivo BDNF can also 
induce glial cell proliferation as well as axonal outgrowth and myelination. 
 
Introduction 
 
Similar to its neurotrophin family members neurotrophin-3 and -4/5, brain-derived 
neurotrophic factor (BDNF) was originally identified as a neuronal survival and 
differentiation factor. BDNF is now also known as a modulator of neurotransmission and 
synaptic plasticity in the central and peripheral nervous systems (CNS and PNS, 
respectively), and for its role in neurite growth (1-11). In addition to these classical 
functions, evidence is emerging that BDNF has a broader role in nervous system 
functionality. For example, BDNF likely functions as a regulator of myelination in that it 
enhances myelin formation by Schwann cells in the peripheral nervous system (12-14) and 
by oligodendrocytes after spinal cord injury in the central nervous system (15). In addition, 
the neurotrophin may be involved in the proliferation of neuronal cells, since infusion of 
BDNF into the lateral ventricle of adult rat led to new neurons in various brain regions (16) 
and bacterial meningitis in mice caused an increase in BDNF expression resulting in 
neurogenesis (17). Finally, BDNF may stimulate the proliferation of glial cells as well (15, 
18-20). 
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For a study on the physiological role of BDNF, the melanotrope cells of the 
intermediate pituitary of the amphibian Xenopus laevis constitute an attractive cell model 
system. BDNF has been found to be expressed in the Xenopus melanotrope cells (21). The 
melanotropes play an essential role in the process of background adaptation of Xenopus. On 
a black background, the melanotrope cells are biosynthetically very active, synthesize large 
amounts of the prohormone proopiomelanocortin (POMC) and release the POMC-derived 
peptide α-melanophore stimulating hormone (α-MSH), which causes pigment dispersion in 
skin melanophores. In contrast, on a white background the cells are biosynthetically 
inactive and α-MSH release is inhibited. Thus, the biosynthetic and secretory activity of the 
melanotrope cells can be physiologically manipulated by placing the animals on either a 
black or a white background. At the cellular level, the activity of the melanotrope cells is 
regulated by hypothalamic neurons that directly contact the melanotrope cells and release 
various neurochemical messengers (reviewed in 22, 23).  
 Previously, effects of BDNF overexpression have been examined in transgenic 
mice, in which an increase in myelination (14), dendrite complexity in hippocampal dentate 
gyrus (24), learning and excitability (25), and sensory innervation and neuron number (26) 
has been observed. In the present study, we combined the unique properties of the Xenopus 
melanotrope cell with the technique of stable Xenopus transgenesis (27, 28) to explore the 
role of BDNF in vivo. Transgene expression of BDNF was driven by a Xenopus POMC 
promoter fragment, allowing expression of the transgene to be physiologically inducible 
and specific to the melanotrope cells (29), and leaving the integrity of the regulatory 
hypothalamic neurons intact. Analysis of the transgenic animals revealed that in vivo BDNF 
can induce Schwann cell and glial cell proliferation, as well as axonal outgrowth and 
myelination. 
 
Materials and Methods 
 
Animals 
South African claw-toed frogs, Xenopus laevis, were reared in green containers (unless 
stated otherwise) in the Central Animal Facility of the Radboud University of Nijmegen 
(Nijmegen, The Netherlands) with a light/dark cycle of 12 h. The animals were adapted to 
their background by keeping them in either white or black buckets for at least three weeks. 
For long-term black adaptation, line-6 transgenic animals were kept on a black background 
for >9 months. Experimental procedures were performed under the guidelines of the Dutch 
law concerning animal welfare. 
 
Antibodies 
Pro- and mature BDNF were detected with an anti-BDNF antibody directed against the first 
20 amino acids of mature BDNF (Santa Cruz Biotechnology, Inc., California). POMC and 
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adrenocorticotropic hormone (ACTH) were detected with an anti-POMC/ACTH antibody 
(generous gift of Dr. E. Roubos, Radboud University, Nijmegen, The Netherlands; 43), 
vasotocin and mesotocin with an anti-vasotocin and anti-mesotocin antibody, respectively 
(generous gifts of Dr. F. Vandesande and Dr. L. Arckens, respectively, Catholic University 
Leuven, Belgium; 44, 45), and prolactin with an anti-prolactin antibody (generous gift of 
Dr. J. Mattheij, Wageningen University, The Netherlands; 46). Glial fibrillary acidic 
protein (GFAP) was detected with a polyclonal anti-GFAP antibody (DAKO, Glostrup, 
Denmark), and tubulin with the monoclonal E7 anti-tubulin antibody (Developmental 
Studies Hybridoma Bank, Rockland, Gilbertsville). 
 
Generation of DNA constructs encoding BDNF 
Two different constructs encoding BDNF (pPCG(A)+-BDNF) and a green fluorescent 
protein (GFP)-BDNF fusion protein (pPOMC(A)+-SP-GFP-BDNF) were generated. For 
the construction of pPCG(A)+-BDNF, first the pPCG(A)2+ vector was made, consisting of 
the pCS2+ backbone (47), a 540 bp SalI-HindIII Xenopus POMC gene A promoter 
sequence (29),  a 0.65 kb SalI-HindIII fragment of the cardiac actin promoter (kindly 
provided by Paul Krieg, University of Arizona Health Sciences Center, Tucson, AZ, USA), 
the GFP sequence and the HSV-tk polyA signal obtained by PCR on the pIRES2-EGFP 
vector (ClonTech, Mountain View, CA, USA). To clone the BDNF sequence, total RNA 
was isolated from rat brain tissue according to the manufacturer’s instructions (Life 
Technologies, Inc., Carlsbad, CA, USA). The RNA was dissolved in 20 µl RNase-free H2O 
and the concentration was measured with a GeneQuant RNA/DNA calculator (Pharmacia, 
New York, New York, USA). For RT-PCR, one μg total rat brain RNA was reverse 
transcribed into cDNA according to the manufacturer’s instructions (Life Technologies, 
Inc.). BDNF was amplified by PCR in a reaction mixture containing Pfu buffer (Fermentas, 
Hanover, MD, USA), 200 μM dNTPs, 0.5 mM 5’ primer (5’- GGGGAAGCTTGTTCCACCAGG 
TGAGAAGAGTGATG -3’), 0.5 mM 3’ primer (5’- GGGGGAATTCTGCGCAAATGACTGTTTCTTTC 
TGGTC -3’), 0.01 U Pfu Turbo DNA polymerase (Fermentas) and 1 μl cDNA (35 
amplification cycles: 30 sec at 95°C, 1 min at 56°C and 1.5 min at 72°C). The amplified 
product was digested with HindIII and EcoRI, and cloned behind the POMC gene A 
promoter fragment in the vector pPCG(A)2+, resulting in the pPCG(A)+-BDNF vector. 
Since the rat and Xenopus laevis protein sequences of mature BDNF are highly conserved 
(amino acid sequence identity is 94%), and in view of the phenotype of the BDNF-
transgenic animals, the transgene product was likely recognized by the frog receptors. For 
the construction of the pPOMC(A)2+-SP-GFP vector, the coding sequence of GFP was 
amplified via PCR and fused in the correct reading frame downstream of the signal peptide 
(SP) sequence of Xenopus Ac45. The SP-GFP fusion was subcloned with BamHI and 
EcoRI into the pCS2+(A) vector, thereby generating pCS2+(A) SP-GFP. Finally, the CMV 
promoter was interchanged with the POMC promoter (29) using the SalI and HindIII 
restriction sites. Next, to generate the GFP-BDNF fusion protein, the sequence of BDNF 
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without the signal peptide was amplified via PCR (35 amplification cycles; 30 sec 95°C, 1 
min 50°C and 1 min and 30 sec 72°C), using 10 ng pPCG(A)+-BDNF vector as input 
DNA, and the primers 5’- GGGGGAATTCGCGCCCACTGAAAGAAGCAAACG -3’ and 5’- 
GGGGTCTAGAGCGCAAATGACTGTTTC -3’. The amplified product was digested with EcoRI 
and XbaI, and cloned in frame behind the sequence of GFP in the pPOMC(A)2+-SP-GFP 
vector. This resulted in the pPOMC(A)+-SP-GFP-BDNF vector. The generated constructs 
were checked by cycle sequencing using the Big Dye Ready Reaction system (Perkin 
Elmer, Wellesley, MA, USA).  
 
Generation of Xenopus transgenic for BDNF 
To generate transgenic frogs, linear 3577-bp and 2546-bp SalI/NotI DNA fragments were 
generated from the pPCG(A)2+-BDNF and pPOMC(A)2+-SP-GFP-BDNF constructs, 
respectively. These linear fragments were used for stable Xenopus transgenesis (27, 28). A 
number of injection rounds resulted in animals transgenic for BDNF (line 6) and the fusion 
protein GFP-BDNF (line 73). To generate F1 and F2 offspring, the testes of male 
transgenic Xenopus frogs were isolated and used for in vitro fertilization of eggs harvested 
from wild-type Xenopus females. 
 
Western blot analysis 
To analyse protein expression in wild-type and transgenic pituitary neurointermediate lobes 
(NILs; consisting of the pars nervosa and intermediate pituitary) and pars distalis, tissue 
homogenates were made in lysis buffer (50 mM HEPES, 140 mM NaCl, 0.1% Triton X-
100, 1% Tween 20, 1 mM EDTA, 1 mg/ml deoxycholate, 1 μM phenylmethylsulfonyl 
fluoride, 0.1 mg/ml soybean tryspin inhibitor). To analyse secreted proteins by NILs, lobes 
were incubated in Ringer’s medium (112 mM NaCl, 15 mM Hepes (pH 7.4), 2 mM KCl, 2 
mM CaCl2, 2 mg/ml glucose and 0.3 mg/ml bovine serum albumine) for 3 h after which 
media were collected and NILs were homogenized. After a 20-min incubation on ice, 
samples were centrifuged for 20 min (15,300 rpm, 4°C) and sample buffer (50 mM TrisCl 
(pH6.8), 100 mM dithiothreitol, 2% sodiumdodecylsulphate, 0.1% bromephenol blue, 10% 
glycerol) was added to the supernatant. Samples were heated for 5 min at 100°C and 
Western blot analysis was performed as described previously (48). Blots were incubated 
overnight with primary antiserum and the antibody dilutions used were 1:1000 for anti-
BDNF and 1:500 for anti-tubulin. The equivalent of ~40% of one NIL or pars distalis was 
loaded per lane. Signals were visualized with a BioChemi Imaging System, and relative 
quantification by densitometry was performed with Labworks 4.0 software (UVP 
BioImaging systems, Cambridge, UK). Densities of mature BDNF signals in NILs of wild-
type, line-6 and line-73 transgenic animals and of white- and black-adapted line-73 animals 
were measured and related to an ~47-kDa non-specific immunoreactive signal as an 
internal control or to tubulin expression, respectively. An unpaired t test was used for 
statistical analysis. 
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Immunocytochemistry 
For cryosectioning, Xenopus brains with pituitary glands attached were immersed in 10% 
sucrose in 0.1 M sodium phosphate buffer (pH 7.4) for 16 h at 4°C, and subsequently 
frozen in Tissue-Tek (Sakura, Tokyo, Japan). Sagittal sections (20 μm) were mounted on 
poly-L-lysine-coated slides and dried at 37°C for 16 h. Finally, direct GFP fluorescence 
was viewed under a fluorescence microscope. Alternatively, Xenopus brains with pituitary 
glands attached were frozen in liquid N2 immediately after dissection. Next, sagittal 
sections (5 μm) were mounted on uncoated slides and dried at room temperature for 12 h. 
For immunocytochemistry, sections were blocked in 0.2% bovine serum albumin (BSA) in 
phosphate-buffered saline (PBS) for 30 min and subsequently incubated with primary 
antiserum (1:100 anti-GFAP) for 1 h and secondary antiserum (1:200 goat anti-rabbit Alexa 
488) for 1 h. 
 For paraffin sectioning, Xenopus brains with pituitary glands attached were fixed 
for 4-12 h in Bouin-Hollande solution, dehydrated and embedded in paraffin. Serial sagittal 
5 μm sections were mounted on gelatine-coated glass slides. After deparaffinization and 
rehydration, sections were blocked with 20% normal goat serum in Tris-buffered saline 
(TBS) for 10 min, and then incubated with primary antiserum (1:300 anti-BDNF, 1:2000 
anti-POMC/ACTH, 1:4000 anti-vasotocin and anti-mesotocin, and 1:500 anti-prolactin) for 
16 h, with goat anti-rabbit immunoglobulin G (1:100; Nordic Immunology, Tilburg, The 
Netherlands) for 1 h, and finally with rabbit peroxidase-antiperoxidase (1:800; Nordic 
Immunology) for 1 h. To detect BDNF, sections were incubated with anti-BDNF antibody 
for 24 h, subsequently with biotinylated goat anti-rabbit immunoglobulin (1:200; 
Vectastain, Vector Laboratories, Burlingame, CA, USA) for 2 h, and finally with ABC 
reagent (1:100; Vectastain) for 30 min. Finally, after antibody incubations and washing in 
TBS without saline, sections were treated with 0.025% 3,3’-diaminobenzidine 
tetrahydrochloride (Sigma), 0.25% nickel ammonium sulphate and 0.01% hydrogen 
peroxide in 0.05M Tris-HCl, pH 7.6 to reveal peroxidase activity. For myelin staining, 
paraffin-embedded sections were incubated in Luxol fast blue (LFB) solution (0.1% LFB 
MBS (Chroma, Muenster, Germany) 0.05% acetic acid in 96% ethanol) for 16 h, followed 
by a differentiation of 1 min in 0.1% lithium carbonate and 3-5 min in 70% ethanol. 
Finally, the sections were stained with hematoxylin and eosin (HE). 
 
Microscopy analysis 
For microscopy analysis of Xenopus wild-type and transgenic pituitaries, paraffin sections 
of the tissues were examined in a Leitz Dialux 22 microscope (Leica Microsystems, 
Wetzlar, Germany) and photographs were taken with a Nikon Coolpix 900 camera (Nikon, 
Tokyo, Japan). Cryosections were directly viewed under a Leica DM RA fluorescent 
microscope and photographs were taken with a Cohu High Performance CCD Camera 
(Cohu, Inc., San Diego, USA) using the Leica Q Fluoro software. Dissection of Xenopus 
brain and pituitary was performed under a Leica MZ FLIII fluorescent stereomicroscope 
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and photographs were taken with a Leica DC200 color camera using the Leica DCviewer 
software. For a more detailed microscopy analysis of Xenopus wild-type and transgenic 
pituitaries, freshly dissected NILs of long-term black-adapted line-6 animals, and 3-weeks 
black-adapted wild-type and line-73 Xenopus were used. Whole lobes were fixed by high-
pressure freezing (Leitz) and substituted by automatic freeze substitution using acetone and 
2% osmium tetroxide. After this, tissues were rinsed with acetone, incubated in 
epon:acetate, and embedded in Epon 812. One-micron thick sections were cut and stained 
with toluidine blue. Subsequently, the sections were examined under a Leica DM6000B 
microscope, and pictures were taken using a Leica DFC480 camera and Leica IM500 
Image manager software. 
 
Quantification of GFAP+ cells 
To estimate the number of GFAP+ cells in GFAP-stained cryosections of the pituitaries of 
wild-type and line-73 transgenic animals, the number of GFAP+ cells was counted in 6 
(wild-type) and 9 (line 73) unit areas (~80 x 80 μm) in two different sections of the 
intermediate pituitary and nodule of wild-type and line-73 animals, respectively. Since in 
line-73 animals the GFAP+ cells were not evenly distributed throughout the nodule, unit 
areas mainly consisting of glial cells were chosen. Cell counts were summed for each 
animal and the mean for line 73 animals was compared to that of wild-type animals. An 
unpaired t test was used for statistical analysis. 
 
Real-time quantitative RT-PCR analysis 
To examine TrkB and p75NTR neurotrophin receptor mRNA expression levels in the NIL 
and cranial nerves III, V and VII, real-time quantitative RT-PCR analysis was performed as 
described previously (48), using the iTaq SYBR Green Supermix with ROX kit (BioRad, 
CA, USA). The following primer sets were used to amplify TrkB, p75NTR and 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH), respectively: 5’- ACCTCTACCGCGA 
GCAAGAC- 3’ and 5’- GAGTAACTCTGCTTCCCGATGAA- 3’ (forward and reverse primer for 
TrkB, respectively), 5’- GGGAAAGTCTGAGCTTGCTG- 3’and 5’- CACTATCTGTGAGGACGGTG- 
3’ (forward and reverse primer for p75NTR, respectively) and 5’-GCCGTGTATGTGGTGG 
AATCT-3’ and 5’-AAGTTGTCGTTGATGACCTTTGC-3’ (forward and reverse primer for 
GAPDH, respectively). 
 
Results 
 
Generation of transgenic Xenopus with overexpression of BDNF specifically in the 
intermediate pituitary melanotrope cells 
To generate frogs transgenic for BDNF, we made and used two different DNA constructs, 
one construct driving transgene expression of BDNF to the melanotrope cells as well as 
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green fluorescent protein (GFP) to muscle cells for identification of the transgenics 
(resulting in transgenic line 6; Fig. 1A), and a second construct encoding BDNF fused to 
the C-terminus of GFP (GFP-BDNF) and driving expression to the melanotrope cells 
(transgenic line 73; Fig. 1B). Melanotrope cell-specific transgene expression was 
accomplished by using constructs in which the BDNF- and GFP-BDNF-encoding 
sequences were cloned behind a POMC gene promoter fragment. The transgenic tadpoles 
were identified via direct screening for GFP fluorescence in muscle (in tadpoles from line 
6; Fig. 1A) or in the intermediate pituitary (in line 73 tadpoles; Fig. 1B).  
 
 
Figure 1: Generation of 
transgenic Xenopus laevis 
with BDNF overexpression 
specifically in intermediate 
pituitary melanotrope 
cells.  
Schematic representation of 
the two different constructs 
that were used to generate 
transgenic lines 6 (A) and 73 
(B). Transgenic tadpoles 
were identified via screening 
for GFP fluorescence in muscle (line 6; A, white arrow) or in the intermediate pituitary (line 73; B, white arrow). 
Abbreviations used are: pPOMC, proopiomelanocortin gene promoter; proBDNF, pro-brain-derived neurotrophic 
factor; pCaC, cardiac actin gene promoter; S, signal peptide; GFP, enhanced green fluorescent protein. 
 
 
 To examine the amount of steady-state BDNF protein in the two transgenic lines 6 
and 73, lysates of the pituitary NIL and pars distalis of adult wild-type and transgenic frogs 
were used for Western blot analysis with an anti-BDNF antibody. NILs from transgenic 
lines 6 and 73 had ~ 5- and ~25-fold higher levels of mature BDNF expression compared to 
wild-type NILs, respectively (Fig. 2). BDNF transgene expression in lines 6 and 73 was 
melanotrope cell specific since the transgene was not expressed in the pars distalis (Fig. 2). 
Analysis of the incubation media showed the secretion of the mature transgene BDNF-
product by line-73 NILs. We did not detect secreted BDNF from wild-type or line-6 
transgenic NILs (Fig. 2, right panel). Since secreted BDNF is known to have a relatively 
short half-life (30, 31), the absence of BDNF in the media is probably caused by protein 
degradation. We thus generated transgenic lines 6 and 73 with moderate and relatively high 
overexpression of mature BDNF specifically in the intermediate pituitary melanotrope 
cells, respectively.  
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Figure 2: BDNF protein expression in the pituitary neurointermediate lobe of wild-type and BDNF-
transgenic Xenopus.  
Western blot analysis of neurointermediate lobe (NIL) and pars distalis (PD) cell lysates and media of wild-type 
(wt) and lines-6 and -73 transgenic animals using an anti-BDNF antibody. Tubulin expression served as a loading 
control.  
 
 
Effect of BDNF transgene expression in the Xenopus melanotrope cells on the 
anatomy and histology of the pituitary 
To examine the effect of BDNF overexpression in the transgenic melanotrope cells on the 
histology of the pituitary, cryo- and paraffin sections were made of wild-type and lines-6 
and -73 pituitaries, and immunocytochemistry screening of the sections was performed 
using a number of antibodies. Staining with an anti-POMC/ACTH antibody to identify the 
melanotrope cells of the intermediate pituitary and the corticotropic cells of the pars distalis 
showed that the localization of these cells in transgenic line 6 animals was comparable to 
that in wild-type animals (Figs. 3A and B). Remarkably, in line 73 animals we observed a 
nodule that was ~10-15 times larger than the intermediate pituitary of wild-type animals, 
and in which the transgenic melanotrope cells were intermingled in tissue that is normally 
not found in the intermediate pituitary (Fig. 3C). Thus, the intermediate pituitary of line 73 
transgenic animals was not intact anymore. Distributed melanotrope cells were also 
observed in sections stained with an anti-BDNF antibody (Fig. 3F) and via direct GFP 
fluorescence in cryosections of transgenic line 73 pituitaries (Fig. 3G). The melanotrope 
cells of lines 6 and 73 transgenic animals showed higher expression levels of BDNF than 
wild-type cells (Figs. 3D to F), in line with the western blot results (Fig. 2A).  
We then wondered what the effect of melanotrope BDNF overexpression would be 
on the histology of the pituitary pars nervosa and pars distalis. Immunocytochemistry 
screening using an anti-vasotocin antibody (specific for vasotocinergic neurons of the pars 
nervosa) and an anti-prolactin antibody (specific for lactotropic cells of the pars distalis) 
showed that in transgenic lines 6 and 73 the two pituitary lobes were similar to those of 
wild-type animals (Figs. 3H-M). However, occasionally a number of vasotocinergic-
positive fibers were found among the scattered melanotrope cells in the nodules of 
transgenic line 73 animals (Fig. 3J).  
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Figure 3: Pituitary histology of wild-type animals and transgenic Xenopus overexpressing BDNF in the 
intermediate pituitary melanotrope cells.  
Serial sagittal paraffin sections were made of the pituitary of wild-type (wt) and lines-6 and -73 transgenic 
animals, and the sections were stained for proopiomelanocortin/ adrenocorticotropic hormone (POMC/ACTH; A, 
B, C), BDNF (D, E, F), vasotocin (H, I, J) and prolactin (K, L, M). (G) Cryosection of the pituitary of a line-73 
transgenic animal showing direct green fluorescent protein (GFP) fluorescence. The arrow in J indicates an 
example of vasotocin-positive fibers localized in the nodule of a line-73 transgenic pituitary. Abbreviations used 
are: pn, pars nervosa; pi, intermediate pituitary; pd, pars distalis and n, nodule. Scale bars: 200 μm (A and B) and 
250 μm (C). 
 
 
In order to characterize the additional tissue that was observed in the nodules of 
transgenic line 73 pituitaries, paraffin sections were stained with HE and LFB solution 
(staining for myelin). We found that in the nodules the melanotrope cells were surrounded 
by hyperplastic Schwann cells and axons of PNS origin, and hyperplastic glial cells and 
axons of CNS origin. Furthermore, a significant part of the various axons was myelinated 
(Fig. 4A). Additional evidence for the presence of Schwann/glial cells was provided by 
immunocytochemistry with anti-GFAP antibody, showing a clear and specific glial staining 
in the nodules of transgenic line 73 pituitaries (Fig. 4B). 
Line-6 animals have a relatively low level of transgene BDNF expression in the 
melanotrope cells. Initially, we did not detect a pituitary phenotype in these animals, and 
we therefore wondered whether a relatively long time of adaptation of these animals to a 
black background (and thus a relatively long time period during which cells had been 
exposed to the transgene product) may cause a pituitary phenotype. For this purpose, line-6 
animals were adapted to a black background for >9 months, a relatively long adaptation 
period since animals are normally adapted for three weeks. Pituitaries of long-term black- 
adapted line-6 animals and 3-weeks black-adapted wild-type and line-73 animals were then 
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prepared for microscopy analysis. Interestingly, in sections of long-term black-adapted lin-
6 animals we detected the same phenotypic characteristics (namely Schwann and glial cells, 
and myelinated axons) as were observed in the nodules of line-73 animals (Fig. 5). Thus, in 
line-6 transgenic animals a prolonged exposure to the transgene BDNF product induced a 
phenotype similar to that observed in line-73 animals. Furthermore, the fact that two 
independent BDNF transgenic animals (lines 6 and 73) display a similar phenotype 
excludes the possibility that the phenotype would be due to a position effect (i.e. due to the 
integration of the transgene). 
 
 
 
Figure 4: Characterization of tissues in the nodules 
of BDNF-transgenic Xenopus line 73. (A) 
Hematoxylin/eosin (HE) and luxol fast blue (LFB) 
staining for myelin (blue) of sagittal paraffin sections 
of the pituitaries of wild-type (wt) and line-73 
transgenic animals. The upper panels represent 
overviews of the whole pituitary, consisting of the pars 
nervosa (pn), intermediate pituitary (pi) and pars 
distalis (pd). The boxed areas are enlarged in the lower 
panels. Scale bars: 200 and 250 μm (upper panels, wt 
and line 73, respectively) and 25 μm (lower panels). 
(B) Glial fibrillary acidic protein (GFAP) staining of 
cryosections of the pituitaries of wt and line-73 
transgenic animals. Shown are details of a wt 
intermediate pituitary (left panel) and of a line-73 
nodule (right panel). Scale bar: 25 μm.  
 
 
 
 
 
  
Together, these results show that relatively high transgene BDNF expression in the 
line-73 pituitaries resulted in the formation of nodules that were 10-15 times larger than 
wild-type intermediate pituitaries. Pituitaries from line-6 transgenic animals that had been 
black adapted for a relatively short time period were morphologically comparable to wild-
type pituitaries, whereas long-term black adaptation of these animals resulted in 
characteristics of the nodule phenotype. In the nodules of line-73 animals, the melanotrope 
cells were intermingled among proliferated Schwann cells and axons from the PNS and 
glial cells and axons of CNS origin, a significant part of which was myelinated. 
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Figure 5: Light-microscopical pictures of one-μm epon sections of the pituitaries of relatively long-term 
black-adapted (BA) line-6 transgenic Xenopus and 3-weeks BA wild-type and line-73 transgenic animals. 
Shown are details of the intermediate pituitaries of wild-type (wt) Xenopus and lines-6 and -73 transgenic 
Xenopus. c: melanotrope cell, a: myelinated axon and g: Schwann/glial cell. Scale bar: 10 μm. 
 
 
Origin of the nodule in transgenic Xenopus line 73  
We then wanted to determine the origin of the induced tissues in the nodules of line-73 
transgenic animals. The amphibian pituitary is surrounded by a number of brain areas and 
cranial nerves that potentially could form the source of the infiltrating tissues (Fig. 6A). 
First, to examine the source of the observed hyperplastic Schwann cells and axons, we 
carefully dissected the brain and pituitary of wild-type, line-6 and line-73 animals under a 
stereomicroscope (Figs. 6B to E). In line-6 transgenic animals that were adapted to a black 
background for three weeks (a relatively short period of adaptation), the morphology of the 
NILs was comparable to that of wild-type NILs (Figs. 6B and C). In contrast, the nodule-
containing pituitaries of line-73 transgenic animals were anatomically connected to two 
cranial nerves, i.e. cranial nerves V and VII (the trigeminal and facial nerves, respectively; 
Figs. 6A and E). In addition, in line-6 transgenic animals that were adapted to a black 
background for 9 months (a relatively long adaptation period) the NILs were also connected 
to these cranial nerves (Fig. 6D). Thus, since the nodules in line-73 transgenic pituitaries 
were anatomically connected to the facial and trigeminal nerves, the infiltrating PNS-
derived Schwann cells and myelinated axons that were present in the nodules probably 
originated from these cranial nerves. 
We next examined in more detail from which CNS region the hyperplastic glial 
cells and axons in the line-73 nodules originated. Staining of paraffin sections of line-73 
pituitaries with an anti-mesotocin or anti-vasotocin antibody revealed in the nodule the 
presence of mesotocinergic and vasotocinergic fibers from the pituitary pars nervosa (Figs. 
6F and G). These results indicated that the glial cells and axons with CNS characteristics 
found in the nodules of line-73 pituitaries most likely originated from the pituitary pars 
nervosa.  
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Figure 6: Origins of the 
hyperplastic Schwann 
cells, glial cells and axons 
in the nodules of BDNF-
transgenic Xenopus line 
73. 
(A) Schematic lateral view 
of a frog brain. Figure was 
derived from Nieuwenhuys 
et al. (49). Indicated are: 
VIIIa, nervus vestibulo-
cochlearis, posterior root; 
VIIIb, nervus vestibulo-
cochlearis, anterior root; 
VII, nervus facialis; V, 
nervus trigeminus; III, 
nervus oculomotorius; pn, 
pars nervosa; pi, inter-
mediate pituitary and pd, 
pars distalis. (B, C, D, E) 
Dorsal view of the brain 
cavity (c) after removal of 
the brain (br) of a wild-
type (wt) animal (B), line-6 
transgenic animals (short- 
and long-term black-
adapted (BA); C and D, 
respectively) and line-73 
transgenic animal (E). The 
pituitary pars distalis (pd) 
and neurointermediate lobe (NIL) are visible lying on the floor of the brain cavity. The numbers V/VII indicate the 
trigeminal and facial nerves, and the white arrowheads indicate connections between these nerves and the NIL 
(line 6) or nodule (line 73). Scale bar used is 1 mm. (F, G) Sagittal paraffin sections of a line-73 pituitary stained 
with anti-mesotocin (F) or anti-vasotocin (G) antibody. Examples of mesotocinergic- or vasotocineric-positive 
fibers in the intermediate pituitary are indicated with arrows. Scale bar: 200 μm. 
 
 
Altogether, our study concerning the origin of the PNS-derived hyperplastic 
Schwann cells and axons, and CNS-derived glial cells and axons in the nodules of line-73 
transgenic animals indicated that the PNS- and CNS-derived infiltrating tissues originated 
from the cranial nerves V and VII, and the pituitary pars nervosa, respectively. 
 
Development of the nodule in transgenic Xenopus line 73 
We were also interested at what time during development of the line-73 transgenic animals 
the pituitary nodule appeared. For this reason, at a number of developmental stages black-
adapted wild-type and line-73 tadpoles were fixed for paraffin sectioning and staining (HE 
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and myelin), and immunocytochemistry for POMC and BDNF. Up to stage 49 (~12 days 
post-fertilization), no differences were found between the developing pituitaries of wild-
type and transgenic tadpoles (Fig. 7A and data not shown). In contrast, in stage 50-51 
tadpoles (~15-17 days post-fertilization) we found that the intermediate pituitary of 
transgenic line 73 was slightly disrupted by infiltrating tissue (Fig. 7B and data not shown). 
This phenotype progressively further developed (Fig. 7C and data not shown) and 
following metamorphosis (stage 66; ~50 days post-fertilization), clearly enlarged nodules 
were present in the pituitaries of line-73 frogs, with the melanotrope cells intermingled 
throughout glial cells (Fig. 7D and data not shown). Thus, the phenotype in line-73 
transgenic animals was observed for the first time in stage 50-51 tadpoles and became 
gradually more pronounced during further development of the transgenic animal. 
 
 
 
 
Figure 7: Development of the nodule phenotype in BDNF-transgenic Xenopus line 73.  
At various developmental stages (stage 49 (A), stage 50-51 (B), stage 56 (C) and immediately after metamorphosis 
(D)) wild-type (wt) and line-73 transgenic tadpoles were fixed for serial paraffin sectioning and 
immunocytochemistry for proopiomelanocortin/ adrenocorticotropic hormone (POMC/ACTH), and BDNF. The 
locations of the intermediate pituitary (pi), pars distalis (pd) and pars nervosa (pn) are indicated. The dotted arrows 
in B indicate displaced intermediate pituitary melanotrope cells in line-73 transgenic animals. Scale bars: 50 μm 
(A, B and C) and 200 μm (D). 
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Physiological induction of the nodule in transgenic Xenopus line 73 
Next, we wondered whether increasing the level of BDNF transgene expression in the 
melanotrope cells of tadpoles and frogs with a low level of transgene expression would 
induce the formation of the nodule. For this purpose, we took advantage of our model 
system by first growing line-73 transgenic tadpoles on a white background, giving lower 
expression of the BDNF transgene. After metamorphosis, paraffin sections were made of 
the brain and pituitary, and immunocytochemistry for POMC and BDNF, as well as HE and 
myelin stainings were performed. We found that pituitaries of white-adapted transgenic 
frogs did not contain nodules and were similar to wild-type pituitaries from animals adapted 
to a white background (Fig. 8). We then performed a longitudinal study by adapting fully 
white-adapted transgenic line-73 frogs to a black background for various time periods, thus 
increasing transgene BDNF expression in a physiological way. Western blot analysis 
indeed showed that transgene BDNF expression was ~8-fold higher in black-compared with 
white-adapted line-73 animals (data not shown). Following 9 weeks of black-background 
adaptation, infiltrating glial cells were observed that displaced the intermediate pituitary 
melanotrope cells of the transgenic animals. After 15 weeks of adaptation, a nodule was 
formed with the melanotrope cells intermingled throughout the glial cells (Fig. 9). When 
the 15-weeks-black-adapted line-73 animals were placed back on a white background 
again, the induced nodule remained (data not shown). Thus, the nodule phenotype of the 
transgenic Xenopus line-73 pituitary was irreversibly induced by enhancing BDNF 
transgene expression. 
 
 
 
 
 
Figure 8: Pituitary histology of white-adapted wild-type Xenopus and 
transgenic Xenopus line 73.  
Serial paraffin sections were made of the brain and pituitary (consisting 
of the pars nervosa (pn), intermediate pituitary (pi) and pars distalis (pd)) 
of wild-type (wt) and line-73 transgenic frogs that were raised on a white 
background (WA). Stainings were performed for proopiomelanocortin/ 
adrenocorticotropic hormone (POMC/ACTH), and BDNF. Scale bar: 200 
μm. 
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Figure 9: In vivo induction of nodule formation in transgenic Xenopus line 73 pituitaries by the 
physiological activation of BDNF transgene expression.  
Wild-type (wt) and line-73 transgenic animals grown on a white background were adapted to a black background 
for four, nine or fifteen weeks (wks BA). After fixation and serial paraffin sectioning of the pituitary (consisting of 
the pars nervosa (pn), intermediate pituitary (pi) and pars distalis (pd)), immunocytochemistry was performed for 
proopiomelanocortin/ adrenocorticotropic hormone (POMC/ACTH), and BDNF. Of 9 wks BA line-73 animals, 
two sections are shown for the POMC/ACTH as well as the BDNF staining, with the lower panel showing a higher 
magnification of part of the pi and pn. Black and dotted arrows indicate infiltrating tissue and displaced 
melanotrope cells, respectively. Scale bar: 200 μm. 
 
 
Discussion 
 
BDNF is a well-known neurotrophic growth factor that plays an important role in neuronal 
cell survival, differentiation, growth and synaptic plasticity (e.g. reviewed in 1-5, 11). 
However, BDNF appears to have more physiological functions than previously thought, 
e.g. it has been implicated also in the formation of myelin in the central and peripheral 
nervous systems (12-15, 32, 33), and may play a role in the proliferation of neuronal cells 
(16, 17). We have examined functional aspects of BDNF using the Xenopus intermediate 
pituitary melanotrope cells as a model system. The melanotrope cells regulate the process 
of background adaptation of the frog via the production and release of the pigment-
dispersing hormone α-MSH by the biosynthetically highly active cells when the animals 
are on a black background, whereas on a white background the cells are inhibited and 
biosynthetically inactive (reviewed in 22, 23).   
In vivo induction of glial cell proliferation and axonal outgrowth and myelination by brain-derived 
neurotrophic factor 
 107 
 In this study, we generated via stable Xenopus transgenesis frogs with 
overexpression of BDNF specifically in the intermediate pituitary melanotrope cells. Two 
independent transgenic lines were created, one with a relatively low (~5-fold; transgenic 
line 6) and a second with a high (~25-fold; transgenic line 73) level of transgene expression 
of mature BDNF. Intriguingly, in transgenic line-73 animals with high levels of BDNF 
transgene expression we found infiltrating hyperplastic Schwann cells, glial cells and axons 
that intermingled with the melanotrope cells of the intermediate pituitary, resulting in a 
nodule with a size 10-15 times larger than a wild-type intermediate pituitary. This 
phenotype was a specific effect of transgene expression of mature BDNF and not of other 
transgene products (e.g. GFP or the prodomain of BDNF), since we detected characteristics 
of the nodule phenotype in line-6 transgenic animals expressing untagged proBDNF, and 
generated other transgenic lines expressing GFP alone or non-cleavable GFP-proBDNF that 
did not show the pituitary phenotype (data not shown). In wild-type Xenopus intermediate 
pituitaries, only a limited number of GFAP+ folliculo-stellate cells are found (34, 35). To 
estimate the increase in Schwann and glial cells in the line-73 nodules, GFAP+ cells per 
unit area were counted, revealing an ~18-fold increase in GFAP+ cells in line-73 nodules 
compared to wild-type intermediate pituitaries (data not shown). A proliferative effect of 
BDNF on glial cells has thus far been described only in a limited number of studies, e.g. 
BDNF increased the cell number of two microglial cell lines (19), [3H]-thymidine 
incorporation in microglia cells (20), the cell number of optic nerve head astrocytes (18), 
and oligodendrocyte proliferation in the contused adult rat spinal cord (15). We show now 
that in vivo BDNF stimulates the proliferation of both glial cells and Schwann cells, 
providing evidence that the neurotrophin may regulate glial cell functioning in the nervous 
system. Furthermore, the presence of many axons in the nodules of line 73 transgenic 
animals suggests that BDNF also stimulates axonal outgrowth.  
 Upon closer examination of the origin of the infiltrating tissues in the nodules of 
line-73 pituitaries, we observed both CNS-derived glial cells and axons, and PNS-derived 
Schwann cells and axons. The mesotocin- and vasotocin-stained paraffin sections of the 
nodules and the HE-stained sections of the early stages of nodule formation in line-73 
transgenic animals showed that the glial cells and axons with CNS characteristics most 
likely originated from the pituitary pars nervosa. The main glial cells that are present in the 
wild-type pituitary pars nervosa form a specialized group of glial cells, called pituicytes 
(36-40), and it is therefore possible that in our line-73 transgenic animals BDNF stimulated 
the proliferation of the pituicytes. Since the nodules were anatomically tightly connected to 
the cranial nerves V and VII (the trigeminal and facial nerves, respectively), the PNS-
derived Schwann cells and axons most likely originated from these cranial nerves. The 
question then arose why only the cranial nerves V and VII and not other also nearby 
situated cranial nerves, such as cranial nerve III, were affected by the overexpression of 
BDNF in the transgenic melanotrope cells. We therefore considered the possibility that the 
BNDF receptors TrkB or p75NTR may be differentially expressed in various cranial nerves. 
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Quantitative RT-PCR analysis of TrkB and p75NTR mRNA expression showed no 
significant differences in the mRNA levels of these receptors between cranial nerves III, V 
and VII of wild-type animals (data not shown), indicating that the TrkB and p75NTR 
receptors are probably not responsible for the effect of the BDNF transgene product 
specifically on cranial nerves V and VII. A more likely explanation for the specific 
induction of the observed phenotype may well be the fact that cranial nerves V and VII are 
localized in close proximity of the pituitary, making them prime targets for the BDNF 
protein that was overexpressed in the intermediate pituitary melanotrope cells. 
A large portion of the infiltrated axons of the line 73 nodules was myelinated, 
indicating that overexpression of BDNF may stimulate myelin formation. Neuronal BDNF 
has previously been shown to stimulate the expression of myelin protein by Schwann cells 
(41), presumably via its interaction with p75NTR (12-15, 32, 33). In the induced nodule of 
line-73 animals, the PNS-derived Schwann cells and axons appeared more sensitive to the 
myelinating effect of BDNF than the CNS-derived glial cells and axons from the pars 
nervosa, possibly because PNS tissue was found to contain higher p75NTR mRNA 
expression levels than CNS tissue (data not shown). 
Our longitudinal study on the development of the nodule phenotype in line-73 
transgenic animals revealed in tadpoles of stage 50/51 the first cells infiltrating the 
intermediate pituitary. In Xenopus laevis, endogenous MSH-containing intermediate 
pituitary cells are found in tadpoles from stage 35/36 onwards (42), and melanotrope cell-
specific GFP transgene expression driven by the POMC transgene promoter has been 
detected from stage 40 onwards (29). Thus, in line-73 embryos the transgene expression of 
BDNF from stage 40 onwards apparently resulted in a detectable phenotype in transgenic 
embryos of stage 50/51, followed by a gradual formation of the nodule during further 
development of the transgenic animals. 
 A number of observations suggest that the severity of the nodule phenotype of the 
transgenic frogs was dependent on the level of BDNF transgene expression. First, initially 
transgenic line-6 animals with an ~5-fold overexpression of BDNF did not show nodule 
formation, but the phenotype was induced following a long adaptation of the animal to a 
black background, i.e. following extensive exposure of the tissue surrounding the 
intermediate pituitary cells to the transgene product. Second, the intermediate pituitary of 
line-73 transgenic frogs that were continuously grown on a white background did not show 
abnormalities, whereas black-background-adapted line-73 frogs had a clearly affected 
intermediate pituitary. Third, when white-adapted, non-affected line-73 frogs were adapted 
to a black background for several weeks, hyperplastic glial cells infiltrating the intermediate 
pituitary were observed, eventually leading to the nodule. The formation of the nodule was 
irreversible, since the phenotype of black animals remained when the animals were placed 
on a white background.  
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 Altogether, the results of our transgenic studies in a physiological context show 
that, besides its classical role as neuronal survival and differentiation factor, in vivo BDNF 
can induce axonal outgrowth and myelination, and stimulate glial cell proliferation. 
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In ancient times, the old Egyptians were not interested in brains: using a spoon the skull of 
a deceased pharaoh was emptied through the nose. Later in time, when it was appreciated 
that in fact our head houses our intellect, not the brain itself but rather the ventricles within 
our brain were thought to be involved. Currently, science is discovering more and more 
about our brain and how it works, and at the same time it appears that the brain is far more 
complicated than we could have ever imagined. One intriguing aspect is the fact that the 
brain is a highly plastic structure, which can adapt or modify itself in response to 
experiences and the environment. This is for example reflected in our capacity to learn and 
memorize enormous amounts of skills and data. Much of the brains ability to change itself 
lies in the plasticity of synaptic connections between neuronal cells, both short- and long 
term. Substantial evidence indicates that the number and strength of synapses can be 
changed by neuronal activity (1-3), and it is now widely accepted that activity-dependent 
modulation of synapse strength is critical for brain development as well as many cognitive 
functions in the adult. However, the molecular mechanisms that translate patterns of 
neuronal activity into specific changes in the structure and function of synapses and other 
brain parts remain largely unknown. To solve a tiny part of this puzzle, we set out to study 
physiological aspects of two proteins that are presumably involved in neuronal plasticity, 
namely neuroserpin and brain-derived neurotrophic factor (BDNF). In our studies, we have 
used as a model system the well-defined neuroendocrine intermediate pituitary melanotrope 
cells of the amphibian Xenopus laevis, which exert plasticity at both the cellular and 
neuronal level. We have explored the endogenous expression of neuroserpin in Xenopus, 
and the effects of neuroserpin and (pro)BDNF transgene expression on melanotrope cell 
functioning. In this final chapter, the results of these studies will be summarized and placed 
into a broader context.  
 
Neuroserpin 
 
Neuroserpin was first described 17 years ago by the group of Sonderegger (4), and ever 
since interest in the protein has steadily increased. A number of observations make 
neuroserpin an interesting protein for more detailed functional analysis. First, during 
development and in adult life neuroserpin has been proposed to play a role in neurite 
outgrowth and synaptogenesis in the nervous system (4-13). Second, neuroserpin appears to 
protect the brain from ischemic injury by inhibiting tissue-type plasminogen activator (t-
PA) (14-18). Third, mutations in the neuroserpin gene can cause the autosomal dominant 
dementia Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB; 19, 20). 
The studies described in chapters 2, 3 and 4 examine in more detail the physiological role 
of neuroserpin in the Xenopus melanotrope cells. 
 
 
 
General Discussion 
 
 115 
Neuroserpin in Xenopus laevis 
 
Since thus far neuroserpin has been described only in a limited number of vertebrate 
species, we first set out to identify and clone neuroserpin in our model system Xenopus 
(chapter 2). Subsequent characterization of neuroserpin mRNA and protein expression 
revealed that in adult Xenopus this serpin is predominantly expressed in neuronal and 
neuroendocrine tissues. In addition, the developmental expression patterns were determined 
in Xenopus tadpoles, revealing expression of both neuroserpin mRNA and protein 
throughout development. These results were in line with findings by others in human, mice 
and rat (7, 8, 12, 21, 22), and imply a role for neuroserpin in nervous system functionality, 
both during development and in later life. Remarkably, we also found neuroserpin mRNA 
and protein expression already in Xenopus developmental stage 0 (unfertilized egg) 
(chapter 2), which suggested additional functions of neuroserpin during early development 
and possibly fertilization. The Xenopus oocyte is surrounded by an extracellular matrix 
(ECM) forming a dynamic filamentous structure, which is of biological significance since it 
is known to play a vital role in sperm binding, polyspermy block and protection of the 
embryo. The distinctive layers that comprise the ECM overlay the plasma membrane and 
undergo specific ultrastructural and biochemical modifications during oogenesis and 
maturation (23). These modifications are for a large part dependent on proteases and 
protease inhibitors (24). For example, the serine protease ovochymase is released from 
Xenopus eggs after fertilization and is involved in the conversion of the ECM to block 
polyspermy and physically ‘harden’ the ECM for embryo protection (25, 26). In addition, 
recently a key role was demonstrated for serpin-27A as an inhibitor of the serine protease 
Easter in pattern formation during embryonic development of Drosophila (27-29). In view 
of these observations, neuroserpin may play a role as serine protease inhibitor in the ECM 
during oocyte development, fertilization and early development of Xenopus. 
 
Physiological target of neuroserpin in Xenopus intermediate pituitary 
 
We have examined in more detail the expression and functional aspects of neuroserpin in 
the Xenopus pituitary (chapters 2 and 3). Remarkably, we observed various forms of the 
neuroserpin protein in the different parts of the pituitary, namely a 55-kDa form in the pars 
nervosa, which was also detected in brain and therefore appeared to be a neuronal form of 
the protein, products of 44-, 47- and 50 kDa in the intermediate pituitary, and a 46-kDa 
product in the pars distalis. In rat pituitary, different forms of the neuroserpin protein have 
also been detected in the intermediate pituitary and pars distalis, with molecular weights of 
55- and 53 kDa, respectively (12). These multiple forms of neuroserpin probably represent 
post-translationally modified products, since we found that the 47-, 50-kDa and 46-kDa 
Xenopus neuroserpin proteins were N-linked glycosylated, whereas the 44-kDa and 55-kDa 
products were not (chapters 2 and 3). The 44-kDa neuroserpin protein most likely 
Chapter 7 
 
 116 
represents the primary translation and still not-modified form, whereas the observed 55-
kDa product may contain a post-translational modification that has not yet been 
characterized. Since protein modifications can considerably increase the information 
content and functional repertoire of proteins, possibly the various forms of the neuroserpin 
protein exert different functions in the distinct pituitary cell types.  
 Intriguingly, we also detected an SDS-stable 130-kDa neuroserpin-containing 
protein complex in the intermediate pituitary melanotrope cells of black-adapted Xenopus. 
Since the complex was dynamically expressed during background adaptation of Xenopus, it 
may play a role in the cellular and synaptic plasticity observed in the intermediate pituitary 
during the adaptation process of the frog (chapter 3). However, a number of questions 
concerning the composition and functional significance of the complex still remain. For 
instance, since serpins are known to form SDS-stable covalent interactions with target 
serine proteases (reviewed in 30, 31), the 130-kDa product may represent a complex of 
newly synthesized neuroserpin with its target protease. Comparison of the Xenopus 
neuroserpin amino acid sequence with the known vertebrate neuroserpin sequences 
revealed an overall identity of 58%, whereas the sequences of the reactive center loop 
(RCL) were 91% identical (chapter 2). The high degree of conservation of the RCL 
indicates a trypsin-like substrate specificity of neuroserpin in Xenopus. The inhibitory 
activity of recombinant purified neuroserpin has been assessed in vitro by the formation of 
SDS-stable complexes with putative target proteases, and in this way mouse, chicken and 
human neuroserpin have been found to inhibit t-PA, urokinase-type plasminogen activator 
(u-PA), plasmin and thrombin (6-8). However, in view of the acidic nature of the 130-kDa 
complex (pI of ~5.4) and its molecular weight it is unlikely that in Xenopus these proteases 
are part of the complex. Several other candidate target serine proteases with trypsin-like 
substrate specificity may be proposed, such as the family of tissue kallikreins, of which 
kallikrein-6 and -8 (also named neuropsin) appear the most interesting since they are 
mainly expressed in neuronal tissues (32, 33). Other possible candidates may be found 
among members of the family of type II transmembrane serine proteases (TTSPs) that form 
a large new family of membrane-anchored serine proteases of which most members are still 
poorly characterized (34-37). Examples of inhibitory complexes of TTSPs with serpins 
exist, like mouse DESC1 with plasminogen activator inhibitor-1 and protein C inhibitor 
(38, 39) or mouse matriptase-3 with an array of serpins, including plasminogen activator 
inhibitor-1, protein C inhibitor, α1-proteinase inhibitor, α2-antiplasmin and antithrombin 
III (40). Two TTSPs cloned from Xenopus, namely Xenopus embryonic serine protease 
(Xesp)-1 and a homolog of human MT-SP1 (Xenopus MT-SP1), have been shown to play a 
role during early Xenopus development (41). Interestingly, these TTSPs have predicted 
molecular weights and pIs that would give an acidic complex of ~130 kDa with Xenopus 
neuroserpin, similar to the complex we observed in the Xenopus intermediate pituitary 
cells.  
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A second issue to be considered concerns a more detailed analysis of the fate and 
(extra)cellular localization of neuroserpin and the 130-kDa complex, for example by 
immuno-electron microscopy. Such an analysis will help to better understand its 
physiological role. We found in our pulse-chase analyses that newly synthesized 47- and 
50-kDa neuroserpin were secreted by the melanotrope cells, whereas the 130-kDa product 
was not (chapter 3). These results imply that the complex is localized intracellularly or in 
the ECM of the melanotropes. At a certain point of time, the 130-kDa complex may be 
endocytosed by the melanotrope cells followed by intracellular degradation, which would 
constitute a clearance mechanism to remove the complex from its site of action. A 
candidate receptor for this process might be the low density lipoprotein (LDL) receptor-
related protein (LRP). LRP has been suggested to be a multifunctional scavenger receptor 
for which numerous ligands already have been identified (42-45) and that has been 
proposed to mediate the internalization of active neuroserpin and neuroserpin/t-PA 
complexes by mouse cortical neurons and embryonic fibroblasts (46). Alternatively, the 
130-kDa complex may be degraded extracellularly, or neuroserpin might be cleaved by its 
target protease resulting in inactive neuroserpin and active protease. In vitro, after 
neuroserpin/t-PA complex formation, neuroserpin was indeed cleaved by t-PA, after which 
cleaved neuroserpin and active t-PA were detected (47).  
Altogether, the elusive target protease will likely determine the physiological 
effect of neuroserpin in the Xenopus intermediate pituitary. Via inhibition of this target 
protease, neuroserpin may affect the integrity of the ECM or the cleavage of 
transmembrane or ECM-related signalling proteins. 
 
Functional studies on neuroserpin 
 
To study the physiological role of neuroserpin in an in vivo context, we used the technique 
of stable Xenopus transgenesis to overexpress neuroserpin and a mutated form of 
neuroserpin specifically and physiologically inducible in the intermediate pituitary 
melanotrope cells (chapter 4). Previously, neuroserpin-transgenic and knock-out mice have 
been generated, which have been analyzed at the behavioural but not at the cell-biologial 
level (48, 49). Phenotypic characterization of these mice has shown that altered expression 
of neuroserpin is associated with deficient exploratory behaviour and abnormal reaction to 
novelty, indicating a role of neuroserpin in the regulation of emotional state (49). In our 
transgenic Xenopus, transgene expression of GFP-neuroserpin (line 55) or mutated GFP-
neuroserpin(G392E) (line 84) did not affect endogenous neuroserpin protein levels and 
melanotrope cell functioning was not detectably altered, as determined by metabolic cell 
labeling and Western blot analysis of various secretory pathway proteins. Remarkably, in 
transgenic line-84 animals, we have not detected the cell-biological characteristics observed 
in cells transfected with FENIB mutant neuroserpin, namely neuroserpin inclusion bodies 
which accumulate in the endoplasmic reticulum (ER) and are formed by polymers of the 
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mutated neuroserpin protein (20, 50). This may be due to the fact that in our transgenic 
animals the level of overexpression of GFP-neuroserpin(G392E) was relatively low when 
compared with that in the transfected cells. Because of the higher expression levels in the 
transfected cells, polymerization and accumulation of the mutant neuroserpin may have 
been observed in these cells. Alternatively, the time of adaptation of the transgenic animals 
to a black background (and therefore the time during which the melanotrope cells were 
exposed to the transgene product) has been too short. We have shown before that the time 
of background adaptation of transgenic frogs can be important to create a phenotypic effect 
of transgene expression (51, 52). Interestingly, the neuroserpin- and mutant 
neuroserpin(G392E)-transgenic Xenopus melanotrope cells did show a difference at the 
ultrastructural level, namely the presence of intercellular gaps, which were not present 
among wild-type melanotrope cells or cells transgenic for proteins other than neuroserpin 
(chapter 4 and data not shown). These gaps may imply a change in the ECM of the 
transgenic cells, and therefore suggest a role for neuroserpin in the regulation of the 
integrity of the ECM. This would be in line with the previously proposed function of 
neuroserpin as an inhibitor in the ECM (12, 21).  
Thus, to investigate functional aspects of neuroserpin we have used Xenopus 
transgenesis to generate transgenic frogs with overexpression of neuroserpin or mutant 
neuroserpin. Further studies are necessary to examine the role of neuroserpin in 
manipulating the melanotrope ECM. 
 
BDNF 
 
The second protein of which in this thesis functional aspects were explored in more detail 
concerns BDNF. Following the discovery of NGF in the early 1950s, BDNF was the 
second member of the neurotrophin (NT) family to be identified in 1982 (53). Since then, 
interest in BDNF has only increased, because studying this NT continues to provide new 
insights into neuronal function. Initially, BDNF was characterized as a neuronal survival- 
and differentiation factor (reviewed in 54, 55), but currently it is also known to play a role 
in axonal and dendritic growth and guidance (reviewed in 56-59), neurogenesis (60-63), 
long term potentiation (LTP) and synaptic plasticity (reviewed in 55, 64-67). In addition, 
the protein has been implicated in numerous pathological diseases, such as epilepsy, 
neurodegenerative diseases like Alzheimer’s, Parkinson’s and Huntington’s disease, and 
neuropsychiatric disorders, like depression, schizophrenia and bipolar disorder (reviewed in 
55). However, despite the obvious wide role of BDNF in nervous system functionality, in 
many cases the underlying molecular and cellular mechanisms remain elusive. In addition, 
the recent discovery that the proforms of NTs also exert a physiological role that appears 
opposite to that of mature NTs adds an additional complication to the understanding of the 
physiological role of NTs in the nervous system. 
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 The studies described in chapters 5 and 6 examined in vivo physiological aspects 
of pro- and mature BDNF functioning. As a model system, we again used the intermediate 
pituitary melanotrope cells of Xenopus laevis. 
 
Physiological aspects of proBDNF 
 
Until recently, little attention has been paid to the NT-proregions, which were originally 
thought to be readily degraded. Now evidence is accumulating that proNTs, and in 
particular proBDNF, can also be secreted by cells (68-74) and subsequently have a 
physiological role, such as facilitating long-term depression and neuronal apoptosis, via 
their high-affinity binding to the p75NTR receptor (75-77). In addition, extracellular 
cleavage by plasmin or selective matrix metalloproteases can convert extracellular 
proBDNF in mature BDNF, and as such may represent a new way to control synaptic 
functioning of BDNF (67, 72, 78, 79).  
In an attempt to explore the physiological role of proBDNF in more detail, we 
generated transgenic Xenopus laevis with overexpression of proBDNF or GFP-tagged 
proBDNF specifically in the intermediate pituitary melanotrope cells. Thus far, analyses of 
transgenic lines with expression of untagged proBDNF did not reveal a clear phenotype, 
possibly due to the relatively low levels of transgene expression (chapter 5 and unpublished 
observations). In contrast, analyses of transgenic melanotrope cells with expression of the 
unprocessed GFP-proBDNF fusion protein revealed ER stress and a block of transport of 
other secretory proteins through the secretory pathway (chapter 5). Since the observed ER 
stress implies an accumulation of misfolded proteins, these results indicate that the GFP 
moiety hampered the prodomain to properly act as an intramolecular chaperone for 
proBDNF. Correct proNGF folding also depends on its prodomain (80, 81). Furthermore, 
the prodomain may control the intracellular trafficking and secretion of proBDNF, since a 
single-nucleotide polymorphism (SNP) in the pro-region of proBDNF (valine instead of 
methionine at residue 66) has been found to affect synaptic targeting and activity-dependent 
secretion of the protein (74). This val66met SNP is a recognized polymorphism of the 
human BDNF gene which is associated with memory impairment and increased 
susceptibility to neuropsychiatric disorders (73). Interestingly, the intracellular perinuclear 
accumulation and lack of secretion of GFP-proBDNF we observed in the GFP-proBDNF-
transgenic melantorope cells (chapter 5) is reminiscent of the concentrated distribution of 
proBDNF(met) in the cell body and the decrease in regulated BDNF secretion by polarized 
proBDNF(met)-transfected neurosecretory PC12 cells and rat cortical neurons (73, 74). We 
therefore hypothesize that the impaired intracellular trafficking of BDNF(met) may also 
impose stress to the ER, resulting in a reduced transport, processing and secretion of other 
neuronal secretory pathway proteins. Eventually, this may lead to multiple effects of 
BDNF(met) on neuronal cell functioning, possibly explaining some aspects of the wide 
variety of phenotypes observed in individuals carrying the BDNF(met) polymorphism. 
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Physiological aspects of mature BDNF: role in glial cell physiology 
 
To study the physiological role of mature BDNF, we generated transgenic Xenopus laevis 
that overexpressed mature BDNF specifically in the intermediate pituitary melanotrope 
cells. Intriguingly, analysis of these animals revealed that BDNF induced proliferation of 
both central nervous system (CNS)-derived glial cells and peripheral nervous system 
(PNS)-derived Schwann cells (chapter 6). 
Various types of glial cells exist, such as astrocytes and oligodendrocytes in the 
CNS and Schwann cells in the PNS, each with their own physiological role and specific 
characteristics. For example, while p75NTR and truncated TrkB expression has been 
detected in oligodendrocytes, astrocytes and Schwann cells, full-length TrkB appears to be 
expressed only in oligodendrocytes (82), and p75NTR mediates the action of NTs differently 
in basal forebrain oligodendrocytes and Schwann cells (83). In our model system, we found 
a proliferating effect of BDNF on both peripheral Schwann cells from cranial nerves V and 
VII, and glial cells with CNS characteristics that most likely originated from the pituitary 
pars nervosa (chapter 6). Since the pituicytes are the main group of glial cells in the 
pituitary pars nervosa (84-87), BDNF presumably affected these cells. Remarkably, we did 
not observe an effect of BDNF on another glial-like cell group in the intermediate and distal 
lobe of the pituitary, namely the folliculo-stellate (FS) cells (88-92). This apparent 
difference in sensitivity to BDNF by the two different types of glial cells may be explained 
by differences in p75NTR and TrkB expression levels in pituicytes and FS cells. Schwann 
cells have been shown to express the p75NTR and truncated TrkB receptors (reviewed in 82). 
In agreement with this, we detected in cranial nerves V and VII of wild-type Xenopus 
relatively high p75NTR mRNA expression levels and relatively low TrkB mRNA expression 
levels (unpublished observations), indicating that in our model system BDNF might induce 
a proliferating signal via the p75NTR and/or possibly the truncated TrkB receptor (we did not 
examine the expression levels of truncated TrkB). However, the intracellular signaling 
pathways that ultimately induced glial cell proliferation remain unknown.  
 In addition to the proliferating effect of BDNF on glial and Schwann cells, we also 
observed in our transgenic Xenopus a stimulating effect of overexpressed mature BDNF on 
axonal outgrowth and myelination (chapter 6). These findings are in line with the results of 
previous studies showing a stimulating effect of BDNF on neuronal growth in a number of 
other systems as well (reviewed in 56-59). Furthermore, evidence is accumulating that 
BDNF plays a stimulatory role in the myelination process in both the PNS and CNS (93-
99). The formation of myelin sheets is achieved by Schwann cells in the PNS, whereas 
oligodendrocytes are the myelinating cells in the CNS. The mechanisms of myelin 
formation, and membrane wrapping and maintenance are dependent on complex 
interactions between axons and the myelinating glial cells (reviewed in 100-102).  Although 
BDNF has been found to stimulate myelin formation in both the CNS and PNS, thus far 
only a molecular mechanism has been proposed for its effect on peripheral Schwann cells, 
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where BDNF appears to stimulate the formation of myelin via p75NTR (reviewed in 97, 98). 
Presumably, another mechanism is used by oligodendrocytes, as in the basal forebrain the 
effect of BDNF on myelination appeared to be dependent on the actions of the trkB and not 
the p75NTR receptor (83). The emerging role of BDNF in PNS and CNS myelination may 
provide new therapeutic opportunities for treating diseases of the nervous system in which 
the myelinating process is affected, such as multiple sclerosis. Possibly, overexpression of 
BDNF in affected CNS and PNS regions, by transplanted genetically modified BDNF-
producing cells or by retroviral infection, may stimulate remyelination of demyelinated 
axons.  
 Altogether, besides its well-known role in neuronal survival and differentiation, 
BDNF appears to be also involved in glial cell physiology. Glial cells have traditionally 
been viewed as myelinating cells (oligodendrocytes and Schwann cells) and support cells 
for neurons by regulating ion concentrations, taking up neurotransmitters and providing 
substrates for energy metabolism (astrocytes). Recent studies have however shown that 
glial cells can actively control the structural and functional plasticity of synapses in 
developing and adult organisms (reviewed in 103-106), indicating active intercellular 
signaling between glial cells and neurons (reviewed in 107-109). It is tempting to speculate 
that NTs, and especially BDNF, are involved in such signaling. For example, BDNF has 
been shown to induce calcium signaling in glial cells (110), and glial cell calcium signaling 
may play an important role in glial-glial and neuron-glial communication (reviewed in 108, 
111-113).  
 
Neuroserpin and BDNF in neuroendocrine and neuronal plasticity: a model 
 
In our studies, we have used the neuroendocrine melanotrope cells of the Xenopus 
intermediate pituitary as a model system to study aspects of the physiological roles of 
neuroserpin and BDNF. The results presented in this thesis allow us to propose the 
following models for the functions of these proteins in neuroendocrine and neuronal 
plasticity.  
 First, we consider the possible role of neuroserpin (Figure 1). This protein forms a 
complex with an up-to-now unidentified serine protease in the melanotropes of black- but 
not of white-adapted animals, indicating that the formation of this complex is linked to 
melanotrope cell activation (chapter 3). More specifically, in black animals adapting to a 
white background we found a relatively fast decrease (already after 1 day of adaptation) in 
the amount of complex, implying that the protease and thus proteolytic activity in the 
melanotrope ECM becomes readily available after transfer to a white background. Since 
clearance of the complex occurs within one day, in the first 24 h of white-background 
adaptation the contacting hypothalamic neurons from the suprachiasmatic nuclues that 
inhibit the melanotrope cells (SMINs) may be activated, resulting in a fast initial inhibition 
of melanotrope cell activity. To sustain this melanotrope inhibition, the initial phase is  
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Figure 1: Model for the role of neuroserpin in neuroendocrine plasticity. 
Neuroserpin is produced and secreted by Xenopus intermediate pituitary melanotrope cells and is proposed to 
inhibit a target serine protease, thereby influencing the remodelling of the extracellular matrix during black- and 
white-background adaptation of the animal. See text for details. Abbreviations: ER, endoplasmic reticulum; ECM, 
extracellular matrix. 
 
 
immediately followed by elaborate synaptic changes (namely an increase in size and 
number) of the SMINs. This plasticity is made possible by changes in the melanotrope 
ECM, as the ECM is thought to play an important role in synaptic plasticity (114, 115). For 
maintenance of the ECM, a proper balance between matrix proteases and their inhibitors is 
essential. Therefore, in black animals that are put on a white background, rapid clearance of 
the complex and increase in protease activity immediately after adaptation will likely result 
in a net breakdown of the ECM, regulating the plasticity of the SMINs during the initial 
stages of white-background adaptation. In contrast, in white animals put on a black 
background, the neuronal activity of the SMINs may be shut down immediately, resulting 
in loss of inhibitory signal and an instantaneous release of α-melanophore stimulating 
hormone (α-MSH) that is stored in the storage granules of the melanotropes. In white 
animals adapting to a black background, the neuroserpin-protease complex was detected 
only after five days of adaptation. This allows protease activity in the cell matrix to remain 
present during the first days of adaptation, regulating ECM integrity and therefore plasticity 
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of the SMINs (namely a decrease in SMIN number and size). Protease activity will then be 
gradually inhibited by neuroserpin, which will lead to a change in the balance of protease 
and inhibitor in the ECM, resulting in a change in architecture of the ECM. The ECM may 
become denser, since the number and sizes of contacting SMINs are smaller in the 
intermediate pituitary of black animals. 
In the second model, a possible role of BDNF in neuroendocrine plasticity is considered 
(Figure 2). In Xenopus, both pro- and mature BDNF have been detected in the melanotrope 
cells (116, 117). Analysis of BDNF-transgenic Xenopus showed that a high level of 
secreted mature BDNF exerts a proliferating effect on nearby glial cells from the pituitary 
pars nervosa and cranial nerves V and VII, and a stimulatory effect on the growth and 
myelination of axons (chapter 6). Notably, this phenotype was detected only in  
transgenic animals with relatively high expression levels of mature BDNF (line 73) or in 
long-term black-adapted transgenic animals with relatively low expression levels (line 6). 
Thus, BDNF can have an effect on glial cell proliferartion and myelination, and therefore 
on glial cell physiology. However, for melanotrope cell functioning in wild-type Xenopus it 
is most likely that other functional aspects of pro- and mature BDNF are important. For 
example, in vitro mature BDNF can stimulate the biosynthesis of proopiomelanocortin 
(POMC) and release of α-MSH in an autocrine manner (117). It remains to be established 
whether these effects also occur in vivo. Furthermore, the proBDNF protein may act on the 
melanotrope cells in an autocrine manner, thereby opposing the effect of mature BDNF. In 
addition, both mature and proBDNF may affect the synaptic varicosities of the 
hypothalamic neurons contacting the melanotrope cells, thus modulating the plasticity of 
these neurons. The balance between mature and proBDNF in the extracellular space and the 
relative BDNF-receptor and co-receptor expression levels on both the melanotrope cells 
and contacting hypothalamic neurons will therefore ultimately determine the physiological 
effect of mature and proBDNF on the Xenopus neurointermediate pituitary.  
Finally, in the third model we propose that a functional link exists between 
neuroserpin and BDNF in species or cell systems other than the Xenopus intermediate 
pituitary (Figure 3). In other systems, t-PA has been suggested to be a main target protease 
of neuroserpin (6, 8, 15). Interestingly, t-PA is known to cleave plasminogen into plasmin 
(17) and, in turn, plasmin can cleave ECM components involved in neuronal plasticity, 
such as laminin (118) or the cell-adhesion molecule L1 (119). Plasmin has been shown to 
also cleave proBDNF (67, 72), providing an additional mechanism for the control of the 
extracellular balance between pro- and mature BDNF. Cleavage of proBDNF by t-
PA/plasmin is essential for long-term hippocampal plasticity in mice (67, 120). Thus, by 
interacting with t-PA, neuroserpin may have an effect on the extracellular cleavage of 
proBDNF into mature BDNF. It remains to be established whether neuroserpin has an 
effect on plasmin or proBDNF in the Xenopus intermediate pituitary. 
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Figure 2: Model for the role of BDNF in neuronal and neuroendocrine plasticity. 
Pro- and mature BDNF are produced and secreted by the Xenopus intermediate pituitary melanotrope cells and are 
proposed to have an effect on the melanotrope cells themselves and on the innervating hypothalamic neurons. In 
addition, transgene mature BDNF expression was shown to stimulate the proliferation of glial cells, and the 
myelination and outgrowth of axons. See text for details. Abbreviations: (pro)BDNF, (pro) brain-derived 
neurotrophic factor; mBDNF, mature brain-derived neurotrophic factor; PC1, prohormone convertase 1; p75NTR, 
p75 neurotrophin receptor; T-TrkB, truncated TrkB receptor; FL-TrkB, full-length TrkB receptor. 
 
 
Future prospects 
 
It is almost a ‘rule’ in science that a research project ends with more questions than initially 
raised, and the studies described in this thesis are not an exception to this apparent rule. 
Concerning the physiological role of neuroserpin, an important question is the identity of 
the putative target substrate of neuroserpin in the 130-kDa complex. To identify this target, 
we have used a number of experimental approaches, such as MALDI-MS and LC/ESI-MS, 
pull-down experiments using recombinant GST-neuroserpin, and Western blot analysis 
with antibodies against suspected candidate targets (data not shown). Unfortunately, these 
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Figure 3: Model of a functional link between neuroserpin and BDNF. 
In other species or cell systems than the Xenopus intermediate pituitary, neuroserpin has been proposed to inhibit 
the serine protease t-PA, which, in turn, is involved in the cleavage of plasminogen into plasmin. Plasmin plays a 
role in ECM remodelling and as such is involved in plasticity. In addition, plasmin can extracellularly cleave 
proBDNF, thus providing a mechanism to control the extracellular balance between pro- and mature BDNF. See 
text for details. 
 
 
attempts have thus far been unsuccessful, probably due to the low expression levels of the  
endogenous complex. Furthermore, the expression of the TTSPs Xesp-1 and Xenopus MT-
SP1 in the Xenopus intermediate pituitary should be examined to consider the possibility 
that these proteases interact with neuroserpin. For this purpose, Western blotting, pull-down 
experiments and co-immunoprecipitation analyses can be performed. 
 Our neuroserpin-transgenic Xenopus have to be further analyzed in detail to learn 
more about the physiological aspects of neuroserpin, in particular the consequences of its 
apparent effect on the ECM. In addition, it might be worthwhile to generate transgenic 
animals with expression levels of mutant neuroserpin(G392E) that are higher than those in 
the presently available lines. Also, generation of lines with transgene expression of 
untagged neuroserpin will be valuable to avoid possible interference of the GFP-moiety on 
the biological activity of the exogenous neuroserpin. Furthermore, the technique of RNA 
interference may be employed to specifically knock-down endogenous neuroserpin 
expression. This technique has been used before in Xenopus to knock-down GFP in GFP-
transgenic embryos (121, 122) and an endogenous protein named Xlim-1 in non-transgenic 
embryos by injection of double stranded Xlim-1 RNA in 4-cell stage embryos (123).  
 Regarding the physiological role of pro- and mature BDNF in our model system, 
an important next step will be the identification and characterization of the various BDNF 
(co-) receptors, such as TrkB, truncated TrkB, p75NTR, and sortilin, in the Xenopus 
intermediate pituitary. For this purpose, in situ hybridization experiments, 
immunocytochemistry, immuno-electron microscopy, quantitative RT-PCR analysis or the 
use of specific receptor antogonists may be helpful. Furthermore, receptor modulation can 
also influence receptor functioning and should therefore be considered. For instance, 
regulated intramembrane proteolysis of the p75NTR by the alpha- and gamma-secretase 
enzymes has been shown to modulate p75NTR association with the TrkA receptor (124). 
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Preliminary results suggest that multiple p75NTR co-receptors can modulate p75 processing 
by either inducing novel p75 ectodomain shedding (by an as yet unidentified serine 
protease) or inhibiting p75 proteolysis (personal communication with Elissa L. Ash, 
Columbia University, New York, USA). In addition, in Xenopus a novel gene encoding a 
protein with substantial sequence identity with p75NTR, named neurotrophin receptor 
homolog 1 (NRH-1) has recently been identified (125). NRH-1 has been shown to undergo 
multiple proteolytic cleavages that ultimately released cytoplasmic fragments with possible 
signalling capacities (126, 127). Thus, Xenopus NRH-1 expression and its possible 
involvement in melanotrope cell functioning should be examined. Furthermore, it will be 
interesting to study the intracellular signaling pathways in the melanotrope cells that may 
be affected by pro- and mature BDNF. In this respect, especially intracellular calcium 
signaling should be investigated, since intracellular calcium is known to play an important 
role in melanotrope cell signaling (128, 129) and BDNF has been shown to induce calcium 
signaling in glial cells (110). 
 For further functional characterization of pro- and mature BDNF, a continuation of 
the use of Xenopus transgenesis may be helpful. For instance, new transgenic lines with 
higher expression levels of intact proBDNF should be generated. The transgenic animals 
with transgene expression of mature BDNF (transgenic lines 6 and 73) should be further 
examined to obtain more detailed insights into its effects on melanotrope cell functioning. 
Thus far, we have not found an effect of mature BDNF transgene expression on the 
biosynthesis and processing of POMC or secretion of POMC-derived peptides, or on 
steady-state POMC protein expression levels (data not shown). This finding was 
unexpected since in vitro studies have shown a stimulatory effect of recombinant BDNF on 
the biosynthesis of POMC and release of α-MSH by the melanotrope cells (117). Finally, 
since the balance between proBDNF and mature BDNF expression appears important for 
the eventual biological effect, the possibility should be considered that plasmin plays a role 
in the extracellular processing of proBDNF in the Xenopus intermediate pituitary. 
Additionally, a transgenic line with overexpression of mature BDNF may be crossed with a 
line with transgene expression of proBDNF, to generate new double-transgenic lines with 
varying ratios of pro- and mature BDNF. It will be interesting to see whether these double-
transgenic animals show differences in for example melanotrope cell activity or in 
background-adaptation capacity. 
 Since we found in Xenopus that mature BDNF can induce glial cell proliferation, it 
will be highly interesting to examine such a role in other species, for example human. A 
role in glial cell proliferation has also been suggested on the basis of the fact that BDNF 
increased the cell number of two microglial cell lines (130), [3H]-thymidine incorporation 
in microglia cells (131), the cell number of optic nerve head astrocytes (132), and 
oligodendrocyte proliferation in the contused adult rat spinal cord (94). Furthermore, glial 
cells not only function as support cells for neurons but actually play an important role in 
nervous system functionality by modulating neuronal plasticity and communicating with 
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neurons, a process in which BDNF is possibly involved (110). However, the molecular 
mechanisms underlying these effects remain to be elucidated, e.g. which receptor complex 
and intracellular signaling pathway are involved. In addition, the emerging role of BDNF in 
PNS and CNS myelination should be examined in more detail, since the exact molecular 
mechanism of its stimulating effect remains unknown. Obviously, a more detailed 
knowledge of these functional aspects of BDNF might prove very useful for the 
development of therapeutic strategies against various disorders of the nervous system, such 
as neurodegenerative and/or neurodevelopmental demyelination disorders or glial tumors.  
 
In conclusion, the data presented in this thesis have provided new insights into the 
physiological roles of neuroserpin and BDNF in neuronal and neuroendocrine plasticity. 
Through our continuously increasing knowledge about functional roles of and interactions 
between proteins, a more detailed picture of neuronal plasticity is emerging, but at the same 
time the puzzle is gaining complexity. Ultimately, a better understanding of the molecular 
mechanisms underlying plasticity will not only increase our knowledge about brain 
functioning, but it will also broaden therapeutic perspectives to combat neurodegenerative 
and neurodevelopmental disorders.   
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Summary 
 
 
 
 
 
 
 
 
 
An intriguing characteristic of the brain is its ability to continuously change its structural 
organization to adapt to new situations that may emerge from a change in developmental 
and environmental circumstances as well as from injuries. This adaptive capacity is called 
neuronal plasticity, and is for example reflected in the processes of learning and memory 
formation. Despite its obvious importance, the molecular mechanisms underlying neuronal 
plasticity are still far from being understood. In this thesis, we set out to explore functional 
aspects of two proteins that are thought to play a role in neuronal plasticity, namely the 
serine protease inhibitor neuroserpin and the brain-derived neurotrophic factor BDNF. In 
chapter 1, a brief outline is given concerning these two proteins. During development and 
in adult life, neuroserpin has been proposed to play a role in neurite outgrowth and 
synaptogenesis. BDNF regulates neuronal survival and differentiation, and modulates 
synaptic plasticity. In addition, BDNF appears to have more physiological functions than 
previously thought, e.g. it has been implicated in the formation of myelin and may play a 
role in the proliferation of neuronal cells. In our studies, we have used the well-defined, 
neuroendocrine intermediate pituitary melanotrope cells of the amphibian Xenopus laevis as 
a model system. These cells exert plasticity at both the cellular and neuronal level. In vivo, 
the melanotropes are responsible for the process of background adaptation of Xenopus by 
regulating the release of the hormone α-melanophore stimulating hormone (α-MSH), 
which causes pigment dispersion in skin melanophores.  On a black background, the 
melanotrope cells are very active, producing vast amounts of proopiomelanocortin 
(POMC), the prohormone of α-MSH. In contrast, on a white background, cellular activity 
is inhibited by hypothalamic neurons that make direct synaptic contacts with the 
melanotrope cells. This inhibition results in biosynthetically inactive melanotropes that do 
not release α-MSH. Thus, the biosynthetic and secretory activity of these neuroendocrine 
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cells and their regulation by hypothalamic neurons can be manipulated in a physiological 
manner by placing the animal on a black or a white background. 
 Since neuroserpin has thus far been described only in a limited number of 
vertebrate species, we first set out to identify and clone this serpin in Xenopus (chapter 2). 
Subsequent studies revealed that throughout Xenopus development neuroserpin mRNA and 
protein are expressed, and in adult Xenopus predominantly in neuronal and neuroendocrine 
tissues. In addition, we found a high degree of amino acid sequence conservation, 
especially of the reactive centre loop, between the Xenopus, mammalian and chicken 
neuroserpin sequences, suggesting conserved substrate specificity. Thus, Xenopus 
neuroserpin may play an important physiological role as a serine protease inhibitor for 
proper neuronal and neuroendocrine cell functioning. To explore the role of neuroserpin in 
more detail, we examined neuroserpin expression in our model system, the neuroendocrine 
Xenopus melanotrope cells (chapter 3). We found that the expression of neuroserpin was 
linked to melanotrope cell activation. Specifically, neuroserpin mRNA and protein levels 
were upregulated in melanotrope cells of black-adapted animals, and neuroserpin formed a 
stable complex with an as yet unidentified target substrate, but only in the active cells. This 
target substrate may well be a serine protease exerting proteolytic activity in the 
extracellular matrix (ECM) of the melanotrope cell, and we thus speculate that by inhibiting 
the target, neuroserpin is involved in remodelling of the ECM during background 
adaptation and thereby plays a role in neuroendocrine plasticity.  
 To perform in vivo studies on the physiological role of neuroserpin, we generated 
transgenic Xenopus in which a POMC gene promoter fragment caused overexpression of 
neuroserpin or mutant neuroserpin(G392E) specifically in the melanotrope cells (chapter 
4). The mutant neuroserpin(G392E) protein is linked to Familial Encephalopathy with 
Neuroserpin Inclusion Bodies (FENIB), an autosomal dominant dementia. Analyses of the 
transgenic Xenopus showed that while overexpression of neuroserpin or 
neuroserpin(G392E) does not have a clear effect on the biosynthetic activity of the 
transgenic melanotrope cells, it does appear to affect the morphology of the melanotrope 
ECM. The mechanism presumably involves a prolonged inhibition of an extracellular target 
protease that regulates ECM integrity.  
 In the second part of this thesis, we have examined physiological aspects of pro- 
and mature BDNF. Although BDNF has been described extensively as a neuronal survival- 
and differentiation factor and as a modulator of synaptic plasticity, interest in the protein 
has increased over recent years, since pro- and mature BDNF have been found to play an 
even broader role in nervous system functionality. To investigate aspects of the role of pro- 
and mature BDNF in neuroendocrine plasticity, we generated transgenic Xenopus with 
overexpression of pro- and mature BDNF, and of a number of their variants specifically in 
the melanotrope cells (chapter 5). We observed that in various transgenic Xenopus lines 
with overexpression of proBDNF that the transgene product was not properly processed 
and secreted. Furthermore, in the proBDNF-transgenic melanotrope cells we detected 
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cellular stress and a block of transport of a number of secretory pathway proteins, similar to 
what others have observed in cells expressing a mutated form of human proBDNF. This 
mutation is a recognized polymorphism in the human bdnf gene that is associated with 
memory impairment and increased susceptibility to neuropsychiatric disorders.  
 In chapter 6, we analyzed transgenic Xenopus with melantrope cell-specific 
overexpression of mature BDNF. In the pituitary of these animals, we observed the 
formation of a nodule consisting of glial cells and axons of which a significant part was 
myelinated. Thus, mature BDNF may induce glial cell proliferation and axonal outgrowth 
and myelination, and as such is involved in neuronal plasticity and possibly glial cell 
physiology. A more detailed knowledge of these functional aspects of BDNF may prove to 
be useful for the development of therapeutic strategies against certain disorders of the 
nervous system, such as neurodegenerative and/or neurodevelopmental demyelination 
disorders.  
 Finally, in chapter 7 the findings described in this thesis are summarized and 
placed into a broader perspective. Based on our results, we present two models proposing 
roles for neuroserpin and BDNF in neuroendocrine and neuronal plasticity, and a third 
model of an indirect interaction between the two proteins.  
 In conclusion, the results described in this thesis enhance our understanding of the 
physiological roles of neuroserpin and BDNF in neuroendocrine and neuronal plasticity. A 
better understanding of the complex molecular mechanisms underlying plasticity will 
ultimately improve our knowledge of brain functioning in health and disease. 
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Samenvatting 
 
 
 
 
 
 
 
Summary in Dutch 
 
Een fascinerende eigenschap van het brein is diens capaciteit om zijn structurele organisatie 
continu aan te passen aan nieuwe situaties. Deze nieuwe situaties ontstaan door 
veranderingen die optreden tijdens de ontwikkeling, in de omgeving, of door 
verwondingen. Dit aanpassingsvermogen wordt neuronale plasticiteit genoemd. Neuronale 
plasticiteit ligt bijvoorbeeld ook ten grondslag aan de processen van leren en 
geheugenvorming. Ondanks het enorme belang van deze plasticiteit voor het goed 
functioneren van het brein, zijn de moleculaire mechanismen die hiervan het uitgangspunt 
vormen nog lang niet geheel begrepen. In dit proefschrift staat het onderzoek beschreven 
dat is uitgevoerd naar de rol van twee eiwitten in het proces van neuronale plasticiteit, 
namelijk van de serine protease remmer neuroserpin en de neurotrofe groeifactor ‘brain-
derived neurotrophic factor’ (BDNF). In hoofdstuk 1 worden deze twee eiwitten kort 
geïntroduceerd. Neuroserpin is mogelijk betrokken bij de groei van zenuwuitlopers en de 
vorming van synapsen zowel tijdens de ontwikkeling  als in een volwassen stadium. BDNF 
is belangrijk voor het overleven en de differentiatie van zenuwcellen, en speelt een 
modulerende rol bij synaptische plasticiteit. Daarnaast lijkt BDNF meer fysiologische 
functies te vervullen dan voorheen werd aangenomen; het is bijvoorbeeld ook betrokken bij 
de vorming van myeline en speelt mogelijk een rol bij de proliferatie van zenuwcellen. 
Voor ons onderzoek hebben we gebruik gemaakt van een goed gedefinieerd model systeem, 
namelijk de neuroendocriene melanotrope cellen van de hypofyse-middenkwab van de 
amfibie Xenopus laevis. Deze cellen vertonen zowel op cellulair als neuronaal niveau een 
grote mate van plasticiteit. In vivo zijn de melanotrope cellen verantwoordelijk voor het 
proces van achtergrondadaptatie van Xenopus doordat ze de afgifte van het α-melanofoor 
stimulerende hormoon (α-MSH) reguleren. α-MSH veroorzaakt de dispersie van pigment 
in huidcellen. Op een zwarte achtergrond zijn de melanotrope cellen zeer actief en 
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produceren grote hoeveelheden proopiomelanocortine (POMC), het prohormoon van α-
MSH. Op een witte achtergrond daarentegen wordt de activiteit van de melanotrope cellen 
geremd door zenuwcellen uit de hypothalamus die direct contact maken met de cellen. 
Deze remming resulteert in biosynthetisch inactieve cellen die geen α-MSH meer afgeven. 
Dus de biosynthetische en afgifte activiteit van deze neuroendocriene melanotrope cellen en 
hun regulerende hypothalame zenuwcellen kunnen op een natuurlijke manier gereguleerd 
worden door het dier eenvoudigweg op een witte of zwarte achtergrond te plaatsen. 
 Aangezien neuroserpin tot nu toe alleen is beschreven in een beperkt aantal 
soorten vertebraten, zijn we begonnen om deze serine protease remmer in Xenopus te 
identificeren en kloneren (hoofdstuk 2). Daarop volgende studies hebben laten zien dat 
neuroserpin mRNA en eiwit tijdens de hele ontwikkeling van Xenopus tot expressie komen, 
en in een volwassen dier met name in neuronaal- en neuroendocrien weefsel. Daarnaast 
hebben we gevonden dat de aminozuursequentie van Xenopus neuroserpin, en met name de 
sequentie van de reactieve center loop,  in hoge mate overeenkomt met die van neuroserpin 
in zoogdieren en kippen. Dit suggereert dat het substraat van neuroserpin geconserveerd is. 
Al met al zijn dit aanwijzingen voor een mogelijk belangrijke fysiologische rol  van 
Xenopus neuroserpin als serine protease remmer voor het goed functioneren van neuronale 
en neuroendocriene cellen. Om de rol van neuroserpin in meer detail te onderzoeken, 
hebben we de expressie van neuroserpin ook onderzocht in ons modelsysteem, de Xenopus 
neuroendocriene melanotrope cellen (hoofdstuk 3). We hebben gevonden dat de expressie 
van neuroserpin gekoppeld was aan de activatie van deze cellen. Namelijk, neuroserpin 
mRNA en eiwit kwamen hoger tot expressie in melanotrope cellen van zwart-geadapteerde 
dieren. Daarnaast vormde neuroserpin specifiek in actieve melanotrope cellen een stabiel 
complex met een tot nu toe niet geïdentificeerd substraat. Dit substraat is mogelijkerwijs 
een serine protease met proteolytische activiteit in de extracellulaire matrix (ECM) van de 
melanotrope cel. We speculeren dan ook dat neuroserpin, door remming van dit substraat, 
betrokken is bij de herstructurering van de ECM gedurende de achtergrondadaptatie van 
Xenopus en zodoende een rol speelt in neuroendocriene plasticiteit. 
 Om in vivo studies uit te voeren naar de fysiologische rol van neuroserpin, hebben 
we transgene Xenopus gegenereert, waarin een POMC-gen promoter fragment zorgde voor 
een overexpressie van neuroserpin of mutant neuroserpin(G392E) specifiek in de 
melanotrope cellen (hoofdstuk 4). Het mutant neuroserpin(G392E) eiwit is betrokken bij 
een autosomale dominante dementie genaamd ‘Familial Encephalopathy with Neuroserpin 
Inclusion Bodies’ (FENIB). Analyses van de transgene dieren liet zien dat overexpressie 
van neuroserpin of neuroserpin(G392E) niet direct een effect had op de biosynthetische 
activiteit van de transgene melanotrope cellen, maar mogelijk wel op de morfologie van de 
ECM. Dit effect kan wellicht verklaard worden door een langere remming van een 
extracellulaire protease die de structuur van de ECM reguleert. 
 In het tweede deel van dit proefschrift hebben we fysiologische aspecten van pro-
en matuur BDNF onderzocht. Alhoewel BDNF reeds uitvoerig is beschreven als een 
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neuronale overlevings- en differentiatiefactor, en als een modulator van synaptische 
plasticiteit, is de interesse in het eiwit de laatste jaren alleen maar toegenomen, omdat pro- 
en matuur BDNF een bredere rol lijken te hebben in het functioneren van het zenuwstelsel. 
Om aspecten van de rol van pro- en matuur BDNF in neuroendocriene plasticiteit te 
onderzoeken, hebben we transgene Xenopus gegenereert met overexpressie van pro- en 
matuur BDNF, en een aantal varianten hiervan, in de melanotrope cellen (hoofdstuk 5). 
We hebben gevonden dat in verschillende transgene lijnen met overexpressie van proBDNF 
het transgen product niet goed verwerkt en afgegeven werd. Daarnaast detecteerden we in 
proBDNF-transgene melanotrope cellen cel stress en een blokkade in het transport van 
verschillende eiwitten van de secretieroute. Deze bevindingen lijken op de resultaten van 
anderen, die gevonden zijn in cellen met overexpressie van een gemuteerde vorm van 
humaan proBDNF. Deze mutatie is een erkend polymorfisme in het humaan bdnf gen dat 
geassocieerd wordt met afwijkingen in geheugenvorming en een grotere vatbaarheid voor 
neuropsychiatrische aandoeningen. 
 In hoofdstuk 6 hebben we transgene Xenopus geanalyseerd met overexpressie van 
matuur BDNF specifiek in de melanotrope cellen. In de hypofyse van deze dieren werd een 
nodus gevormd die bestond uit glia cellen en axonen, waarvan een aanzienlijk deel 
gemyeliniseerd was. Dus matuur BDNF induceert mogelijk de proliferatie van glia cellen 
en de uitgroei en myelinisatie van axonen, en speelt zodoende een rol in neuronale 
plasticiteit en glia cel fysiologie. Een gedetailleerde kennis van deze functionele aspecten 
van BDNF kan nuttig zijn voor de ontwikkeling van therapeutische strategieën voor 
bepaalde aandoeningen van het zenuwstelsel, zoals neurodegeneratieve en/of 
demyelinisatie aandoeningen tijdens de ontwikkeling. 
 Tenslotte worden in hoofdstuk 7 de bevindingen die in dit proefschrift zijn 
beschreven samengevat en in een bredere context geplaatst. Gebaseerd op onze resultaten 
presenteren we twee modellen waarin een rol voor neuroserpin en BDNF in 
neuroendocriene en neuronale plasticiteit voorgesteld wordt, en een derde model 
betreffende een indirecte interactie tussen de twee eiwitten. 
 Samengevat, de resultaten beschreven in dit proefschrift vergroten onze kennis 
over de fysiologische rol van neuroserpin en BDNF in neuroendocriene en neuronale 
plasticiteit. Een beter begrip van de comlexe moleculaire mechanismen die ten grondslag 
liggen aan plasticiteit zal uiteindelijk onze kennis over het functioneren van het brein in 
ziekte en gezondheid vergroten. 
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konden we juist het werk helemaal achter ons laten en genieten van andere dingen... 
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